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ABSTRACT 
 
Guy Aaron Hobbs: Regulation of Ras and Rho GTPases by Post-Translational Modification: 
Cysteine Oxidation and Ubiquitination 
(Under the direction of Sharon L. Campbell) 
 
Ras superfamily GTPases cycle between active GTP-bound and inactive GDP-bound 
forms to regulate a multitude of cellular processes, including cell growth, differentiation, and 
apoptosis. The activation state of Ras superfamily GTPases is regulated by protein 
modulatory agents that accelerate the slow intrinsic rates of GDP dissociation and GTP 
hydrolysis. In addition, evidence for the redox regulation of Ras superfamily GTPases is 
growing, and current data supports regulation by the generation of a thiyl radical. Oxidation 
and reduction events are critical to physiological and pathological processes and are highly 
regulated. In Ras GTPases, the redox-sensitive cysteine is in the NKCD motif, which is a 
motif that is critical for nucleotide binding. However, we show that oxidation that occurs 
absent of the generation of a thiyl radical does not result in Ras activation.  
In the Rho subfamily of GTPases, there is increasing in vitro and cell-based data 
supporting the oxidant-mediated regulation of Rho GTPases that contain a redox-sensitive 
cysteine at the end of the conserved phosphoryl-binding loop motif (GXXXXG[S/T]C). 
While this motif is distinct from Ras, our data suggest that Rho GTPases are regulated by 
free radical-generation as well as oxidation of the thiol. Specifically for RhoA and other Rho 
GTPases that have two cysteine residues within the phosphoryl-binding loop motif 
(GXXCXG[S/T]C), oxidation can result in internal disulfide bond formation that can 
inactivate these GTPases. In addition, we characterized relevant cellular oxidation states of 
RhoA and show that oxidation can result in the activation and deactivation of RhoA.  
iv 
 
Thus, from data presented herein, it is evident that Ras and Rho family GTPases are 
uniquely regulated by free radical and non-radical oxidants, and the modulation of activity 
of the GTPase due to oxidation is dependent on the position(s) of the redox-sensitive thiol. 
While Ras GTPases are only activated by free radicals because the redox-sensitive thiol does 
not make interactions with the bound nucleotide, in Rho GTPases, the redox-sensitive thiol 
makes direct interactions with the bound nucleotide, which results in activation upon 
modification of the redox-sensitive thiol in RhoA and related GTPases.   
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Chapter 1: Introduction and Background 
Introduction 
Ras and Rho GTPases are involved in many fundamental signaling pathways that 
affect cell cycle, growth, apoptosis, motility, and morphology (4). Dysregulation of these 
proteins can lead to numerous disease states, including cancer, cardiovascular disease, and 
neurological disorders. Ras and Rho GTPases are molecular “switches.” GTP binding alters 
their conformation, which promotes effector binding and turns downstream signaling “on” 
(guanine exchange factors [GEFs]), whereas the GDP-bound form reduces effector binding, 
turning signaling “off” (GTPase activating proteins [GAPs]). In general, three distinct classes 
of proteins regulate the level of activated GTPases in the cell (Figure 1). 
Ras superfamily GTPases can be modified by a variety of post-translational 
modifications (PTMs) that drive differences in localization and activity (5). Ras and Rho 
GTPases associate with the membrane upon lipid modification at the carboxyl-terminus (6, 
7). Rac1, RhoA, and Cdc42 are geranylgeranylated and associate with the inner leaflet of the 
plasma membrane (8). Rho guanine dissociation inhibitors (GDIs) recognize the lipid 
moiety and prevent the GTPase from re-associating with the lipid membrane after 
dissociation (9). 
Rac1 has also been shown to be palmitoylated at Cys178 (10). Palmitoylation has been 
shown to be critical for Rac1-mediated actin cytoskeleton remodeling in Cos-7 cells. Further, 
mutation of Cys178 to Ser resulted in decreased partitioning to the plasma membrane and 
reduced Rac1 activation. Another PTM observed in a subset of Rho GTPases is 
phosphorylation. RhoA, RhoG, and Cdc42 have been shown to be phosphorylated at Ser188 
(RhoA numbering) (11, 12). For RhoA, phosphorylation increases association with GDIs, 
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Figure 1. The GTPase cycle of Ras family GTPases 
Ras GTPases cycle between GTP-bound active states and GDP-bound inactive states. 
Guanine nucleotide dissociation inhibitors (RhoGDIs), which are specific to the Rho subclass of 
GTPases, extract lipid-modified Rho GTPases from membrane to cytosol and prevent GDP 
dissociation until released upon stimulus. Following signal input, the exchange of the bound GDP 
is facilitated by the guanine nucleotide exchange factor (GEF) that dramatically increases the 
dissociation rate of nucleotides. This promotes GTP binding due to the 10-fold higher in cell 
concentration of GTP compared to GDP. Once GTP-bound, the active GTPase is capable of binding 
downstream effectors and executing its biological functions. The GTPase remains active until GTP 
is converted to GDP due to its intrinsic hydrolytic capacity, or through catalysis by GTPase 
activating factors (GAPs).  
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which causes release from the membrane and inactivation. The biological effect of Ser188 
phosphorylation in RhoG and Cdc42, as well as in other Rho family GTPases, is currently 
unclear. 
Ubiquitination, including mono,- di-, and polyubiquitination, is another PTM that has 
been recently discovered for Rho GTPases (13). These modifications result in the addition of 
single or multiple ubiquitin moieties (76-residue protein) that affects protein localization, 
stability, and trafficking (14). Recently, the reversible monoubiquitination of select lysine 
residues in Ras has been observed, which directly regulates its activity (15, 16). Recent 
evidence indicates that a subset of Rho GTPases can be ubiquitinated (17); however, Rac1 is 
the only Rho family GTPases that has been shown to be monoubiquitinated (18), whereas 
RhoA and Cdc42 have only been observed to be polyubiquitinated, which results in 
deactivation and degradation (17, 19, 20). Further, monoubiquitin can be removed by 
deubiquitinating enzymes (DUBs); however, Ras- and Rho-specific DUBs have yet to be 
discovered. 
Another type of PTM in Ras superfamily GTPases is cysteine oxidation. Cysteine 
oxidation is a form of redox regulation and is a field that is often described of as an 
‘emerging’ and ‘novel’ mechanism of GTPase regulation; however, cysteine oxidation was 
originally identified in Ras over 15 years ago (21). What makes cysteine oxidation a unique 
PTM is that these modifications are not directly catalyzed by an enzyme, which is the case 
for phosphorylation, lipid modification, and ubiquitination, but rather are modified by ROS 
and RNS. While enzymes produce redox agents capable of oxidizing proteins, such as nitric 
oxide synthase (NOS), NADPH oxidase (NOX), and superoxide dismutase (SOD), the 
oxidants themselves have long been viewed as hallmarks of oxidative stress and nonspecific. 
However, it has become increasingly apparent that RNS and ROS, including nitrogen 
dioxide (NO2•), nitric oxide (NO•), superoxide (O2•-), and peroxide (H2O2), target specific 
proteins containing redox-sensitive cysteine residues under physiological conditions (22-
4 
24). A cysteine residue within a protein is generally considered ‘redox-sensitive’ if it is 
solvent accessible and contains a depressed pKa, which has been shown to increase the 
reactivity of the thiol to oxidants (25). If a cysteine forms interactions within the protein that 
stabilize the thiolate (S-) form, then the residue will have a lower pKa relative to free cysteine 
(26). In general, a free cysteine has a pKa of approximately 8.5, which leaves it in the thiol 
(SH) form at physiological pH. The rate of thiol reactivity depends on the thiol ionization 
state and the oxidant, with the thiolate state being more sensitive to oxidation than the thiol 
state (27). Furthermore, there is no known consensus sequence that can be used to predict 
redox-sensitive cysteines (28). While peroxynitrite has been shown to be able to oxidize the 
thiol form, it is more reactive with the thiolate form, although the radical-mediated 
breakdown products are more likely to oxidize cellular thiols (Figure 2) (29). In addition, 
peroxide will only react with the thiolate (S-) form of cysteines (30), whereas, nitric oxide has 
been shown to react too slowly with thiols to be physiologically relevant (31). However, an 
altered pKa is not always a prerequisite for redox sensitivity as Ras Cys118, a known redox-
sensitive cysteine, does not have an altered pKa; however, Ras is only regulated through 
Cys118 by free radical-mediated oxidants.  
Thus, as the Ras field is still largely unfamiliar with the redox regulation of GTPases 
and the redox field as a whole, in this review, we will present some basic information on 
redox signaling in cells and describe the current understanding of the redox regulation of 
Rho GTPases.  
Generation of ROS and RNS in cells and antioxidant defense 
Deregulation of the cellular redox potential is often correlated with various levels of 
oxidative stress and elevated levels of reactive oxygen (ROS) and nitrogen species (RNS) and 
contributes to and promotes a variety of diseases (32), including cancer, neurodegeneration 
(33), atherosclerosis, diabetes, and aging (34). As such, ROS and RNS are often considered 
damaging to cellular tissue, including proteins, lipids, and DNA. Thus, before we can fully  
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Figure 2. Generation and interconversion of ROS and RNS in cells 
Select oxidation end products are presented, including radical-mediated glutathiolation (1), 
glutathiolation with O2•- production (2), disulfide exchange-mediated glutathiolation (3), and 
nitrosation by a non-radical pathway (4). Not all reactions shown are chemically balanced. Key: 
Cat, catalase; GPX, glutathione peroxidase; NOS, nitric oxide synthase; Nox, NADPH oxidase; 
SOD1, superoxide dismutase 1. 
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detail the role of ROS and RNS in the regulation of Rho GTPases, we will give a brief 
overview of the production of ROS and RNS in cells, antioxidant defense, and 
interconversion of cellular ROS and RNS (outlined in Figure 2).  
While ROS and RNS are generally grouped into a category of reactive intermediates, it 
is important to understand that there are two classes of oxidants, one-electron and two-
electron oxidants. Two electron oxidants have been shown to oxidize thiols to generate 
sulfenic acid and a predominant cellular two-electron oxidant is hydrogen peroxide (26). 
One-electron oxidants, such as nitrogen dioxide, generates a thiol radical, which will 
predominantly react with other thiols, including cellular glutathione, to form disulfide bonds 
and produces superoxide (Figure 2) (35, 36). Under normal cellular signaling, only the 
most reactive thiols will be subject to oxidation and signaling through ROS and RNS, and 
ROS and RNS have been observed to function as second messengers (23). However, it is 
important to note that oxidation observed in vitro does not always correlate with oxidation 
in vivo. This is because in vitro experiments tend to have few substrates in solution, which 
leaves the oxidant little competition. Therefore, for a protein to function in oxidative 
signaling, it needs to be readily oxidized in vivo under normal cellular conditions (27). 
A primary source of cellular ROS exists within the mitochondria (37). As all aerobic 
organisms require oxygen for oxidative phosphorylation, the mitochondria is a central 
organelle that generates a number of cellular oxidants. One of the most common ROS 
generated by the mitochondria is superoxide (O2•-) due to incomplete reduction of molecular 
oxygen (O2). Superoxide does not readily diffuse across membranes, which limits the 
molecule to the compartment where it was generated. Furthermore, in aqueous solution, O2•- 
undergoes a fast dismutation reaction (rate constant of 5 x 105 M-1s-1 at pH 7.0) to H2O2. 
Superoxide Dismutase, an enzyme capable of reducing O2•- to H2O2, speeds up this reaction 
nearly 104-fold. In the mitochondria, SOD is maintained at a high concentration such that it 
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is unlikely that any mitochondria-derived O2•- escapes to the cytoplasm. However, H2O2 can 
easily cross the membrane and move into the cytoplasm (38).  
Phagocytes are another common source of cellular ROS and can produce superoxide in 
‘bursts’ due to the action of Nox enzymes. There are currently 7 known Nox enzymes 
(Nox1/2/3/4/5, Duox1, and Duox2). Nox1, Nox2, and Nox3 all require Rac1 for activation 
(39). Nox isoforms are highly regulated and tissue specific. In phagocytes, cytochrome b559 
(a heterodimer consisting of Nox2 (formerly gp91phox) and p22phox) combines with p47phox, 
p67phox, and Rac1 to form the membrane-associated NADPH oxidase complex, which 
catalyzes the one-electron reduction of oxygen to superoxide (O2•-) to eliminate invading 
pathogens by oxidation (40). In addition, superoxide (O2•-) generated in the arteries by Nox2 
and Nox4 compete with antihypertensive effects of nitric oxide (NO•) by reacting with nitric 
oxide to form peroxynitrite (ONOO-; Figure 2) (41). In lung fibroblasts, the presence of 
different Nox isoforms promotes superoxide (O2•-) production in the cytosol and 
extracellular space.  
Another source of cellular ROS is in liver and kidney cells. These cells use cellular 
substructures called peroxisomes, which contain a variety of ROS and RNS generating 
enzymes and peroxisomal catalase that function in metabolic pathways and have been 
shown to produce as much as 35% of cellular peroxide (42). 
Nitric oxide is perhaps the best known cellular RNS and is produced by a class of 
enzymes called NOSs. There are three isoforms of NOS, endothelial NOS (eNOS), inducible 
NOS (iNOS), and neuronal NOS (nNOS), all of which function as homodimers and generate 
nitric oxide from L-arginine (43). Some functions of nitric oxide (NO•) produced by NOS 
include the regulation of erectile function, blood pressure, vasodilation, and inflammation. 
Neuronal NOS is a cytosolic protein that is found primarily in the central nervous system 
and is activated by phosphorylation, calcium, and interactions with proteins with PDZ 
domains (44). Endothelial NOS is constitutively expressed and localized to the membranes 
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in cells and when activated, can produce low levels of nitric oxide (NO•). Activation of eNOS, 
like nNOS, is regulated by calcium-bound calmodulin (45), interactions with various effector 
proteins (46), and phosphorylation (47). Lastly, iNOS expression is induced in macrophages 
and other cell types and is constitutively active once expressed (48). The function of iNOS is 
to produce nitric oxide (NO•) to inhibit iron-sulfur proteins, damage tumor cells, and oxidize 
the DNA of invading parasites.  
Discussion regarding the generation of endogenous oxidants would not be complete 
without considering the lungs. The lungs are constantly exposed to pollutants, cigarette 
smoke, ozone, and other industrial oxidants. This extra exposure to exogenous ROS and 
RNS makes the lungs more susceptible to oxidative stress, which can have different effects 
on protein function than oxidative signaling, which are beyond the scope of this 
introduction.  
The cell has also evolved a network of antioxidant enzymes and small molecules to 
protect the cell from oxidative damage. An abundant antioxidant enzyme that deserves 
consideration is SOD. Three distinct isoforms of SOD: SOD1, a dimeric protein that binds 
copper and zinc and is localized in the cytosol; SOD2, a homotetrameric protein that binds 
one manganese ion per subunit and is localized in the mitochondria; and SOD3, a 
homotetrameric protein anchored to the extracellular matrix. SODs reduce O2•- to H2O2. 
Peroxide, in turn, can be reduced to H2O by catalase and glutathione peroxidase (Figure 2). 
In addition, GSH-Pxs can reduce lipid peroxidases to their respective lipid alcohols. Other 
antioxidant enzymes include thioredoxin reductases, peroxiredoxins, and glutaredoxins, 
which all function in the removal of peroxide (49).  
In addition to enzymatic antioxidants, the cell has evolved a host of small molecule 
antioxidants as well. Common cellular antioxidants include glutathione, ascorbic acid, 
tocopherol, and β-carotene. Glutathione is a tripeptide that contains cysteine thiol group and 
is the major cellular antioxidant. The cellular regulation of the GSH:GSSG ratio is critical for 
9 
managing oxidative stress (50). GSH functions with GSH-Pxs to reduce peroxides in the cell 
and can reduce other oxidized species (Figure 2). Ascorbic acid, more commonly known as 
Vitamin C, scavenges free radicals in the cytosol, whereas tocopherol (vitamin E) protects 
cellular membranes from oxidative damage (51). Β-carotene serves to scavenge radicals as 
well, including peroxyl, hydroxyl, and superoxide radicals (52).  
Reactive oxygen and nitrogen species as second messengers 
Some examples of ROS are peroxide (H2O2), superoxide (O2•-), and hydroxyl radical 
(HO•), and examples of RNS are nitric oxide (NO•), nitrogen dioxide (NO2•), peroxynitrite 
(ONOO-), and dintrogen trioxide (N2O3). However, for these molecules to function in cellular 
signaling, they must meet the definition of second messengers. As second messengers, RNS 
and ROS are generated in response to a specific stimulus, short lived, specifically target 
effectors, and transiently and reversible effect signaling. Superoxide (O2•-) and peroxide 
(H2O2) are considered second messengers as these reactive species are less reactive than 
other ROS, such as HO•, which lacks specificity as it reacts at the rate of diffusion with any 
molecule it contacts. For RNS, nitrogen dioxide (NO2•), not nitric oxide (NO•), is thought to 
be the major source of free radical-mediated oxidation of thiols. Peroxynitrite undergoes 
homolytic cleavage to generate nitrogen dioxide and carbonate radicals (CO3•-) in the 
presence of CO2, which can directly oxidize thiols; however, dinitrogen trioxide, and the 
nitrosonium ion (NO+) are capable of nitrosating thiols through two-electron mechanisms 
(53) to generate nitrosothiols (RSNO). 
Protein thiols in cysteine residues are amongst the most common sites of protein 
oxidation. However, for ROS and RNS to be considered as a second messenger, these PTMs 
should be reversible. Reversible oxidation states of protein thiols in vivo include sulfenic 
acid (RSO-), nitrosation (RSNO), glutathiolation (RSSG; mixed disulfide bonds), and 
disulfide bonds (RSSR’; intramolecular disulfide bonds) (54). There is some evidence that 
sulfiredoxins can reduce sulfinic acid (RSO2-); however, sulfiredoxins have only been shown  
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to function on specific peroxiredoxin enzymes (55). Sulfonic acid (RSO3-) is another form of 
thiol oxidation; however, this oxidation state is irreversible and generally results in 
proteasome-mediated degradation (56).  
Free radicals modify and activate Ras through a reactive cysteine in the NKCD 
motif 
As we have recently published a detailed review on RNS regulation of Ras activity and 
biology (57), we will only highlight the most recent and salient data herein. Lander et al first 
observed NO-mediated Ras activation in T cells (58), which was transient and 
concentration-dependent. Later, it was shown that treatment with sodium nitroprusside, a 
nitric oxide-generating compound, increased Ras downstream signaling through the 
mitogen-activated kinase pathway (59). An important tool in such studies, RasC118S is a 
variant that aids in determining the direct and indirect effects of RIs on Ras because it is RI-
insensitive and does not alter Ras structure and activity (60). A recent study on 
macrophages demonstrated that Ras S-nitrosation was required for Erk1/2-mediated 
apoptosis using the NO• donor S-nitrosoglutathione (61). The RasC118S variant reversed the 
pro-apoptotic effects, indicating that the effects on cell survival were mediated by direct 
reaction with Ras. In this study, Tsujita et al suggested that the process of nitrosation, rather 
than covalent modification, activated Ras (61). Our lab extended these observations and 
showed that Ras activation depends on 1e- (radical)-mediated oxidation, which induces 
nucleotide dissociation (62). As most of these earlier studies used exogenous NO• and/or 
were conducted in cells that overexpressed Ras, it was unclear whether NO• regulated Ras 
activity under physiological conditions.  
However, recent evidence has linked eNOS to Ras nitrosation and activation in Ras-
mediated tumorigenesis initiation and maintenance in mice. In the proposed activation 
pathway, oncogenic Ras activates the phosphoinositide 3-kinases (PI3K) pathway, which 
results in Akt-mediated (also protein kinase B) eNOS phosphorylation. Through a feedback 
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mechanism, eNOS-generated NO• activates RasWT and stimulates Ras downstream pathways 
(63). Further, Lim et al showed that, for H- and N-Ras, introducing the RasC118S mutation 
circumvented PI3K pathway activation and reduced tumor growth. In a separate cell-based 
study, eNOS-derived NO• activated N-Ras in T cells engaged with antigen presenting cells; 
Cys118 was required for activation (64). These data suggest that NO• mediates Ras activation 
directly through Cys118. 
Ras superfamily GTPases have four conserved nucleotide-binding motifs (65). While 
the X residue in the NKXD motif is not well-conserved, several Ras subclass members 
contain a redox-active cysteine at this position. GTPases with a redox-sensitive NKCD motif 
can be activated by NO2• and other RIs; however, NO-mediated regulation is best 
characterized for Ras. Several cell-based and in vitro studies have shown that NO2• reacts 
with Ras through Cys118 to promote nucleotide exchange and Ras activation (57). Our lab has 
employed NMR and biochemical approaches to show that S-nitrosation of Ras does not 
affect Ras structure or nucleotide binding (66). We speculated that an intermediate formed 
during the reaction of Ras with NO2• modulates Ras activity and investigated several 
reactions involved in thiol S-nitrosation. Furthermore, we observed that 1e- oxidation 
(radical-mediated) reactions, which have been postulated to promote thiyl radical formation, 
enhance nucleotide dissociation from Ras (62). In support of these observations, we have 
recently confirmed Cys118 radical formation upon exposure of Ras to diethylamine NONOate 
(NO•-generating agent) and NO2•, using immune-spin trapping and Fourier transform ion 
cyclotron resonance mass spectrometry (67). As guanine bases are susceptible to radical-
mediated oxidation, we speculated that thiyl radical generation promoted oxidation of the 
Ras-bound guanine nucleotide. Supporting this premise, we used mass spectrometry (MS) to 
demonstrate that 5-guanidino-4-nitroimidazole diphosphate (NIm-DP) is formed in the 
presence of NO•/O2 and NO2•. NIm-DP is a reported breakdown product of 5-nitro-guanine 
ribose diphosphate (5-nitro-GDP), which can be generated upon reaction of guanosine 
13 
diphosphate with NO2• (68). Further, mutation of the redox-sensitive cysteine (RasC118S) 
prevented NO-mediated nucleotide oxidation and dissociation (69). These results suggest 
that NO•/O2 or NO2• can produce a Ras thiyl radical (RasC118•) that propagates to the guanine 
base by electron transfer. Guanine base oxidation disrupts critical intermolecular contacts 
between the nucleotide and Ras nucleotide binding pocket, which enhances nucleotide 
dissociation. These data suggest that RasC118 thiol nitrosation does not promote nucleotide 
exchange; rather, exchange is promoted by thiyl radical formation at RasC118. Further 
supporting this model, we demonstrated that nucleotide binding is not altered by either 
RasC118 mutation or S- nitrosation (69). A proposed thiyl radical-based mechanism has been 
described in detail elsewhere (70) but remains inconclusive, as direct evidence to support 
the proposed radical intermediates has not yet been obtained. 
In contrast to our observations that Cys118 nitrosation does not alter Ras activity, 
Clavreul et al suggested that covalent modification of Ras by glutathione enhances 
nucleotide exchange (71). In these experiments, RasWT, but not RasC118S, was activated by 
glutathiolation using peroxynitrite, and it was hypothesized that RasC118 glutathiolation by 
2e- oxidation perturbs nucleotide binding because glutathione is negatively charged and 
larger than nitric oxide. Clavreul et al concluded that glutathiolation significantly altered Ras 
structure at the nucleotide-binding pocket and enhanced nucleotide exchange (72, 73). 
However, peroxynitrite was used in these experiments, and its breakdown products can 
generate RIs capable of thiyl radical formation. Peroxynitrite can undergo homolysis to 
generate NO2• and HO•. Moreover, in the presence of CO2, peroxynitrite can produce 
carbonate radicals (74). While Kissner and Koppenol have observed that ‘radical-free’ 
peroxynitrite homolysis produces nitrite and molecular oxygen (75), Szabo et al discussed 
peroxynitrite homolysis products and concluded that it generates radical products (76).  
Therefore, it is impossible to judge whether the effects of glutathiolation on Ras 
activity were induced by free radicals or direct Cys118 modification. While Adachi et al 
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suggested that Ras S-nitrosation may be an intermediate during glutathione modification of 
Ras, they concluded that covalent (2e-) glutathione modification of Ras leads to Ras 
activation (77). However, the observation that Ras glutathiolation alters nucleotide exchange 
contradicts our previous studies, which demonstrated that Cys118 and 1e- oxidants are 
required for regulation of Ras nucleotide binding and activity. To address this discrepancy, 
we have recently demonstrated that treatment of Ras with oxidized glutathione (GSSG) 
results in glutathiolation of Ras at Cys118. However, similar to S-nitrosation, glutathione 
modification of Ras does not alter Ras nucleotide binding. Therefore, we propose that Ras 
activation requires Cys118 thiyl-radical formation for nucleotide dissociation and subsequent 
activation. One end product of RasC118 thiyl-radical generation is RasSSG. Thus, the presence 
of RasSSG may reflect Ras activation if it was generated by a reaction with the RasC118 thiyl 
radical; this is also the most likely mechanism in cells given the slow reaction rate for the 
Ras thiol and GSSG under physiological conditions.  
Redox regulation of Rho GTPases by 1e- and 2e- mechanisms through a redox-
active cysteine in the phosphoryl-binding loop  
We have demonstrated that select Rho GTPases are redox sensitive; however, Rho 
GTPases contain a different redox motif than Ras (78). Over fifty percent of Rho GTPases 
contain a redox sensitive cysteine at the end of the nucleotide-binding p-loop motif, 
GXXXXGK[S/T]C. Based on the Rac1, Cdc42, and RhoA crystal structures, the solvent-
exposed cysteine in the p-loop motif likely has an altered pKa and is accessible to RIs. We 
have previously shown that the reactive phosphoryl binding loop (p-loop) cysteines in Rho 
GTPases are sensitive to oxidation, resulting in altered GTPase regulation (79).  
Whereas treatment of RhoA with NO2• can promote nucleotide oxidation and 
dissociation similar to Rac1 and Cdc42, it can inhibit nucleotide binding in the absence of 
reducing agents. Distinct from Rac1 and Cdc42, RhoA contains two cysteines in its p-loop 
(Cys16 and Cys20). Exposure of RhoA with NO2• can promote disulfide bond formation 
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between Cys16 and Cys20 , which occludes nucleotide binding (80). However, nucleotide 
binding can be restored with disulfide reducing agents. Our findings indicate that thiyl 
radical formation at RhoAC20 upon NO2• treatment facilitates nucleotide oxidation and 
release, which increases RhoAC16 accessibility and promotes intramolecular disulfide bond 
formation with Cys20. RhoA disulfide-bond formation occludes nucleotide binding and 
promotes RhoA inactivation. Based on these observations, we postulate that RhoA is likely 
activated by thiyl radical-promoting RIs under conditions where the redox potential is 
capable of promoting disulfide reduction and restoration of RhoA nucleotide binding (81, 
82). Redox-mediated inactivation of Ras may occur when the cellular reduction potential is 
reduced, such as during oxidative stress. It is intriguing to speculate that enzymes, such as 
thioredoxin and glutaredoxin, which are capable of reducing protein disulfides, may act on 
RhoA and contribute to activation. 
The addition of cisplatin or arsenic trioxide has been shown to inactivate RhoA by 
promoting mixed disulfide formation between the two p-loop cysteines (80). In contrast to 
Ras, these results suggest that 2e- oxidation can regulate RhoA activity. In support of this 
hypothesis, Gerhard et al showed that phenylarsine oxide (PAO) generates a mixed disulfide 
crosslink between RhoA Cys16 and Cys20 using MALDI-MS (matrix-assisted laser 
desorption/ionization-MS) and demonstrated that the modification inhibits stress fiber 
formation through the inactivation of RhoA in Caco-2 cells (83).  
H2O2 has also been shown to regulate RhoA activity in vitro and in cells (78, 81). 
Unlike RasC118, RhoAC20 directly interacts with the bound nucleotide, and 2e- oxidation of this 
cysteine likely perturbs nucleotide binding. We observed that 2e--oxidation by peroxide at 
the p-loop cysteines can enhance the rate of nucleotide dissociation by approximately 10-
fold. In addition, 1e- oxidation has also been shown to induce nucleotide dissociation. Our 
lab has shown that 1e- oxidants (O2• -, NO2•, and HO•) enhance RhoA nucleotide exchange by 
nearly 500-fold (78).  
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While work from our lab indicates that only 1e- oxidation reactions that generate a 
thiyl radical at Cys118 in Ras affect Ras activity, discrepancies remain regarding 2e- oxidation. 
Given the distinct Rho GTPase redox motif, 1e- and 2e- mechanisms can modulate their 
activity. RhoA is unique because 1e- oxidants can induce a disulfide bond between Cys16 and 
Cys20, which can inactivate RhoA by occluding nucleotide binding. While the reduction 
potential under most physiological conditions will likely promote disulfide bond reduction 
and RhoA activation, under conditions of oxidative stress, radical quenching and/or 
disulfide reduction may not occur, which could render RhoA inactive (44). Further cell-
based studies are needed to clarify the mechanisms of Rho GTPase regulation by redox 
agents. 
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Chapter 2: Glutathiolated Ras: Characterization and Implications for 
Ras Activation 
Introduction  
Ras proteins belong to a large superfamily of GTPases that bind to GDP and GTP with 
high specificity and affinity. They function as molecular switches that cycle between the 
inactive GDP-bound and active GTP-bound forms. Once activated, Ras GTPases interact 
with a variety of effectors to activate signaling pathways that regulate gene expression, cell 
growth and differentiation, and programmed cell death (84-86). The structural differences 
between the GDP- and GTP-bound states of Ras are primarily localized within two regions, 
Switch I (residues 30-37) and Switch II (residues 60-76) (65). The intrinsic rates of GDP 
exchange and GTP hydrolysis are too slow to respond to cell signaling events (87), and 
consequently, protein factors associate with Ras and accelerate these rates in a regulated 
manner. Guanine nucleotide exchange factors (GEFs) accelerate exchange of bound GDP for 
GTP, which leads to Ras activation (88), whereas GTPase activating proteins (GAPs) 
inactivate the GTPase by facilitating GTP hydrolysis (89, 90). Ras is considered the most 
prevalent oncogene in human cancer, and oncogenic mutations have been identified in 
approximately 30% of human tumors (91, 92). Oncogenic Ras mutations render Ras 
constitutively active by impeding down regulation by GAPs (93).  
In addition to GEFs, reactive oxygen and nitrogen species (ROS; RNS) have been 
shown to enhance guanine nucleotide exchange and activate Ras (57). Two of the most 
common oxidative modifications identified for Ras in vivo are nitrosation and 
glutathiolation (94). Specifically, nitrogen dioxide (NO2•) has been shown to induce Ras 
guanine nucleotide dissociation by causing guanine base oxidation through reaction with 
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cysteine 118 (Cys118) (62). As the GTP:GDP ratio in cells is approximately 10:1, oxidation-
mediated GDP dissociation can promote GTP loading of Ras, analogous to the action of 
GEFs (69). While the reaction of nitric oxide and its auto-oxidation product, NO2•, with Ras 
have been characterized, it is less clear how other thiol modifications (i.e., glutathiolation) 
affect Ras activity. As numerous studies have described activity modulation of Ras in the 
presence of ROS and RNS, we refer the reader to two recent reviews that detail the redox 
regulation of Ras and Ras-related GTPases (57, 95).  
Ras contains a solvent accessible cysteine (X) in the nucleotide-binding NKXD motif. 
While this cysteine is conserved in H-, K- and N-Ras, it does not form interactions with 
other residues in Ras or the guanine nucleotide ligand and is poorly conserved in the Ras 
superfamily. We have previously postulated that Cys118 is conserved in N-, K-, and H-Ras due 
to its role in the redox regulation of Ras (69). In fact, Cys118 has been shown to react in vitro 
and in vivo with a variety of thiol oxidizing agents, including oxidized glutathione, 
superoxide, and nitric oxide-derived oxidants (94). We have previously characterized a 
redox inactive variant of Ras (RasC118S) that retains similar structure and biochemical 
properties as RasWT (21, 59). RasC118S has been used in numerous in vitro and cell-based 
studies to discriminate between direct and indirect mechanisms of Ras activity modulation 
by Cys118-mediated oxidation (reviewed in 57, 94). As we have previously shown that S-
nitrosation of Ras (RasSNO) at Cys118 does not significantly alter Ras structure, biochemical 
properties, or binding to the Ras-binding domain of Raf-1 (66), we postulated that NO 
modulates Ras activity by formation of a thiyl-radical intermediate, which leads to oxidation 
of the bound guanine base, likely through electron transfer. In support of this premise, we 
have previously shown that treatment of Ras with NO2• promotes the oxidation and release 
of the bound guanine nucleotide (62). In addition, we have recently detected the presence of 
a Ras-thiyl radical upon treatment of RasWT with NO using the immuno-spin trapping (IST) 
reagent 5,5-dimethyl-1-pyrroline N-oxide (DMPO); no radical was detected when RasC118S 
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was used (67). Thus, we propose that Ras thiyl-radical formation, as opposed to S-
nitrosation, induces oxidation and release of the guanine nucleotide base, which can lead to 
Ras activation.  
In addition to S-nitrosation, several studies have observed that Ras can undergo 
glutathiolation. This oxidative modification was suggested to increase nucleotide exchange 
and promote Ras activation (71, 77, 96-100). In particular, detection of Ras glutathiolation 
coincident with Ras activation was observed after exposure of bovine aortic endothelial cells 
(BAECs) to peroxynitrite (71, 100), addition of angiotensin II to vascular smooth muscle cells 
(VSMCs) (77, 101), and exposure of H2O2 to rat ventricular myocytes (97, 99). However, 
addition of these agents to cultured cells can produce redox agents capable of protein thiyl 
radical formation. For example, peroxynitrite can react with cellular CO2 to produce CO3•- 
and NO2• radicals, and under acidic conditions (peroxynitrite pKa is ~6.6), peroxynitrite can 
decompose to hydroxyl radical and NO2• (102). Furthermore, peroxynitrite and angiotensin 
II can dysregulate several kinase pathways, including the PI3K/Akt pathway, and increase 
the production of cellular NO by activation of endothelial nitric oxide synthase (eNOS) (103, 
104). The NO produced by eNOS can auto-oxidize to produce NO2•, which is a powerful 
oxidant capable of thiyl radical formation. Consistent with observations of Liaudet et al and 
Ushio-Fukai et al, the PI3K/Akt pathway was activated after exposure of BAECs to 
peroxynitrite (71). Intriguingly, in a pancreatic cancer cell line and a severe combined 
immunodeficiency/Beige mouse model, activation of PI3K has been shown to activate Ras 
via eNOS stimulation through a redox-mediated mechanism dependent on Cys118 (63). 
Furthermore, peroxynitrite and angiotensin II signaling both activate NADPH oxidase, 
which can produce waves of reactive oxygen species long after peroxynitrite decomposition 
(105). Lastly, H2O2 can produce free radicals through the Fenton reaction by reacting with 
transition metals present in cells. Thus, based on our previous characterization of nitrosated 
Ras (66), we postulate that Ras activation observed by Clavreul et al (71, 100) and Adachi et 
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al (77) results from a radical-mediated mechanism, which occurs prior to the modification 
by glutathione. However, due to the larger size of glutathione compared to NO•, it was 
hypothesized that Ras glutathiolation at Cys118 causes structural changes in the nucleotide 
binding pocket, leading to perturbation of guanine nucleotide binding and an increased rate 
of nucleotide exchange (71). As Cys118 is critical for the radical-mediated regulation of Ras 
activity, we sought to circumvent the confounding factors of peroxynitrite and angiotensin II 
use in cells by directly determining whether glutathiolation at Cys118 alters Ras structure and 
activity in vitro.  
While Ras has been shown to be glutathiolated in cells (71, 77, 97, 100), it is unclear 
how glutathiolation alters Ras activity. Therefore, we employed NMR and fluorescence-
based biochemical assays to assess whether glutathione modification of Ras perturbs Ras 
structure or activity. We find that treatment of Ras with oxidized glutathione leads to 
glutathiolation specifically at Cys118, which does not alter Ras tertiary structure or guanine 
nucleotide binding. These results are consistent with our previous observations that S-
nitrosation of Ras Cys118 does not perturb the structure or activity of Ras (66). Therefore, our 
data suggests that glutathiolation can only affect Ras activity if modification proceeds 
through a radical-mediated reaction. Moreover, Ras glutathiolation prevents further redox-
mediated activation of Ras by free radical-based mechanisms, which may serve to protect 
Ras from future radical-mediated oxidation events under conditions of oxidative stress.  
Materials and Methods 
Ras purification and glutathiolation  
Truncated human H-ras (H-Ras1-166) was cloned into the pQlinkH vector (Addgene; 
Cambridge, MA), which contains an N-terminal 6x-His purification tag followed by a 
Tobacco Etch Virus protease cleavage site for removal of the affinity tag. The hypervariable 
region of Ras, including the C-terminal CAAX box, was removed as this region does not 
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undergo post-translational lipid modification in bacteria, is unstructured, and its removal 
does not affect guanine nucleotide binding or GTP hydrolysis (106). All proteins were 
expressed in BL21 (DE3) RIPL cells (Stratagene; La Jolla, CA) and purified following the 
Qiagen Nickel NTA purification protocol (Germantown, MD). Ras was further purified by 
size exclusion chromatography (Superdex-75 10/300 GL column; GE Life Sciences; 
Piscataway, NJ) and judged greater than 95% pure by SDS-PAGE analysis.  
Ras was modified with glutathione by the addition of 1000× oxidized glutathione to 
purified Ras in glutathiolation buffer (50 mM Tricine pH 8.0, 50 mM NaCl, 5 mM MgCl2, 
and 30 μM GDP) at 37˚C for 15 min. Prior the addition of glutathione, Ras was reduced with 
dithiothreitol (DTT) for 30 min at pH 8.5 before being buffer exchanged into glutathiolation 
buffer that was flushed with N2 gas to remove dissolved oxygen and prevent auto-oxidation.  
Mass Spectrometry of glutathiolated-Ras and Ras  
Ras mass measurements were performed on an LTQ-Orbitrap Velos mass 
spectrometer (Thermo Scientific; San Jose, CA). The mass analysis of intact Ras samples was 
achieved in full-mass spectrometry (MS), selected-ion monitoring (SIM), and higher energy 
collisional dissociation-(HCD)-MS/MS modes with a resolution of 120,000 at m/z 400 Da. 
The intact MS spectra were deconvoluted using ProMass, and HCD-MS/MS product ion 
spectra were processed manually by assigning sequence ions to theoretical masses 
corresponding to RasSSG. The bottom-up peptide identification of trypsinized Ras samples 
was performed using reversed phase LC-MS/MS on a nano-LC ultra 2D plus (Eksigent Inc; 
Dublin, CA) coupled to an LTQ-Orbitrap Velos as described previously (107). Briefly, data 
acquisition included a full-MS scan on the Orbitrap (externally calibrated to a mass accuracy 
of < 1 ppm and instrumental resolving power of 60,000 at m/z 400 Da) followed by 
intensity-dependent CAD-MS/MS of the top 10 most abundant peptide ions. Mass spectra 
were processed, and peptide identification was performed using Mascot (Matrix Science 
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Inc.) against a Human Uniprot database. Peptides were confidently identified using a target-
decoy approach with a false-discovery-rate (FDR) of 1%. A precursor ion mass tolerance of 
200 ppm and product ion mass tolerance 0.5 Da with a maximum of two missed cleavages 
and variable modifications of cysteine glutathiolation and oxidation were used as a protein 
database search parameter. All peptides were filtered and reported within a mass accuracy of 
5 ppm.  
Nucleotide exchange and hydrolysis assays  
The rate of GDP dissociation from Ras was measured using 2'-/3'-O-(N'-
methylanthraniloyl)guanosine-5'-O-diphosphate (mantGDP) as previously reported (108, 
109). One micromolar Ras (RasWT, RasSSG, or RasC118S) loaded with mantGDP (BioLog; San 
Diego, CA) was added to 1 mL of degassed assay buffer (50 mM Tris pH 7.4, 50 mM NaCl, 5 
mM MgCl2, 2 mM GDP, and 100 μM diethylenetriaminepentaacetic dianhydride; DTPA), 
and the rate of guanine nucleotide dissociation was measured by monitoring the change in 
fluorescence (excitation: 365 nm; emission: 435 nm; 25˚C) over time using a Perkin Elmer 
LS50B fluorimeter (Waltham, MA). All experiments were performed in triplicate. 
Fluorescent nucleotide dissociation curves were fit to a one-phase exponential decay 
equation using GraphPad Prism version 3.03 (GraphPad Software; San Diego, CA). For 
GEF-induced Ras-GDP dissociation assays, the minimal catalytic domain of Son of Sevenless 
(SOScat) was used at a 1:1 ratio to Ras. This concentration of SOScat was selected as the rate 
enhancement of nucleotide exchange was easy to measure using fluorimetric assays and 
other labs have published using the GEF at this concentration. The SOScat construct (from 
John Kuriyan; University of California, Berkeley) was expressed and purified as previously 
described (110). 
Rates of GTP hydrolysis were determined using a Spectramax M5 (Molecular Devices; 
Sunnyvale, CA) fluorimeter by monitoring phosphate production upon GTP hydrolysis (111). 
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FlipPi 5U (Addgene; Cambridge, MA) was used as the phosphate sensor, and the minimal 
catalytic domain of p120GAP (112) was added to stimulate the rate of Ras GTP hydrolysis. The 
expression, purification, and use of this sensor have been previously reported (113). Briefly, 
all assays used 10 µM FlipPi with 10 µM GTP-loaded Ras. GTP loading was performed as 
previously described (111). Trace phosphate was removed from all buffers using a ‘phosphate 
mop’ (114). The rate of GTP hydrolysis was measured by taking the ratio of the 535- and 485-
nm emission wavelengths (excitation: 435 nm; 25˚C) of kinetic runs performed in triplicate 
and fit to a one-phase exponential association curve. For these experiments, the ratio of GAP 
to Ras was 1:200, and the minimal catalytic domain of p120 RasGAP was used.  
Nitric oxide-induced nucleotide dissociation 
To determine whether addition of nitric oxide to RasWT, RasSSG, and RasC118S alters the 
rates of GDP dissociation, we used the NO• donor DEANO (diethylammonium (Z)-1-(N,N-
diethylamino)diazen-1-ium-1,2-diolate; Alexis Chemicals; Farmingdale, NY). Previous 
studies have shown that NO• in the presence of O2 forms NO2•, which promotes nucleotide 
dissociation in Ras (62). Therefore, all buffers used with DEANO were not degassed and 
were vigorously shaken prior to use. To verify the time-dependent formation of NO• by 
DEANO in our buffers, diaminofluorescein (DAF; Sigma) was used (data not shown). DAF 
displays an increased fluorescence upon exposure to NO• radicals with an excitation 
wavelength of 445 nm and an emission wavelength of 515 nm. All runs were performed in 
triplicate with 1 µM MANT-loaded Ras in assay buffer. DEANO was added at the indicated 
concentrations at the start of each run. Fluorescent nucleotide dissociation curves were fit 
using one-phase exponential decay using GraphPad Prism as described above.  
NMR analysis 
NMR experiments were collected on a Varian Inova 700 MHz spectrometer at 25˚C. 
The 2D 1H–15N heteronuclear single quantum coherence spectroscopy (HSQC) experiments 
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were performed with pulsed field gradient and water flip-back methods as previously 
described (115). Uniformly labeled 15N-enriched Ras was purified as previously described 
(116). 2D 1H-15N HSQC experiments were acquired on 0.8 mM 15N-enriched RasWT and 
RasSSG with 1,024 x 128 complex data points and a spectral width of 8,000 Hz for the 1H 
dimension and 1,709 Hz for the 15N dimension. Buffer contained 10 mM maleate (pH 6.5), 5 
mM MgCl2, 40 mM NaCl, 20 μM GDP, and 10% D2O. NMR data were processed and 
analyzed using NMR PIPE (117) and NMR ViewJ (One Moon Scientific; Newark, NJ). 
Results  
Modification of RasC118 by glutathione  
As RasC118 has been previously identified as the site of oxidative modification by nitric 
oxide (66), we used a combination of top-down and bottom-up MS to confirm that Cys118 is 
the preferred site of glutathiolation. Whereas partial modification of Ras by glutathione was 
obtained at a ratio of 50:1 GSSG to Ras upon incubation for 15 min at pH 8.5 (Figure 3a), 
increasing the GSSG to Ras ratio to 1000:1 resulted in conversion of hRas1-166 to a 
predominantly single glutathiolated form. However, Ras glutathiolation was not observed 
when the redox insensitive RasC118S variant was treated under the same conditions (Figure 
3b). All full-MS and selected-ion monitoring (SIM) scans corresponding to glutathiolated 
RasC118 and redox-insensitive RasC118S are available in supporting data (Fig. S1). We have also 
confirmed the site-specificity of hRas1-166 glutathiolation using top-down HCD-MS/MS of the 
13+ charge state (Fig. S2) and bottom-up identification of surrogate triply charged tryptic 
peptides that constitute Cys118 (Figure 3c-d). The top-down data contain diagnostic neutral 
loss ions corresponding to Cys-glutathionyl and glutathione as well as backbone product 
ions, which suggests that the glutathione moiety is present exclusively on Cys118. In 
concordance with hRas1-166, bottom-up peptide mass spectra show diagnostic neutral loss of 
Cys-glutathionyl and sequence ions that unambiguously localize glutathione on Cys118. Our  
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Figure 3. Mass spectrometry of glutathiolated Ras. 
(a) Intact deconvoluted mass spectrum resulting from the reaction of RasWT with GSSG. The 
major peaks correspond to unmodified and singly glutathiolated Ras. (b) Intact deconvoluted MS 
resulting from the reaction of RASC118S with GSSG. The peak corresponds to unmodified RASC118S. 
Note: The deconvoluted mass spectra in Fig 1 a-b also consist of gas-phase sodium adducts of Ras. 
(c) MS/MS-CID spectrum of a triply charged RASWT peptide glutathiolated at Cys118. The 
glutathione modification is localized at Cys118, and the diagnostic neutral loss of 129 Da 
corresponds to glutathionyl-cysteine [60]. (d) MS/MS-CID spectrum of the unmodified triply 
charged peptide counterpart. Mass spectrometry data collected in collaboration with Harsha 
Gunawardena. 
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mass spectrometry data indicate that RasC118, which is solvent exposed in the structure of 
hRas1-166 (pdb: 1crp), is susceptible to glutathiolation, whereas the two solvent inaccessible 
cysteine residues (Cys51 and Cys80) were unmodified under the tested conditions. 
Glutathiolation of RasC118 does not significantly affect Ras-GDP nucleotide dissociation or 
GTP hydrolysis 
It has previously been observed that peroxynitrite addition to BAECs and VSMCs 
promotes the formation of glutathiolated Ras at Cys118. Moreover, glutathiolation was 
concluded to be an activating modification as the population of activated Ras was also 
glutathiolated (71, 77, 96). As exposure of Ras to peroxynitrite in cells could generate RasC118• 
and RasSSG, it is difficult to distinguish which modification, the thiyl radical or glutathione, 
leads to Ras activity changes under the experimental conditions used. To assess whether 
glutathiolation alters Ras guanine nucleotide binding and/or GTP hydrolysis, we performed 
nucleotide dissociation and GTP hydrolysis assays on unmodified and glutathiolated hRas1-
166 in vitro. As shown in Figure 4a and b, the intrinsic rates of GDP dissociation (kobs) for 
RasWT and RasSSG (Figure 4a-b) were determined to be similar (3.9 ± 0.1×10-5 s-1 vs. 4.7 ± 
0.5×10-5 s-1). As the intrinsic rate of nucleotide dissociation for Ras is slow, interactions with 
GEFs are required to facilitate nucleotide exchange in vivo. Therefore, we measured the rate 
of GDP dissociation in the presence of SOS, a Ras GEF, as previously described (108). When 
the minimal catalytic domain of SOS (SOScat) was added to Ras, the rate of nucleotide 
dissociation for RasSSG and RasWT was similar (18.5 ± 0.5×10-4 s-1 vs. 20.2 ± 0.7×10-4 s-1, 
respectively). 
To determine the effect of glutathiolation on Ras-GTP hydrolysis rates, we measured 
the rate of GTP hydrolysis in the presence and absence of the minimal catalytic domain of 
the Ras-specific GAP, p120GAP (112). For this assay, the phosphate binding protein FlipPi 5U 
was employed as a phosphate sensor. FlipPi binds to free phosphate in solution and has a 
measurable change in fluorescence upon phosphate binding (113). By performing single- 
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Figure 4. Biochemical characterization of glutathione-modified Ras.  
(A) Rates of GDP dissociation were determined for RasWT, RasC118S, and RasSSG (1 μM). 
Nucleotide dissociation kinetic traces in the absence (open symbols) and presence (closed) of the 
GEF SOScat are shown. (B) The relative rates of GDP dissociation (kobs) are presented. (C) 
Representative Ras GTP hydrolysis kinetic traces in the absence (open symbols) and presence 
(closed) of p120RasGAPcat. (D) The relative rates of hydrolysis in the absence and presence of GAP 
are presented. All reactions were performed in triplicate and were fit to a single exponential 
dissociation/association curve using GraphPad Prism, and the error is reported as the standard 
deviation of the replicates. Normalized results are presented for graphical comparison of the 
experiments. The experimental conditions and data analysis for these assays are described in the 
Materials and Methods. 
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turnover hydrolysis assays, the intrinsic rate of GTP hydrolysis for RasWT was determined to 
be 0.6 ± 0.04×10-4 s-1 at 25˚C (Figure 4c-d), similar to previously reported values of 
4.4×10-4 s-1, which were performed at a higher temperature of 30˚C (118). The rates of GTP 
hydrolysis determined using the FlipPi sensor compared to previously reported values, 
indicating that this method is suitable for comparing GTP hydrolysis rates. The intrinsic rate 
of GTP hydrolysis for RasSSG was determined to be ~4-fold slower (0.14 ± 0.06×10-4 s-1) than 
for RasWT. However, as the intrinsic rate of GTP hydrolysis is too slow to be biologically 
relevant and requires catalysis by GAPs in vivo to regulate Ras activity, we measured the rate 
of hydrolysis in the presence of catalytic amounts of p120GAP. The rate of GAP-mediated GTP 
hydrolysis for RasWT and RasSSG were observed to be similar (20.6 ± 2.3×10-4 s-1 and 19.4 ± 
1.7×10-4 s-1, respectively; Figure 4c-d). Thus, glutathiolation of RasC118 does not affect 
p120GAP-mediated GTP hydrolysis.  
Glutathiolation at Cys118 does not perturb Ras structure  
As it was previously suggested that Ras glutathiolation alters the structure of Ras and 
leads to increased nucleotide exchange (71), we glutathiolated 15N-enriched hRas1-166 and 
performed 2D NMR HSQC analyses. A 2D 1H-15N NMR HSQC allows for observation of 
backbone and side chain N-H groups and provides a site-specific probe for every residue in a 
protein aside from proline. An overlay of the RasWT and RasSSG HSQC spectra is shown in 
Figure 5a. Consistent with our MS data that Cys118 is the site of glutathiolation, the amide 
resonance corresponding to Cys118 is perturbed upon Ras glutathiolation, whereas the 
chemical shifts associated with Cys51 and Cys80 are unaltered. Glutathione is a tripeptide 
(Gly-Cys-Glu), and modification of Ras at Cys118 is likely to alter the chemical environment 
(chemical shift) of resonances proximal to the site of modification. As shown in Figure 5a, 
most resonances are unperturbed by glutathiolation of Ras at Cys118. By mapping the 
residues that show chemical shift perturbations (14 peaks with chemical shift differences 
greater than one linewidth, 0.05 ppm in the 1H dimension or 0.4 ppm in the 15N dimension)  
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Figure 5. 2D NMR 1H-15N HSQC comparison of RasWT and RasSSG.  
(A) A 1H-15N 2D HSQC overlay of RasWT (black) with RasSSG (red). The black-labeled 
residues indicate Ras NH resonances associated with residues that shift upon glutathione 
modification (peak shifts greater than 1 linewidth, 0.05 ppm in the 1H dimension or 0.4 ppm in 
the 15N dimension), and the blue-labeled residues correspond to the other two cysteines in Ras 
(Cys51 and Cys80), which do not show amide peak shifts between RasWT and RasSSG. (B) Residues 
corresponding to the NH resonances that show chemical shift changes for RasSSG but not RasSNO 
are highlighted in green on a surface representation of hRas1-166, while residues that show chemical 
shift changes in RasSNO are highlighted in orange. The residues that showed chemical shifts in both 
RasSSG and RasSNO are highlighted in purple. Cys118, the site of modification, is shown in yellow, 
GDP is shown as sticks, magnesium is shown as a red sphere, and Switch I (blue), Switch II (teal), 
and the p-loop (pale blue) are shown for clarity. Surface rendering was generated with PyMol 
using pdb: 1crp. 
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onto the surface of the Ras structure (Figure 5b), only residues proximal to the modified 
cysteine show chemical shift changes. Interestingly, the chemical shift perturbations for 
RasSSG (green in Figure 5B) compared to RasSNO (orange; overlap is shown in purple, Cys118 
in yellow) are similar, and we have previously shown that RasSNO does not alter Ras structure 
(66). Thus, the limited chemical shift changes close to the site of glutathiolation and 
similarity between the HSQC spectra of RasWT, RasSSG, and RasSNO suggest minimal 
structural perturbation by glutathiolation, consistent with our findings that the biochemical 
properties of Ras are unaltered. Furthermore, the residues important for Ras recognition by 
regulatory factors and effectors, including the p-loop (residues 10-17), Switch I, and Switch 
II, do not show chemical shift changes upon glutathiolation. These data are consistent with 
our findings that GEF- and GAP-mediated stimulation of GDP dissociation and GTP 
hydrolysis were unaffected by Ras glutathiolation. 
Glutathiolation impedes redox-mediated nucleotide dissociation  
Previous studies have shown that treatment of Ras with NO2• enhances the rate of 
nucleotide dissociation, whereas nitrosation of Ras at this site prevents radical-mediated 
nucleotide dissociation (69). To determine whether Ras glutathiolation, like nitrosation, 
impedes free radical-mediated dissociation in Ras, the rate of nucleotide dissociation was 
determined using a MANTGDP-dissociation assay in the presence of the NO•-releasing agent 
DEANO (1). As shown in Figure 6a, we observe an enhanced rate of RasWT-GDP 
dissociation in the presence of DEANO (greater than 200-fold faster). In contrast, the rate of 
GDP dissociation for the redox inactive RasC118S variant was insensitive to the presence of 
DEANO. Furthermore, RasSSG was resistant towards DEANO-mediated nucleotide 
dissociation. Although 1 mM DEANO was used in these experiments, only a small fraction 
generates NO2•. DEANO releases NO• with a half-life of 15 minutes at pH 7.0, and NO•, once 
generated, reacts with O2 to generate NO2• (119, 120). Moreover, the estimated dissolved 
oxygen content in aqueous solution is only 250 μM, which limits the amount of NO2• that can  
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Figure 6. MANTGDP nucleotide dissociation assays in the presence of the NO-generating 
agent DEANO.  
(A) RasWT was pre-loaded with MANTGDP and exposed to increasing concentrations of 
DEANO in the absence of unlabeled GDP. All conditions contained 1 μM RasWT and ♦ 250 μM 
DEANO, ▼ 500 μM DEANO, or ♦ 1 mM DEANO added at the start of the experiment. (B) ♦ RasWT, 
* RasC118S, and ○ RasSSG (1 μM) were preloaded with MANTGDP and exposed to 1 mM DEANO. All 
reactions were performed in triplicate and were fit to a single exponential dissociation curve using 
GraphPad Prism. Normalized results are presented for graphical comparison of the experiments. 
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be formed. Thus, our results show that glutathiolation impedes free radical-dependent Ras 
GDP dissociation, whereas glutathiolation does not significantly affect Ras structure, 
activity, or interactions with modulatory proteins. 
Discussion  
A number of studies have reported Ras activity modulation by ROS and RNS (94). 
Most of these studies point to RasC118 as the redox-sensitive site because this cysteine has 
been shown to be oxidized by a number of cysteine-modifying agents and is required for 
redox-mediated regulation of Ras activity (57). Two of the most common oxidative 
modifications identified for Ras in vivo are nitrosation and glutathiolation. We have 
previously reported that radical-mediated nitrosation of Ras leads to increased guanine 
nucleotide dissociation (68), whereas non-radical-mediated nitrosation of RasC118 does not 
affect Ras guanine nucleotide binding (66). Given these observations, we were intrigued by 
reports that glutathiolation of Ras alters Ras activity (71, 77, 96, 100). 
To better understand how Ras activity is modulated by glutathione, we considered 
radical- and non-radical-mediated reactions that can result in Ras glutathiolation. Three 
potential pathways of glutathiolation are presented in Figure 8 (radical-mediated, 8a; and 
non-radical-mediated, 8b and 8c). Earlier reports have suggested that glutathiolation leads 
to Ras activation. For example, the fraction of activated GTP-bound Ras was higher in the 
pool shown to be glutathiolated upon peroxynitrite exposure to BAECs (71) and after 
administration of angiotensin II to VSMCs (77). However, angiotensin II and peroxynitrite 
produce free radicals. Angiotensin II produces ROS through NAD(P)H oxidase activation 
(104, 121), and peroxynitrite can undergo homolysis to generate ROS and RNS. In fact, 
under most physiological conditions, CO2 reacts with peroxynitrite to generate CO3•- and 
NO2• byproducts in fairly high yields (>30%) (75, 76); in addition, under acidic conditions, 
peroxynitrite can undergo proton catalyzed homolysis to form HO• and NO2• (74). An  
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Figure 7. Effect of oxidized glutathione on nucleotide binding in Ras. 
mantGDP dissociation measured for RasWT (♦) and RasC118S (▲) in the presence of 100 μM 
GSSG (closed symbols) and in the presence of SOScat (open symbols). mantGDP nucleotide 
dissociation was performed as described; however, no unlabeled GDP was present and 100 μM 
oxidized glutathione was added to the reaction cuvette. All reactions were performed in triplicate 
and were fit to a single exponential dissociation curve using GraphPad Prism. Error bars have 
been removed for clarity. Ras and RasC118S with 1 µM GEF are shown for comparison. Normalized 
results are presented for graphical comparison of the experiments. 
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important consideration that must guide in vitro experimentation with peroxynitrite is that 
in the absence of CO2, peroxynitrite reacts directly with many biochemical targets, 
particularly thiols. This oxidative reaction produces predominately non-radical 
oxidativeproducts and is faster than its homolysis to HO• and NO2•. Therefore, peroxynitrite 
reactions are heavily context dependent. Importantly, given the high glutathione 
concentration in cells, once peroxynitrite is decomposed and the free radical chain reactions 
are completed, glutathiolated Ras will predictably be a major end product that is 
indistinguishable by all means from the end product produced directly by the reaction of 
oxidized glutathione with RasWT. Therefore, we postulate that the exogenous addition of 
peroxynitrite and angiotensin II promotes Ras thiyl radical-mediated oxidation of the bound 
guanine nucleotide, leading to Ras activation. Further, the resulting thiyl radical can react 
with glutathione to produce RasSSG•, which aerobically decays to RasSSG and O2•-. This route 
of activation is shown in Figure 8A, and based on our analysis, is the likely pathway of 
glutathiolation that would result in Ras activation in vivo. Interestingly, Ras glutathiolation 
appears to protect Ras from further free radical-mediated events. We evaluated guanine 
nucleotide binding of RasWT, RasC118S, and RasSSG in the presence of the NO-releasing agent 
DEANO. In these experiments (Figure 6), glutathiolated Ras was protected from free 
radical-mediated nucleotide dissociation. Therefore, glutathione, which likely modifies Ras 
after an initial activating event, could protect Ras from over-oxidation in cells under 
conditions of oxidative stress.  
The other potential pathways of Ras glutathiolation shown in Figure 8 are unlikely to 
lead to Ras activation (Figure 8b and 8c). To demonstrate this, we generated glutathione-
modified Ras through a non-radical-mediated pathway by treating Ras with oxidized 
glutathione (Figure 8b), which glutathiolates Ras at Cys118, and find that neither the 
intrinsic or regulator (GEF/GAP)-mediated rates of guanine nucleotide dissociation and 
hydrolysis are altered (Figure 4). However, as the cellular concentration of oxidized 
35 
glutathione is generally quite low (GSH:GSSG ratio in cells is >100:1) (122) and the reaction 
rate slow, this is an unlikely pathway of Ras glutathiolation in cells. To experimentally 
validate the role of glutathione on nucleotide exchange, we exposed RasWT and RasC118S to 
oxidized glutathione (similar to the pathway presented in Figure 8b) and found that Ras 
guanine nucleotide binding was not affected by the presence of oxidized glutathione (Figure 
7). While this data appears contradictory to the results described by Clavreul et al (71), 
identical levels of Ras nucleotide dissociation were observed, which was approximately 5% of 
the bound nucleotide after 300 s. In our experiments, we also tested RasC118S and observed 
identical levels of nucleotide dissociation, indicating that glutathione does not promote 
guanine nucleotide release from Ras. We also present GEF-induced dissociation of RasWT 
and RasC118S within Figure 4 to highlight the difference in GSSG-mediated dissociation and 
GEF-mediated dissociation. Furthermore, as the experimental conditions used in Clavreul et 
al (71) were not conducive to peroxynitrite-mediated radical formation [7], glutathiolation is 
unlikely to result in Ras activation. Thus, results from this study do not support Ras activity 
modulation due to the presence of the glutathione moiety on Ras. 
Seemingly in direct contradiction with our results, Adachi et al observed that 
overexpression of glutaredoxin-1 (GRX-1) in VSMCs inhibited Ras glutathiolation and 
activation upon stimulation with peroxynitrite (77). However, overexpressed redox proteins 
can have profound effects on the cellular oxidation state, and it has been previously shown 
that downregulation of GRX-1 can sensitize lens epithelial cells to oxidative stress-induced 
apoptosis (123). Moreover, overexpression of GRX-1 protects against doxorubicin-induced 
cell death (124, 125), which mediates cell death through increased oxidative stress (126). 
Therefore, overexpression of GRX-1, as in Adachi et al, likely decreased the level of oxidative 
stress, which would result in reduced Ras activation by radical-mediated oxidation. 
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Figure 8. Modification of Ras by glutathione can proceed by three different mechanisms.  
In pathway A, redox agents capable to generating a Ras thiyl radical can induce radical formation 
on RasC118; electron transfer results in guanine-radical formation, guanine-base oxidation, and 
release of the oxidized base from Ras. Given the ratio of GTP/GDP in cells (~10:1), release of GDP 
promotes GTP binding. Free radical-induced oxidation leaves Ras in the thiyl anion form, which is 
more reactive to oxidation and can result in glutathione modification. In pathway B, Ras can react 
with oxidized glutathione through disulfide exchange to form glutathiolated Ras. Given the slow 
rate of this reaction and concentration of GSSG in cells, this pathway is unlikely to have a large 
contribution to Ras glutathiolation in vivo. In pathway C, Ras is oxidized by a non-radical oxidant, 
such as H2O2, which results in sulfenic acid formation at RasC118. Sulfenic acids are an 
intermediate step in disulfide bond formation; therefore, this form of Ras can interact with 
reduced glutathione to form glutathiolated Ras. However, RasSSG formed by non-radical means 
does not affect guanine nucleotide binding, nucleotide hydrolysis, or Ras activation. Thus, Ras 
activation and glutathiolation likely occurs in cells by reaction of Ras with thiyl radical-generating 
agents (pathway A), which promotes activation through nucleotide dissociation and GTP binding. 
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Another possible reaction pathway to consider is shown in Figure 8c. As disulfide 
bond formation generally proceeds through a sulfenic acid intermediate, it is possible that 
oxidation of Cys118 to a sulfenic acid will lead to RasSSG formation in the presence of reduced 
glutathione, which is present at a high levels in cells (GSH:GSSG ratio in cells is >100:1). 
Asthis pathway does not generate radical intermediates, we postulate that it is unlikely to 
alter Ras activity. While the products of angiotensin II or peroxynitrite exposure to cells can 
lead to Ras glutathiolation by the pathway presented in Figure 8c; the relative rate of 
oxidation is likely too slow to be physiologically relevant. It is more likely that glutathiolation 
occurs through radical-mediated interactions in cells. However, as Ras glutathiolation can 
proceed through pathways that do not alter Ras activity, it is difficult to use Ras 
glutathiolation as a marker of Ras activity regulation unless Ras radical formation can be 
detected coincident with Ras glutathiolation.  
Conclusions 
We have previously shown that NO2• can increase the rate of nucleotide dissociation in 
Ras and that modification of Ras by NO• renders Ras less sensitive to radical-mediated 
oxidation (66). Consistent with these observations, RasSSG does not affect the structure or 
activity of Ras. When considering the faster reaction rates of radical vs. non-radical-
mediated cysteine oxidation, we postulate that activation mediated through oxidation of Ras 
in vivo occurs through the formation of a Ras thiyl-radical intermediate (Figure 8). The Ras 
thiyl radical can promote Ras activation under appropriate redox conditions by facilitating 
nucleotide exchange and can react with NO• or GS• radicals to form RasSNO or RasSSG 
(Figure 8). While these end products do not alter Ras guanine nucleotide binding or 
hydrolysis, they impede Cys118 from engaging in further free radical-mediated reactions. 
Therefore, we postulate that coincident detection of Ras glutathiolation and activation 
results from Cys118 thiyl radical-mediated oxidation of the guanine base and GDP release. 
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Supplemental Figure 1. Intact mass spectra resulting from the reaction of RasWT and 
RasC118S with GSSG.  
(a) ESI-SIM scan of 15+ Ras. (b) ESI-SIM scan of 15+ RasSSG. (c) ESI-Full MS scan of 
unmodified and singly glutathiolated RasWT. (d) ESI-SIM scan of 15+ RasSSG. (e) ESI-Full MS scan 
of RasSSG. Mass spectrometry data collected in collaboration with Harsha Gunawardena. 
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Supplemental Figure 2. Detection of glutathiolated Ras at Cys118. 
(a) HCD-MS/MC spectrum of z=13+ glutathiolated RasWT with inset showing neutral loss 
of ions corresponding to cys-glutathionyl and glutathione (GSH). (b) Sequence ions mapped to the 
theoretical sequence of the Cys118 glutathiolated Ras constructs. The sequence ions b63, b100, 
b107, and (b134+GS) were used to localize the single glutathione exclusively on Cys118. (Note that 
Ras constructs contained two additional residues on the N-terminus that were ignored in the 
positional annotation of cysteine residues of Ras. Mass spectrometry collected in collaboration 
with Harsha Gunawardena. 
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Chapter 3: Characterization and Nitrosation of Oncogenic K-RasG12C 
Introduction 
Ras GTPases are part of the Ras superfamily of GTPases, which play a major role in 
many cellular signaling pathways, including gene expression, cell growth, transport, and 
apoptosis (84). These proteins function as molecular switches by cycling between the active 
GTP- and inactive GDP-bound states to regulate activity. Ras alternates between the GTP-
bound and GDP-bound forms through regulation by GTPase activating proteins (GAPs) and 
guanine nucleotide exchange factors (GEFs). GAPs bind and stimulate GTP hydrolysis to 
GDP, which inactivates the GTPase, whereas GEFs promote activation by facilitating the 
exchange of GDP for GTP (127). 
Mutations to Ras family proteins account for approximately 30% of all oncogenic 
mutations (128). There are three isoforms of Ras in the cell, H-Ras, N-Ras, and K-Ras. 
However, K-Ras is the most frequently mutated isoform in cancer (128). Oncogenesis due to 
Ras most commonly arises from single mutations at Gly12, Gly13, and Gln61. Gly12 and Gly13 
are within the phosphoryl binding loop (p-loop), a structural motif in Ras to interacts with 
the phosphate moieties of the bound nucleotide. Gln61 functions as the catalytic residue of 
GTP hydrolysis and serves as the catalytic base in cleavage of the γ phosphate of GTP (90). 
Mutations to these specific residues often result in loss of GAP sensitivity and constitutive 
activation (93, 129). For K-Ras, the majority of the mutations occur at Gly12 and account for 
the majority of mutations in lung and pancreatic cancers; the most common Gly12 mutations 
in K-Ras are K-RasG12C, K-RasG12D and K-RasG12V (128, 130).  
Ras has been shown to be susceptible to oxidation by small molecule oxidants, which 
induce nucleotide dissociation and activate Ras (57). Ras GTPases are sensitive to free 
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radical oxidation; in vivo, this can occur by interaction with various reactive nitrogen and 
oxygen species (RNS, ROS), which are often produced by enzymes such as nitric oxide 
synthases (NOS) and NADPH oxidases. In the cell, endothelial NOS (eNOS) specifically 
catalyzes NO• synthesis, which promotes Ras activation through the reaction of Cys118 (63). 
The free radical NO2• has been shown to react with the thiol of Cys118 and produce a thiyl 
radical (RS•), which likely results in degradation of the base and nucleotide dissociation (62, 
67). The redox sensitivity and importance of Cys118 was further confirmed from the 
characterization of the variant RasC118S, which was found to be insensitive to oxidants but 
otherwise behaved identically as RasWT (21). 
The RasG12C mutation, which is common in lung cancer, places a thiol in the p-loop of 
Ras. Thus, given the reactivity of Cys118 to oxidants and the altered redox environment in the 
lung, it was proposed that RasG12C may be redox sensitive. Toward this end, K-Ras was 
modified with the fluorophore ABD-F (4-fluoro-7-aminosulfonylbenzofurazan), which 
preferentially interacts with the thiolate state, and was used in a pH screen to determine the 
pKa of the thiol of RasG12C. RasG12C was s-nitrosated using nitric oxide and CysNO, a non-
radical nitrosating agent, to determine the effects of oxidation at this cysteine. Further, while 
all mutations at Gly12 are predicted to decrease GAP sensitivity, RasG12C has not been studied. 
Therefore, we investigated the GAP sensitivity of RasG12C to the catalytic domains of RasGAP 
and NF1, two Ras-specific GAPs. The stability and secondary structure of native K-Ras and 
K-RasG12C was analyzed using circular dichroism (CD) spectroscopy. In addition, we 
performed NMR spectroscopy to determine whether RasG12C showed an altered structure 
from other oncogenic Gly12 mutants, such as RasG12D. We found that K-RasG12C has an altered 
pKa and was susceptible to free radical and two-electron oxidation. Gly12 mutants were also 
reaffirmed to have reduced sensitivity to GAPs, and the structure of RasG12C was not 
significantly altered when compared to other Gly12 mutants. 
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Methods 
Purification of Ras proteins 
Protein purification was performed exactly as previously described (131). K-Ras was a 
gift of Genentech and is in the pET52b vector, which contains a 6x-His purification tag and a 
TEV (tobacco etch virus) protease site to remove the His tag. This vector was expressed in 
BL21 (DE3) Rosetta 2 pLysS cells, purified following the Qiagen nickel NTA purification 
protocol, and verified by SDS-PAGE.  
ABD-F modification assays 
ABD-F modification buffer (15 mM MES [(2-(N-morpholino)ethanesulfonic acid], 5 
mM MgCl2, 30 mM NaCl, 200 µM DTPA, pH 8.0) was prepared with 10 mM dithiothreitol 
(DTT). An Amicon centricon was used to buffer exchange K-Ras and the protein was reduced 
for 30 minutes on ice. At the same time, ABD-F modification buffer without DTT was 
sparged with N2 gas to remove dissolved oxygen. The protein was exchanged into this buffer 
to remove DTT from the sample prior to reaction with ABD-F.  
In a black 96-well plate, 20 µM K-Ras was added in 100 µL of reaction buffer (100 mM 
MES, 100 mM HEPES, 5 mM MgCl2, 200 µM DTPA) with a pH that was predetermined. To 
a separate plate, ABD-F was added to 2 mM in 100 µL of reaction buffer at the same pH as 
the corresponding well in the original plate. Using a multi-channel pipette, ABD-F was 
added to the K-Ras plate to start the reaction. The fluorescence of the reaction was 
monitored using a Spectramax M5 plate reader over a pH range of 5.8 to 8.5. The excitation 
wavelength for ABD-F is 389 nm, and the emission wavelength is 513 nm.  
Nucleotide exchange and hydrolysis assays 
K-Ras was loaded with mantGDP (2’-/3’-O-(N’-methylanthraniloyl)-GDP) for nucleotide 
exchange as previously described (108, 109, 131). K-Ras was added to 1 µM in 1 mL of 
exchange buffer, and the rate of nucleotide dissociation was determined by monitoring the 
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change in fluorescence of the mantGDP-loaded protein (excitation wavelength of 365 nm, 
emission wavelength of 435 nm) using a fluorimeter. 
The nitrosating agent CysNO was generated for usage in the dissociation assays by 
reacting 100 µL of 50 mM L-cysteine (in 0.2 M HCl) with 100 µL of 50 mM NaNO2. The 
reaction was allowed to proceed in the dark for 10 min, after which 20 µL of 40 mM 
ammonium sulfamate was added to remove any unreacted nitrate. After allowing 2 min for 
the reaction to quench, the CysNO solution was diluted to 1100 µL with 100 mM Hepes, 5 
mM MgCl2, and 1 mM DTPA (pH 7.5) to neutralize the acidic pH and remove free metal ions 
aside from Mg2+ (132). The concentration of CysNO was determined from an absorbance 
measurement taken at 336 nm (ε = 900 M-1cm-1). 
The reactions with RNS were performed with either CysNO or DEANO NONOate 
(diethylammonium(Z)-1-(N,N-diethylamino)dia-zen-1-ium-1,2-diolate). DEANO was added 
in an excess of 40:1 to the protein to induce nucleotide dissociation by free radical oxidation. 
Nucleotide dissociation assays with CysNO were performed with 100:1 CysNO to induce 
modification by two-electron/non-radical oxidation. The addition of the oxidants was 
performed in the presence of 2 mM unlabeled GDP.  
GTP hydrolysis assays with K-Ras were performed as previously described (111, 133) 
using FlipPi (Addgene; Cambridge, MA, USA) as the phosphate sensor (113). K-Ras (10 µM) 
was loaded with GTP and used with 10 µM FlipPi. Trace phosphates were removed from all 
reaction components to minimize background fluorescence. The rate of hydrolysis was 
determined from the fluorescence ratio of the emission wavelengths at 535 and 485 nm with 
an excitation wavelength of 435 nm as previously described (113).  
Circular dichroism (CD) spectroscopy 
Circular dichroism data were collected on a JASCO J-815 CD spectrometer with a 
JASCO Peltier device and water bath to control the temperature. Experiments were 
performed in a 1-mm cuvette at a protein concentration of 15 μM in 10 mM Tris, 1 mM 
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MgSO4 (pH 7.45) and 10 μM GDP. Far UV scans were from 200 nm to 250 nm. Thermal 
denaturation of RhoA and the selected variants were monitored at a 221 nm to estimate the 
protein melting temperature. The temperature ramp rate was 1˚C/min and data points were 
collected every 1˚C. All data are reported in units of mean residue ellipticity, which was 
calculated as follows:[θ]MRE=(θraw×MRW)/(10×c×l), where θraw is the ellipticity in degrees, 
MRW is (Molecular Weight (Da))/((no.of residues)-1), c is the protein concentration in g/ml, 
and l is the pathlength of the cuvette in cm, according to (134). For nitrosated Ras, Ras was 
reacted with 50× CysNO for 10 min, which was prepared as previously stated, prior to 
performing the CD analysis. 
NMR analysis 
NMR experiments were collected on a Varian Inova 700 MHz spectrometer at 25˚C. 
The 2D 1H–15N heteronuclear single quantum coherence spectroscopy (HSQC) experiments 
were performed with pulsed field gradient and water flip-back methods as previously 
described (115). Uniformly labeled 15N-enriched Ras was purified as previously described 
(116). 2D 1H-15N HSQC experiments were acquired on 0.8 mM 15N-enriched RasWT and Ras 
mutants with 1,024 x 128 complex data points and a spectral width of 8,000 Hz for the 1H 
dimension and 1,709 Hz for the 15N dimension. Buffer contained 10 mM maleate (pH 6.5), 5 
mM MgCl2, 40 mM NaCl, 20 μM GDP, and 10% D2O. NMR data were processed and 
analyzed using NMR PIPE (117) and NMR ViewJ (One Moon Scientific; Newark, NJ). 
Results 
The thermal stability of K-RasG12C is not altered 
As shown in Figure 9A, the CD spectra for K-RasG12C shows that there were no 
significant changes in the secondary structure of oncogenic K-Ras. Interestingly, the 
modification of the protein with CysNO does not influence the overall secondary structure of 
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the protein. To avoid modification at Cys118, all mutations were performed in the K-RasC118S 
background. Thus, all proteins are in the context of additional mutations beyond RasC118S. 
The thermal denaturation study indicates that there is no significant loss in overall protein 
stability resulting from the K-RasG12C mutant or s-nitrosation (Figure 9, Table 1). 
Furthermore, modification by CysNO resulted in a slightly increased thermodynamic 
stability compared to K-RasWT and K-RasG12C; however, the increased stability was not 
significant. 
K-RasG12C has an altered pKa 
Figure 10 shows that K-RasG12C is susceptible to modification by ABD-F in a pH-
dependent manner. Figure 10B shows that there is a shift in the pKa of K-RasG12C with 
respect to K-RasWT. The pKa for K-RasG12C and H-RasG12C was found to be ~7.5; however, the 
pH screen used for the ABD-F assay did not extend far enough to allow for the pH plot of K-
RasWT to reach a plateau. As Ras has been shown to be unstable above pH 8.5, it was not 
possible to determine the pKa of Cys118. However, this cysteine is not predicted to have an 
altered pKa as it is solvent accessible and has no intra-protein contacts.  
K-RasG12S was used as a negative control for this experiment. Aside from Cys118, K-Ras 
has two other cysteine residues; however, these sites are not solvent accessible and are 
unlikely to be modified during reaction with ABD-F. Thus, mutation at Gly12 in combination 
with C118S results in only G12C modification by ABD-F, an observation that was further 
determined using mass spectrometry (data not shown). This is clearly shown from the 
superimposed ABD-F plot of K-RasG12S in Figure 10A. This analysis confirmed that ABD-F 
modification was specific to residue 12 in K-RasG12C as modification was not observed in K-
RasG12S. 
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Figure 9. CD spectroscopy of K-RasWT and K-RasG12C. 
(A) Far-UV CD scan of K-Ras. K-Ras was used at 25 µM. The raw data was used to calculate the 
mean residue ellipticity (ϴ) for each protein sample.(B) The thermal stability of K-Ras. Each curve 
was normalized to total % of protein unfolding. The data were fitted to a Boltzmann sigmoidal 
curve to determine the melting temperature, which corresponds to the protein’s respective Tm 
(melting temperature). 
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  Table 1. Tm of K-Ras determined by CD spectroscopy 
Protein Tm 
K-RasWT 64.51°C 
K-RasWT + CysNO 65.73°C 
K-RasG12C 67.12°C 
K-RasG12C + CysNO 67.83°C 
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Nitrosation of K-RasG12C 
It is important to note that although Ras is specifically sensitive to radical oxidation (21, 62), 
the rates of dissociation shown here cannot be directly compared for computational 
purposes for several reasons. As shown in Figure 11, the amount of CysNO and DEANO 
added to react with K-Ras were not identical, so equimolar reactions did not occur. In 
addition, DEANO is initially slower to modify K-Ras than CysNO because it must first 
decompose and recombine with O2 in solution to form NO2• that can oxidize G12C. As shown 
in Figure 11, modification at G12C by RNS (CysNO and DEANO) causes complete loss of 
mantGDP fluorescence over the course of the reaction. The ratios of oxidant to protein were 
selected to ensure complete modification of K-Ras on an appropriate timescale. Higher and 
lower ratios of oxidant to protein were also tested; however, the ratios plotted here were 
sufficient in showing a moderate rate of modification.  
After completion of the NO reaction, DTT was added in equimolar concentrations to 
the CysNO/DEANO reaction cuvettes to reduce the protein to determine whether the 
reaction was reversible (resulting in nucleotide re-binding). This additional step resulted in a 
60-70% recovery of fluorescence in the CysNO and DEANO reactions. However, because 
these assays were performed with an excess of GDP present in the solution (about 1000:1 
excess GDP compared to mantGDP), a fluorescence recovery of this magnitude should not be 
expected as this implies that K-Ras is selectively rebinding with the released mantGDP.  
Mutations at Gly12 result in a loss of GAP-mediated hydrolysis 
Intrinsic and GAP-mediated GTP hydrolysis rates are shown Figure 12. Results from 
these analyses confirm that mutations at position 12 impair the rate of GAP-mediated GTP 
hydrolysis. At ratio of GAP:Ras that resulted in catalytic GTP hydrolysis in RasWT, we 
observed minimal increase in the rate of hydrolysis with Gly12 mutants, which is consistent 
with the current model on GAP-mediated hydrolysis (112). Although RasG12C had not been 
tested before, this mutation, as likely with all mutations at Gly12, effectively make K-Ras 
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Figure 10. Nitrosylated K-Ras and nucleotide binding. 
(A) CysNO modification of K-Ras. K-Ras was preloaded with mantGDP and added to the 
cuvette at 1 µM. CysNO was added at a final concentration of 100× to the reaction cuvette at the 
start of the experiment. (B) Oxidation of K-RasG12C with DEANO. DEANO was added at a final 
concentration of 40 µM. DTT was added to the reaction cuvette after 1200 s to reduce nitrosylated 
Ras. All reaction were performed in the presence of 2 mM GDP at pH 7.4. mantGDP fluorescence 
was measured as previously described. 
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Figure 11. Nucleotide exchange and hydrolysis kinetics of RasG12C and RasG12S. 
(A) Rates of GDP dissociation were determined for RasWT, RasG12S, and RasG12C (1 μM). 
Nucleotide dissociation kinetic traces in the absence (closed symbols) and presence (open) of the 
GEF SOScat are shown. GEF-mediated dissociation rates for the Gly12 mutants were approximately 
2-fold slower compared to RasWT. (B) Representative Ras GTP hydrolysis kinetic traces in the 
presence (open symbols) and absence (closed) of p120RasGAPcat. All reactions were performed in 
triplicate and were fit to a single exponential dissociation/association curve using GraphPad 
Prism, and the error is reported as the standard deviation of the replicates. Normalized results are 
presented for graphical comparison of the experiments. The experimental conditions and data 
analysis for these assays are described in the Materials and Methods. 
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Figure 12. NMR analysis of Ras position 12 mutants. 
(A) HSQC spectra of RasWT (black) overlaid with RasG12C (red) and RasG12D (yellow). All 
proteins were 15N-enriched and data collection was at 0.8 mM protein. Figure was prepared with 
NMRViewJ. Numbering represents the RasWT assignments. (B) RasG12D (pdb 1AGP) crystal 
structure shown for reference. The nucleotide is shown in colored sticks, Mg2+ is a red sphere, 
switch I is shown in cyan, switch II is in purple, and the p-loop is in brown. (C) The RasG12D crystal 
structure with residues showing a chemical shift in RasG12C HSQC spectra plotted on the structure 
in red (peak shifts greater than 1 linewidth, 0.05 ppm in the 1H dimension or 0.4 ppm in the 15N 
dimension). The RasG12D residue is shown in pink sticks. 
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GAP-dead.  
HSQC analysis of RasG12C shows minimal chemical shifts 
As the RasG12C structure has not been reported, we wished to determine whether the 
structure of this mutant was significantly different from other Ras mutants. However, as 
many Gly12 mutants have been solved, including RasG12D (135), RasG12V (136), and RasG12P 
(135), we opted against determining yet another Ras structure. Instead, we analyzed the 2D 
HSQC data of Ras and two variants, RasG12C and RasG12D, to determine whether the RasG12C 
variant was likely to have a significantly different structure. As the RasG12D structure had 
been previously determined, this mutant was used to compare the chemical shifts of a 
mutant with a structure known to be similar to RasWT. Thus, the data show that mutation of 
RasG12C has a similar spectra to RasG12D, which was expected, and helps confirm that the 
RasG12C mutant does not have a significantly altered structure. 
Discussion 
Activating mutations in Ras lead to the development of cancer in humans. Mutations 
at positions 12, 13, and 61 alter GAP-mediated nucleotide hydrolysis, which leads to Ras 
activation in cells. Gly12 mutants are present in developmental disorders, such as Costello 
syndrome and Cardio-facio-cutaneous (CFC) syndrome (137), and have been associated with 
an increased occurrence of tumorigenesis. Mutations at this site lead to non-small cell lung 
cancer occurring in 30-50% of human lung cancer patients (138, 139) and any mutation at 
this position (except proline) leads to Ras activation (140, 141).  
According to the model put forth by Scheffzek et al on GAP-mediated hydrolysis, 
mutations at position 12, 13, and 61 all interfere with GAP-mediated hydrolysis by steric 
clashes. The mutations prevent the arginine finger of the GAP from aligning the γ phosphate 
for hydrolysis. Specifically, at position 12, the model suggests that any mutation would lead 
to steric clashes and prevent nucleotide hydrolysis (112). This model is supported by data 
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that shows that RasG12A , in addition to other Gly12 mutants, is resistant to GAP-mediated 
hydrolysis (142). Therefore, one would expect all Gly12 mutations to show similar phenotypes 
in vivo. However, various mutations found at Gly12 lead to different levels of Ras activation, 
for example, the RasG12C substitution is less transforming than the RasG12D mutation, but 
both variants are associated with poor patient survival (143). In murine lung cancer studies, 
lesions harboring Val12 or Asp12 mutations were more likely to progress to adenocarcinomas 
than the Cys12 mutants (143, 144). However, increased expression of the RasG12C in mice 
displayed a higher occurrence of hyperplasia and adenomas (138).  
Redox agents have been shown to modulate Ras superfamily GTPases at the NKCD 
motif (62, 69, 84, 86, 145-148). In particular, ROS and RNS activate Ras superfamily 
GTPases by increasing the rate of nucleotide exchange (65, 68, 80, 149, 150). ROS and RNS 
activate select redox-sensitive GTPases by reacting with the thiol of a solvent-accessible 
cysteine residue. Distinct from the NKCD motif in Ras (78), Rho GTPases contain a redox-
sensitive cysteine at the end of the p-loop (GXXXXGK(S/T)C) (151-153). RasG12C is located in 
the p-loop similarly to Rho GTPases and given their redox reactivity, we hypothesized that 
the RasG12C mutant results in the generation of a new redox-sensitive cysteine that may alter 
the interaction with modulatory proteins (i.e., GAP proteins) and oxidants compared to 
other Gly12 mutants.  
Ras Gly12 mutants have been shown to have varying phenotypes in tumors, with tumor 
aggressiveness being RasG12V>RasG12D>RasG12C (154, 155). The RasG12C mutant introduces a 
thiol into the p-loop of Ras, which could potentially generate an oncogenic variant with a 
redox-sensitive thiol. We used the thiolate-specific compound ABD-F to measure the 
reactivity of the thiol in RasG12C/C118S. In these experiments, we used the RasC118S variant to 
detect only the RasG12C thiol. As the RasC118S variant has no reactivity to ABD-F, it was 
determined that the fluorescence observed in the ABD-F pKa assay was the result of RasG12C 
modification. From this study, we determined that RasG12C has an altered pKa of ~7.5 
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(Figure 10). As a free cysteine in solution has a pKa of ~8.5, this pKa indicates that RasG12C 
has an altered pKa and is solvent accessible, which are two requirements for a thiol to be 
redox sensitive. 
To test the reactivity of RasG12C to oxidants, we treated mantGDP-loaded RasG12C with 
CysNO and NO• from DEANO (Figure 11). Exposure to both nitrosation agents resulted in a 
rapid and complete loss of mantGDP fluorescence. As it has been surmised that RasG12V is 
more oncogenic than RasG12D because of steric repulsions between the aspartate residue and 
negatively charged phosphates (156), we postulated that the loss of mantGDP fluorescence was 
due to the presence of negatively charged oxygen on nitric oxide decreasing the binding 
affinity for the nucleotide.  
However, the loss of fluorescence from modification of K-Ras upon addition of 
CysNO/DEANO may be the result of a conformational change in the protein and does not 
effect nucleotide binding. This hypothesis is supported by the reduction the Cys-NO bond 
using DTT after treatment with both oxidants. After treatment with NO in the presence of 
1000× unlabeled GDP, the addition of DTT and the reduction of the nitroso-thiol should 
result in a minimal gain of mantGDP fluorescence. However, we observed nearly 70% of the 
fluorescence due to mantGDP return, which indicates that the mantGDP never dissociates from 
the GTPase. The mantGDP fluorescence may have been quenched by the modification with 
NO. This conformational change may have altered the effective environment that the 
fluorophore experiences without changing the secondary structure (Figure 9), thereby 
changing the observed fluorescence. Further experimentation will be needed to determine 
the reason behind the loss of fluorescence and what changes result from NO modification. A 
proposed test to investigate this behavior will be to modify K-Ras with each respective RNS 
and examine the protein for any changes in structure or the dissociation of bound nucleotide 
with mass spectrometry or x-ray crystallography. 
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In summary, we have shown that K-RasG12C is a thermodynamically stable mutant and 
mutation does not effect protein structure. The RasG12C mutation resulted in a lowered pKa 
for the thiol, which is likely to be reactive to RNS and ROS under physiological conditions. 
The RasG12C mutation has been shown to be modified by nitric oxide in vitro; however, the 
physiological consequences of this modification are not currently understood. Further 
experiments to examine the structural changes to K-Ras because of nitric oxide modification 
will be performed to determine the exact source of the fluorescence change and to what 
extent nitrosation effects nucleotide binding.  
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Chapter 4: Oxidation of RhoA at Cys20 regulates nucleotide binding 
Introduction 
RhoA is part of the Rho family of GTPases, which comprise a distinct subclass of Ras 
GTPases. Rho family GTPases regulate pathways involved in cell growth, differentiation, cell 
death (145, 157, 158), regulation of cell morphology and motility through cytoskeletal 
rearrangements (159-163). Rho GTPases behave as molecular switches and cycle between 
the GTP-bound ‘on’ and GDP-bound ‘off’ states. Like most Ras superfamily GTPases, Rho 
GTPases have regulatory proteins that catalyze nucleotide exchange (guanine nucleotide 
exchange factors; GEFs), which activate the GTPase, and GTP hydrolysis (GTPase 
accelerating proteins; GAPs), which deactivate the GTPase by hydrolyzing GTP to GDP. In 
addition, Rho GTPases are bound to guanine dissociation inhibitors (GDIs) when in the 
GDP-bound state, which sequesters the GTPase from the membrane and maintains the 
inactive state.  
In addition to protein regulatory factors, select Ras family GTPases have been shown 
to be regulated by reactive oxygen and reactive nitrogen species (ROS and RNS, respectively) 
(164). The role of reactive species (RNS, ROS) in regulating Ras superfamily GTPases is best 
characterized for the Ras subclass, where select free radical oxidants have been shown to 
induce nucleotide dissociation through a redox-sensitive motif at Cys118 (67, 69). In contrast 
to Ras GTPases, Rho GTPases contain a distinct redox-sensitive motif in the phosphoryl-
binding loop (p-loop; GXXXXGK(S/T)C20). Nearly 50% of Rho GTPases contain a cysteine 
immediately adjacent to the p-loop. In addition, many Rho GTPases, including RhoA, RhoB, 
and RhoC, possess a second cysteine within the p-loop motif (GXXC16XGKTC20), which 
makes these GTPases susceptible to internal disulfide bond formation and inactivation. Free 
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radical-mediated oxidants, such as nitrogen dioxide (NO2•) and superoxide (O2•-), have been 
shown to induce nucleotide dissociation in Rho GTPases by directly reacting with the redox-
sensitive cysteine (79). In addition, it has been shown that exposure to non-radical oxidants, 
such as H2O2, can effect nucleotide binding as well as increase the rate of nucleotide 
exchange (79), presumably due to perturbation of the nucleotide binding pocket. As the 
cellular GTP concentration is approximately 10-fold greater than GDP, events that increase 
the rate of nucleotide exchange will populate the GTPases in the active, GTP-bound state. 
Thus, oxidation of these cysteines in Rho family GTPases has been shown to effect 
nucleotide binding and activation.  
In addition, the p-loop has been shown to be critical for Mg2+ and nucleotide binding 
(165). From the crystal structure, many residues within the p-loop make direct interactions 
with the bound nucleotide. Furthermore, Mg2+ has been shown to stabilize nucleotide 
binding and play a role in GEF-mediated nucleotide exchange (166). While the Kd of RhoA 
for GDP and GTPγS do not vary greatly with and without Mg2+, the koff rate of nucleotide 
dissociation is greatly enhanced in the absence of Mg2+. Therefore, Mg2+ is considered a 
gatekeeper of nucleotide binding. Thus, oxidation of Cys20 and Cys16 could mediate effects 
on RhoA activity by regulating Mg2+ binding. 
RhoA has been shown to be activated and deactivated by ROS/RNS in cell-based 
experiments (81, 83, 167), which has complicated observations of RhoA function due to 
oxidants. While activation is likely due to oxidation of Cys20 and increasing the rate of 
nucleotide dissociation (79), deactivation likely occurs because RhoA possesses two 
cysteines within the p-loop (Cys16 and Cys20) that can form a disulfide (80, 83). However, 
many of these studies have not discriminated between direct and indirect oxidation nor have 
these studies determined the oxidative modification. Further, the use of exogenous oxidants 
and non-physiological concentrations of oxidants have made interpretation of these data 
difficult.  
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We have previously shown that exposure of RhoA to NO2• in vitro promotes disulfide 
formation and occludes nucleotide binding (80). Consistent with this observation, RhoA 
shows decreased GTP binding when exposed to the nitric oxide-generating species PAPA-
NONOate in vascular smooth muscle cells (167). In this study, it was shown that RhoA was s-
nitrosated using a nitrosocysteine-specific antibody. It is also possible that a disulfide was 
formed between Cys16 and Cys20, with the nitrosated product an intermediate to disulfide 
bond formation; however, other oxidation states aside from nitrosation were not tested. 
Furthermore, RhoA has been shown to be modified by phenylarsine oxide (PAO). Whereas 
PAO is a thiol-modifying compound that was originally developed as a protein tyrosine 
phosphatase inhibitor, RhoA can be modified and inactivated after PAO exposure in Caco-2 
cells. Analysis by mass spectrometry showed mixed disulfide formation between Cys16 and 
Cys20 (83), resulting in deactivation of RhoA by occluding nucleotide binding; however, 
Rac1, which only has one p-loop thiol, was not inactivated upon exposure to PAO.  
In contrast to the studies showing RhoA inactivation by oxidants, Cys16 and Cys20 of 
RhoA have been shown to be critical for peroxide-mediated activation of RhoA in REF52 
cells (81). In this study, RhoA and a redox-insensitive variant, C16A/C20A, were ectopically 
expressed and exposed to exogenous and endogenous peroxide. RhoAWT was activated by 
peroxide under serum free conditions, whereas RhoAC16A/C20A was not activated under 
identical conditions. RhoA activation by peroxide concentrations as low as 0.1 μM was 
observed using the Rhotekin-RBD pull-down assay and microscopy to observe stress fiber 
formation, which is indicative of RhoA activation; however, RhoAC16A/C20A was not activated 
due to exogenous or endogenously produced peroxide (through antimycin A).  
While there are a numerous studies that have observed regulation of RhoA activity 
through oxidation, many of these studies have shown that RhoA activity is indirectly 
regulated by ROS and RNS. According to Chang et al (168), NO•-induced activation of SHP-2 
led to the inactivation of RhoA in rat aortic smooth muscle cells. However, the RhoA 
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pathway was activated by 3-morpholino-sydnonimine (SIN-1), a NO• donor, and peroxide 
through oxidant-mediated activation of Protein Kinase C (PKC) in bovine aortic endothelial 
cells. In this study, PKC was activated by oxidation, which in turn, activated RhoA through 
p115-Rho-GEF (169). However, in both of these studies, RNS were used to regulate RhoA-
mediated pathways in the cell, but direct oxidation of RhoA was not probed. Therefore, while 
it would be useful to directly determine the types of modifications and oxidation events in 
the cell, the level of oxidation is likely small, which would make direct detection difficult. 
Thus, a carefully designed redox-insensitive variant that functions similarly to RhoAWT 
would aid in determining whether the effects of oxidants on RhoA are direct, or the result of 
indirect activation.  
Thus, in this study, we characterized redox-insensitive variants of RhoA, demonstrate 
that Cys20 has an altered pKa, and Cys20 sensitizes RhoA to free radical and nonradical 
oxidants. Our data also indicate that oxidation of Cys20 by glutathione increases the rates of 
nucleotide exchange whereas nitrosation does not increase nucleotide exchange rates. 
Further, we generated a RhoAC20D variant, which is a structural mimic of sulfinic acid. 
RhoAC20D, like glutathiolated RhoA, showed greatly enhanced rates of nucleotide exchange 
but did not affect GAP-mediated hydrolysis. Consistent with these observations, RhoAC20D 
was constitutively active in Swis3T3 cells, most likely due to the high rate of nucleotide 
exchange, and may prove as a useful oxidation mimetic. These results show that RhoA can 
be directly activated by oxidants and that activation is mediated through Cys20. In the future, 
studies looking at RhoA-mediated signaling regulation by oxidants should consider the 
direct activation of RhoA, which can be tested using the RhoAC20S variant, in addition to the 
indirect activation of the RhoA signaling pathway. 
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Methods  
RhoA protein purification 
Truncated human RhoA (RhoA1-181) was cloned into the pQlinkH vector (Addgene; 
Cambridge, MA), which contains an N-terminal 6x-His purification tag followed by a 
Tobacco Etch Virus protease cleavage site for removal of the affinity tag. The hypervariable 
region of RhoA, including the C-terminal CAAX box, was removed as this region does not 
undergo post-translational lipid modification in bacteria, is unstructured, and its removal 
does not affect guanine nucleotide binding or GTP hydrolysis in Ras GTPases (106). All 
proteins were expressed in BL21 Rosetta2 cells (Millipore; Darmstadt, Germany) and 
purified following the Qiagen Nickel NTA purification protocol (Germantown, MD). RhoA 
was further purified using size exclusion chromatography (Superdex-75 10/300 GL column; 
GE Life Sciences; Piscataway, NJ) and judged greater than 95% pure by SDS-PAGE analysis.  
Nucleotide exchange and hydrolysis assays 
The rate of GDP dissociation from Rho proteins was measured using 2'-/3'-O-(N'-
methylanthraniloyl)guanosine-5'-O-diphosphate (mantGDP) as previously described (108, 
109). Briefly, 1 μM RhoA and RhoA variants were preloaded with mantGDP (BioLog; San 
Diego, CA) and added to 1 mL of degassed assay buffer (50 mM Hepes pH 7.4, 50 mM NaCl, 
5 mM MgCl2, 2 mM GDP, and 200 μM diethylenetriaminepentaacetic dianhydride; DTPA), 
and the rate of guanine nucleotide dissociation was measured by monitoring the change in 
fluorescence (excitation: 365 nm; emission: 435 nm; 25˚C) over time using a Perkin Elmer 
LS50B fluorimeter (Waltham, MA). All experiments were performed in triplicate. 
Fluorescent nucleotide dissociation curves were fit to a one-phase exponential decay 
equation using GraphPad Prism version 3.03 (GraphPad Software; San Diego, CA). For 
GEF-induced RhoA-GDP dissociation assays, the minimal catalytic domain of Dbs 
(DbsDH/PH) was used at a 1:10 ratio to RhoA. This concentration of DbsDH/PH was selected as 
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the rate enhancement of nucleotide exchange was easy to measure using the fluorimetric 
assays. The Dbs construct was expressed and purified as previously described (170). For 
experiments where CysNO was employed, the oxidant was generated exactly as previously 
described and then diluted into 100 mM Hepes (pH 7.4) and 1 mM DTPA. 
Rates of GTP hydrolysis were determined using a Spectramax M5 (Molecular Devices; 
Sunnyvale, CA) fluorimeter by monitoring phosphate production upon GTP hydrolysis (111). 
FlipPi 5U (Addgene; Cambridge, MA) was used as the phosphate sensor, and the expression, 
purification, and use of this sensor have been previously reported (113). Briefly, all assays 
used 10 µM FlipPi with 10 µM GTP-loaded RhoA. GTP loading was performed as previously 
described with minor modifications (111). Briefly, RhoA was loaded with GTP in loading 
buffer (20 mM Hepes, 50 mM NaCl, 1 mM EDTA, 20 mM (NH4)2SO4 and 1 mM inosine, pH 
8.0) for 3 min at 37˚C. Excess nucleotide was removed using a PD-10 desalting column with 
hydrolysis buffer (20 mM Hepes, 50 mM NaCl, 100 μM EDTA, and 1 mM inosine, pH 7.4) 
and placed in a 96-well plate. Hydrolysis was initiated by adding 1 mM MgCl2 to the well. 
Trace phosphate was removed from all buffers using a ‘phosphate mop’ (114). The rate of 
GTP hydrolysis was measured by taking the ratio of the 535- and 485-nm emission 
wavelengths (excitation: 435 nm; 25˚C) of kinetic runs performed in triplicate and fit to a 
one-phase exponential association curve. For these experiments, the ratio of GAP to RhoA 
was 1:1000, and the minimal catalytic domain of p50 RhoGAP was used for hydrolysis.  
4-fluoro-7-aminosulfonylbenzofurazan (ABD-F) modification of RhoA 
To modify RhoA and select variants with ABD-F, Rho proteins were reduced with DTT 
before reaction. RhoA and RhoA variants were reduced using 5 mM DTT for 30 min on ice 
on the day of the experiment in reducing buffer (20 mM HEPES pH 8.0, 50 mM NaCl, 5 mM 
MgCl2, and 200 μM DTPA) before being buffer exchanged into ABD-F reaction buffer (100 
mM MES pH 6.5 and 5 mM MgCl2) that was sparged with N2 gas to remove oxygen content 
in the buffer and limit air oxidation during the reaction. 
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The reaction was performed in a Spectramax M5 plate reader using 96-well black 
plates. All reactions were performed in triplicate in ABD-F reaction buffer at a final volume 
of 200 μl with 10 μM protein and 1 mM ABD-F. ABD-F was stored at -20˚C in DMSO, and 
the concentration of ABD-F was determined using the extinction coefficient of 4200 M-1cm-1 
at 313 nm. The fluorescence of ABDF was measured at an excitation wavelength of 389 nm 
and emission wavelength of 513 nm.  
Circular Dichroism spectroscopy 
Circular Dichroism data were collected on a JASCO J-815 CD spectrometer with a 
JASCO Peltier device and water bath to control the temperature. Experiments were 
performed in a 1-mm cuvette at a protein concentration of 15 μM in 10 mM potassium 
phosphate (pH 6.5) containing 500 μM MgCl2 and 10 μM GDP. Far UV scans were from 200 
nm to 250 nm. Thermal denaturation of RhoA and the selected variants were monitored at a 
221 nm to estimate the protein melting temperature. The temperature ramp rate was 
1˚C/min and data points were collected every 1˚C. CD scans are reported in units of mean 
residue ellipticity, which was calculated as follows:ሾߠሿெோா ൌ ఏೝೌೢൈெோௐଵ଴ൈ௖ൈ௟ , where θraw is the 
ellipticity in degrees, MRW is ெ௢௟௘௖௨௟௔௥	ௐ௘௜௚௛௧	ሺ஽௔ሻሺ௡௢.௢௙	௥௘௦௜ௗ௨௘௦ሻିଵ , c is the protein concentration in g/ml, and 
l is the pathlength of the cuvette in cm, according to (171). 
Glutathiolation and oxidation of Rho samples 
Before the addition of oxidants, RhoA was reduced with DTT for 30 min at pH 8.0 
before being buffer-exchanged into the selected buffer that was flushed with N2 gas to 
remove dissolved oxygen and prevent autoxidation. RhoAWT and RhoAC16S were modified 
with glutathione by the addition of 1000× oxidized glutathione to purified protein in 
glutathiolation buffer (50 mM NaH2PO4, pH 6.5, 100 mM NaCl, 10 mM MgCl2, and 50 μM 
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GDP) for 30 min at room temperature. After, the samples were dialyzed into glutathiolation 
buffer without glutathione at 4˚C overnight.  
To oxidize Rho with peroxide, the samples were reduced as described above. After, the 
samples were exposed to 250× hydrogen peroxide for 1.5 h at room temperature in oxidation 
buffer (50 mM Hepes pH 7.4, 50 mM NaCl, 5 mM EDTA, and 200 μM DTPA). After the 
samples were run over a PD-10 column equilibrated with assay buffer. The oxidized proteins 
were used in nucleotide association assays. 
Mass spectrometry of Rho Samples 
To prepare Rho samples for MS, the proteins were first modified with the selected 
oxidant before denaturation in 100 mM NH4CO3 (pH 7.8), 6 M urea, and 10 mM 
iodoacetamide (IAA). The iodoacetamide-containing buffer was prepared fresh daily and 
used in amber-colored eppendorf tubes. The reaction was performed in the dark as IAA is 
deactivated by light. After reaction for 1 h at room temperature, the Rho proteins were buffer 
exchanged into 50 mM NH4CO3 (pH 7.8) and digested with trypsin overnight at 37˚C. The 
peptides were cleaned up using a C-18 spin column (Pierce) following the manufacturer’s 
recommended protocol. The cleaned peptide samples were lyophilized in a speedvac to 
powder and suspended in H2O with 0.1% formic acid. The bottom-up peptide identification 
of trypsinized Rho samples was performed using reversed-phase LC–MS/MS on a nano-LC 
Ultra 2D Plus (Eksigent; Dublin, CA, USA) coupled to an LTQ-Orbitrap Velos as described 
previously [35]. Briefly, data acquisition included a full-MS scan on the Orbitrap (externally 
calibrated to a mass accuracy of <1 ppm and instrumental resolving power of 60,000 atm/z 
400 Da) followed by intensity-dependent CAD–MS/MS of the top 10 most abundant peptide 
ions. Mass spectra were processed, and peptide identification was performed using Mascot 
(Matrix Science) against a Human UniProt database. Peptides were confidently identified 
using a target–decoy approach with a false discovery rate of 1%. A precursor ion mass 
tolerance of 200 ppm and product ion mass tolerance 0.5 Da with a maximum of two missed 
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cleavages and variable modifications of cysteine glutathiolation and oxidation were used as a 
protein database search parameter. All peptides were filtered and reported within a mass 
accuracy of 5 ppm. 
NMR spectroscopy 
NMR experiments were collected on a Varian Inova 700 MHz spectrometer at 25˚C. 
The 2D 1H–15N heteronuclear single quantum coherence spectroscopy (HSQC) experiments 
were performed with pulsed field gradient and water flip-back methods as previously 
described (91). Uniformly labeled 15N-enriched Rho was purified as previously described. 2D 
1H-15N HSQC experiments were acquired on 0.5 mM 15N-enriched RhoAWT, RhoAC20S, 
RhoAC16S/C20S, and RhoAC20D with 1,024 x 128 complex data points and a spectral width of 
8,000 Hz for the 1H dimension and 1,709 Hz for the 15N dimension. Buffer contained 10 mM 
MOPS, 100 mM NaCl, 10 mM MgCl2, 10 μM GDP, 0.1% azide, and 10% D2O. NMR data were 
processed and analyzed using NMR PIPE and NMR ViewJ (One Moon Scientific; Newark, 
NJ). 
Results 
While RhoA activity can be modulated by cysteine oxidation in vitro (79, 80), few 
studies have demonstrated direct oxidation of RhoA in cellular-based experiments. The lack 
of studies that have directly detected oxidized RhoA in cells is likely a result of the difficulty 
detecting low levels of oxidation in physiological settings. However, mass spectrometry was 
used to verify direct oxidation of RhoA by PAO in Caco-2 cells (83), which was shown to 
inhibit RhoA by occluding nucleotide binding. RhoA has been shown to be directly activated 
by both exogenous and endogenous peroxide in REF52 cells, and RhoA activation was 
shown to be regulated through Cys16 and Cys20 (81). Other studies have tied RhoA regulation 
to oxidants through indirect oxidation (168, 169), although similar oxidants were used that 
have been previously been shown to activate RhoA in vitro (79, 80). The only variants 
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previously used as redox-insensitive controls, which mutated Cys16 and Cys20 to alanine, 
were not biochemically characterized (80, 81). Thus, we have shown that Cys20 of RhoA has 
an altered pKa and characterized the effect of oxidation at Cys20 by glutathione, peroxide, 
and NO. We characterized the previously used RhoAC16A/C20A variant and determined that 
this variant has altered nucleotide-binding properties. Therefore, we characterized several 
redox-insensitive variants, which should serve as powerful tools to determine the effects of 
RhoA oxidation in cells.  
Thiol accessibility and 4-fluoro-7-aminosulfonylbenzofurazan (ABD-F) modification of 
RhoA 
Due to the observed reactivity of RhoA Cys20 to oxidants, we hypothesized that RhoA 
Cys20 has an altered pKa. We tested the reactivity of the cysteines in RhoA by monitoring the 
reaction of RhoA at various concentrations of ABD-F. ABD-F reacts with the thiolate state of 
cysteine residues with an approximate 10-fold faster rate than the thiol state and shows 
enhanced fluorescence upon modification.  
The computational program nAccess was used to probe the surface of RhoA thiol side chains 
that are accessible to the solvent relative to an Ala-x-Ala peptide, where x is the residue 
being considered (Table 2). Analysis with nAccess indicates that only Cys20 is solvent 
accessible in the GTP-bound states when accounting for the bound nucleotide. However, as 
the guanine nucleotide is exchangeable, we performed nAccess without considering the 
bound nucleotide. By omitting the bound nucleotide, the relative accessibility of Cys20 is 
increased. In the GEF-bound state, which is not bound to nucleotide, the solvent 
accessibility of Cys20 is similar to RhoA without the considering the bound nucleotide. In 
GAP, GDI, and effector bound states, the relative accessibility of all thiols is minimal. The 
only other thiol that is readily accessible in any structure is Cys107. However, nAccess 
considers the relative accessibility of the entire side chain. In Cys107, visual analysis of the 
structures indicate that the majority of Cys105 that is solvent accessible is the β carbon. Thus,  
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  Table 2. Thiol accessibility in RhoA crystal structures 
Cys16 Cys20 Cys83 Cys107 Cys159 
RhoA
GTP
 
1A2B 
1.9 4.3 0.0 7.9 1.3 
RhoA 
1A2B 1.9 35.4 0.0 7.9 1.3 
RhoA
GDP
 
1FTN 
1.8 0.0 0.0 5.4 0.0 
RhoA 
1FTN 1.8 19.7 0.0 5.4 0.0 
RhoA‐RhoGEF 
3T06 3.0 33.5 0.1 3.7 0.0 
RhoA‐RhoGAP 
1OW3 3.5 2.2 0.0 4.0 0.5 
RhoA‐GDI 
1CC0 1.8 0.0 0.0 4.8 0.0 
RhoA‐PKN/PRK 
1CXZ 2.3 2.4 0.0 4.9 0.3 
All values are presented as % accessibility compared to an Ala-x-Ala peptide. Value considers the 
total side chain solvent accessibility. In the second and fourth rows, nAccess was performed on 
crystal structures where the bound nucleotide was omitted. 
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this data suggests that Cys20 is the most accessible thiol in RhoA. As the GDP-bound form is 
generally bound to GDI in cells, it is likely that RhoA will only be accessible to oxidation in 
the GTP-bound form in the cellular context. 
As RhoA contains a solvent-accessible cysteine at position 105 that does not play a 
role in nucleotide binding or effector interaction, we tested ABD-F reactivity at a pH (pH 
6.5) that was unlikely to modify accessible thiols that do not possess altered reactivity 
(Figure 14). Thus, if Cys20 has an altered pKa, this pH should highlight the reactivity of this 
residue while minimizing modification at other sites. The ABD-F fluorescence intensity was 
found to be the highest for RhoAWT upon modification with ABD-F, and RhoAC16S resulted in 
40% of the fluorescence observed for RhoAWT. In contrast, RhoAC20S and RhoAC16S/C20S 
showed only ~15% of the fluorescence of RhoAWT. Mass spectrometry confirmed that Cys20 
was modified in RhoAWT. Lastly, Cys159, which is buried by the bound nucleotide (Table 2), 
was also partially modified by ABD-F in all RhoA proteins tested. This data, in combination 
with the nAccess study, suggests that oxidation of RhoA will primarily occur at Cys20. 
Oxidation of RhoA differentially effects nucleotide binding 
 To test the effect of RhoA oxidation, we exposed RhoA to CysNO, peroxide, and 
glutathione in vitro. Interestingly, we observed different nucleotide binding in response to 
the tested oxidants. As exposure to NO2• radicals can promote disulfide formation between 
Cys16 and Cys20, we used CysNO, which nitrosates cysteines by non-radical oxidation, to 
determine the effect of 2e- nitrosation on RhoA. As shown in Figure 15A, oxidation of RhoA 
and RhoAC20S by CysNO had no effect on nucleotide exchange rates. Thus, the rate of 
nucleotide exchange after CysNO addition was nearly identical to the rate observed prior to 
the addition of the oxidant.  
We also treated RhoA with peroxide and observed nucleotide association. However, 
treating mantGDP-loaded RhoA with peroxide in the reaction cuvette did not appear to effect 
nucleotide dissociation rates by the mantGDP assay, which prevented the measurement of  
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Figure 13. Reaction of RhoA and RhoA variants with ABD-F. 
Reaction of RhoA with ABD-F shows increased reactivity at Cys20, likely because of a 
decreased pKa of the thiol moiety. All reactions were performed with 10 μM RhoAWT, RhoAC16S, 
RhoAC20S , or RhoAC16S/C20S and 1 mM ABDF at pH 6.5 for 350 minutes. Reactions were performed 
in triplicate using a 96-well plate reader and were plotted using GraphPad Prism. Data are 
presented as a relative % modification by counting the maximal RhoA modification to be 100%. 
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nucleotide dissociation due to direct peroxide exposure (data not shown). We treated RhoA, 
RhoAC20S, and RhoAC16S/C20S with 250× peroxide for 1.5 h prior to measuring nucleotide 
association using mantGDP (Figure 15B). While RhoAC20S and RhoAC16S/C20S were unaffected 
due to peroxide treatment, RhoAWT showed decreased nucleotide association, which suggests 
that oxidation proceeds initially through Cys20 of RhoA. 
Further, we also treated RhoAWT with oxidized glutathione and used MS to analyze the 
consequences of RhoA oxidation. We find that glutathiolation is specific to Cys20 of RhoA 
(data not shown). Glutathiolation at Cys20 resulted in significantly enhanced nucleotide 
dissociation rates with an approximate 140-fold increase in intrinsic exchange in RhoAWT 
and 250-fold in RhoAC16S. As we were unable to preload glutathiolated RhoA with mantGDP, 
we measured nucleotide cycling with 0.1 μM mantGDP and 1 μM protein and measured the 
subsequent dissociation curves (Figure 15C). Association was performed for 30 s to 1 min 
(data not shown) and dissociation was initiated by adding 2 mM GDP into the reaction 
cuvette. The results show that glutathiolated RhoA is able to bind nucleotide and that 
glutathiolated RhoA shows greatly enhance nucleotide exchange rates. 
As sulfenic acid-modified proteins are generally unstable and in equilibrium with 
sulfinic and sulfonic acid oxidation states, we used the RhoAC20D variant to serve as an 
oxidation mimetic (Figure 16). As Cys20 is the initial site of oxidation, the RhoAC20D variant 
allows for studies of oxidized RhoA that cannot form a disulfide with Cys16. As shown in 
Figure 16, we characterized intrinsic and GEF/GAP-mediated rates of nucleotide exchange 
and hydrolysis. We find that the RhoAC20D variant possess greatly enhanced rates of 
nucleotide dissociation, which was ~480-fold faster than intrinsic nucleotide dissociation. 
The rate of intrinsic GTP hydrolysis was slower than RhoAWT, which was likely due to the 
fast exchange rate as we employed a single-turnover hydrolysis assay. In the presence of 
GAP, the rate of hydrolysis was restored to a rate that was similar to RhoAWT. 
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Figure 14. Nucleotide binding assays of oxidized RhoA. 
(A) RhoAWT and RhoAC20S preloaded with mantGDP and exposed to CysNO. RhoA (1 μM) was 
exposed to 100 μM CysNO in the reaction cuvette at the indicated time point and dissociation was 
monitored. (B) RhoA and the redox-insensitive variants were exposed to H2O2 as described in the 
methods and mantGDP association assays were performed. (C) Nucleotide dissociation assays of 
glutathiolated RhoA and RhoAC16S. The site of oxidation was determined by mass spectrometry. All 
reactions were performed in triplicate and were fit to a single exponential dissociation curve 
(where applicable) using GraphPad Prism, and the error is reported as the standard deviation of 
the replicates. 
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Figure 15. Oxidation mimetic RhoAC20D shows the critical role of Cys20 in nucleotide 
binding. 
(A) Graphical depiction of cysteine oxidized to sulfinic acid and aspartic acid for 
comparison. (B) Intrinsic nucleotide dissociation of RhoAC20D that was loaded with mantGDP and 
performed as described previously. (C) Nucleotide hydrolysis of RhoAC20D with and without GAP 
present. RhoAC20D was preloaded with GTP and hydrolysis was measured as described previously. 
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Nucleotide exchange and hydrolysis kinetics of RhoA variants 
We generated a series of mutations at both Cys20 and Cys16 and analyzed the effects of 
these mutations on RhoA nucleotide binding kinetics to evaluate which redox insensitive 
variant(s) best mimic the biochemical, stability, and structural properties of RhoAWT. 
As the RhoAC16A/C20A variant was previously used as a redox-insensitive variant in a 
cellular context (81), we initially compared the intrinsic rates of nucleotide exchange of 
RhoAWT and RhoAC16A/C20A using the mantGDP dissociation assay. In this assay, the rate of 
nucleotide dissociation can be determined by monitoring the loss of mantGDP fluorescence in 
the presence of unlabeled nucleotide. As shown in Figure 17 (and in Table 3), the 
RhoAC16A/C20A variant shows a greatly increased rate of intrinsic dissociation of ~150-fold. 
This result indicates that this variant impairs nucleotide binding in RhoA; therefore, we 
characterized additional variants to identify a redox-insensitive variant that did not 
significantly alter RhoA activity. As the serine side chain is the closest mimetic to cysteine, 
we next compared Cys>Ser variants in effort to obtain a redox-insensitive variant with 
similar biochemical properties to RhoAWT. 
While introducing double mutations at Cys20 and Cys16 (RhoAC16S/C20S) significantly 
enhanced the rate of nucleotide dissociation relative to RhoAWT by ~40-fold, this is 4-fold 
less than that observed for the RhoAC16A/C20A variant. However, single mutations at these 
positions better retain the intrinsic rates of nucleotide dissociation relative to RhoAWT as 
RhoAC16S and RhoAC20S enhanced intrinsic rates GDP dissociation by ~3-fold and ~5-fold, 
respectively. As the nucleotide binding constant in RhoA is so high, increased nucleotide 
dissociation is an indirect readout of nucleotide affinity. Taken together, these data indicate 
that single mutations at Cys16 and Cys20 retain nucleotide binding most similar to that of 
RhoAWT (Figure 17A).  
In the cellular context, the intrinsic rate exchange is too slow to respond to stimuli and 
GEP-mediated nucleotide exchange better mimics the ability to become activated. Therefore,  
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Figure 16. Biochemical characterization of RhoA redox-insensitive mutants. 
A) Intrinsic nucleotide dissociation measured in RhoA and RhoA variants lacking the p-loop 
cysteine residues using mantGDP. B) GEF-mediated nucleotide dissociation performed in RhoA and 
RhoA variants in the presence of the minimum catalytic fragment of DBS. All reactions contained 
the GEF at a 1:10 ratio to RhoA. All reactions were performed in triplicate and were fit to a single 
exponential dissociation curve using GraphPad Prism, and the error is reported as the standard 
deviation of the replicates. Normalized results are presented for graphical comparison of the 
experiments. The experimental conditions and data analyses for these assays are described in the 
Materials and Methods. 
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we exposed RhoA to the minimal catalytic domain (DH/PH domains) of the Rho-specific 
GEF Dbs at a GEF:RhoA ratio of 1:10 (Figure 17B). Under these conditions, the Rho 
Cys>Ser variants all showed increased sensitivity to the RhoGEF, Dbs. Thus, RhoAC16S and 
RhoAC20S showed increased rates of 8- and 18-fold, respectively, compared to their GEF- 
mediated RhoAWT rates (all rates are presented in Table 3).  
In addition to GEFs, GAPs regulate the activation state of GTPases by promoting GTP 
hydrolysis and inactivating the GTPase. To examine whether the redox-insensitivevariants 
were sensitive to GAP-mediated hydrolysis, we measured intrinsic and GAP-mediated GTP 
hydrolysis. Using the FlipPi GTP-hydrolysis assay that has been previously described (15, 
131), the rate of nucleotide hydrolysis for each variant was determined (Figure 18). While 
RhoAC20S and RhoAC16S/C20S showed faster intrinsic hydrolysis rates, the increases were 
marginal and unlikely to play a major role in the cellular regulation of these variants. In the 
presence of the catalytic domain of p50 RhoGAP, all variants showed sensitivity to GAP-
mediated hydrolysis with only the RhoAC20S and RhoAC16S/C20S variants showing slightly 
faster rates with the same concentration of GAP.  
RhoA Cys>Ser stability by Circular Dichroism  
Circular Dichroism (CD) thermal melts were performed on the RhoA variants to study 
the stability of the variants generated. The thermal denaturation curves were performed at 
pH 6.5 with 500 µM MgCl2 and 10 μM GDP and were collected at 221 nm (Figure 19). 
These results indicate that none of the redox-insensitive variants significantly destabilize 
RhoA. However, the sulfenic acid oxidation mimetic RhoAC20D showed decreased thermal 
stability by ~7°C compared to RhoAWT. 
2D NMR of RhoA variants 
As the RhoAC16A/C20A variant showed a high rate of nucleotide dissociation in our 
assays, we performed 2D NMR analyses of this variant and compared the spectra to RhoAWT  
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Figure 17. GTP hydrolysis of RhoA and RhoA redox-insensitive mutants. 
(A) RhoA GTP hydrolysis kinetic traces in the absence and presence of the minimal catalytic 
domain of p50 RhoGAP. (B) The relative rates of hydrolysis in the absence and presence of GAP at 
1:1000 GAP:RhoA are presented for all redox insensitive variants. All reactions were performed in 
triplicate and were fit to a single exponential dissociation curve using GraphPad Prism, and the 
error is reported as the standard deviation of the replicates. The experimental conditions and data 
analyses for these assays are described in the Materials and Methods. 
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Figure 18. Thermal denaturation of RhoA and RhoA variants. 
The thermal stability of RhoA was measured using circular dichroism at 221 nm. Tm values 
were as follows: RhoAWT, 61.2 ± 0.6; RhoAC16S, 60.7 ± 1.8; RhoAC20S, 63.8 ± 1.9; RhoAC16S/C20S, 62.0 
± 0.5; and RhoAC20D, 54.67 ± 0.05. All denaturation curves were performed in duplicate and 
normalized to represent the relative unfolding over the selected temperature range. 
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Table 3. Nucleotide dissociation and hydrolysis rates in the presence and absence of GEFs 
and GAPs 
Nucleotide 
release 
Intrinsic 
koff (e-5 s
-1
) 
Fold 
Increase 
x/RhoA
WT
 
DBS
DH/PH
 
koff (e-5 s
-1
) 
Fold 
Increase 
x/RhoA
WT
 
RhoA
WT
 3.6 ± 0.1 1 71.8 ± 0.6 1 
RhoA
C16S
 11.56 ± 0.1 3.2 604 ± 7 8.4 
RhoA
C20S
 18.17 ± 0.1 5.0 1098 ± 28 15.25 
RhoA
C20D
 1738 ± 39 482 N/A -- 
RhoA
C16S/C20S
 150.8 ± 0.6 41.9 1270 ± 14 17.6 
RhoA
C16A/C20A
 536.3 ± 4.65 149 2220 ± 36 30.8 
Nucleotide 
hydrolysis 
Intrinsic 
koff (e-5 min
-1
) 
Fold 
Increase 
x/RhoA
WT
 
P50 RhoGAP 
koff (e-5 s
-1
) 
Fold 
Increase 
x/RhoA
WT
 
RhoA
WT
 27.1 ± 0.8 1 169.8 ± 37 1 
RhoA
C16S
 28.1 ± 2.8 1.0 159.1 ± 46 0.9 
RhoA
C20S
 54.9 ± 8.4 2.0 245.3 ± 13 1.4 
RhoA
C20D
 6.3 ± 1.8 0.23 154.1 ± 41 0.9 
RhoA
C16S/C20S
 74.1 ± 4.8 2.7 232.2 ± 25 1.4 
RhoA
C16A/C20A
 16.6 ± 1.8 0.6 154.1 ± 42 0.9 
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(Figure 18A). Backbone NH resonances of GDP-bound RhoA have been previously 
assigned (172) and were used in our NMR analyses. A 2D 1H-15N NMR HSQC allows for 
observation of backbone and side chain N-H groups and provides a site-specific probe for 
every residue in a protein aside from proline. In Figure 18B, RhoAC16A/C20A is overlayed with 
RhoAWT. We determined that the RhoAC16A/C20A variant had 29 detected peaks with altered 
chemical shifts (peaks with chemical shift differences greater than one linewidth, 0.05 ppm 
in the 1H dimension or 0.4 ppm in the 15N dimension) compared to RhoAWT. The RhoAC20S 
redox-insensitive variant (Figure 18C) had an NMR spectra that was more similar to 
RhoAWT with only 16 peaks showing altered chemical shifts compared to RhoAWT. Lastly, 
RhoAC20D (Figure 18D) showed 43 peaks with chemical shifts, indicating that the structure 
of this variant had the largest degree of variation. All residues that showed chemical shifts 
are plotted on the RhoAWT structure to indicate where on the structure was effected by the 
tested variants (Figure 19).  
Cys20 is sensitive to oxidation in SDS-PAGE 
SDS-PAGE of RhoA purified from E. coli has always shown a diffuse band for RhoAWT. 
While the SDS-PAGE loading buffer contains 100 mM DTT, this does not remove the smear 
observed on the gel. This effect appears to depend on Cys20 in RhoA. When running 
RhoAC20S and RhoAC16S/C20S, RhoA appears as a clean band (Figure 20). However, RhoAC16S, 
which still contains Cys20, retains the smeared band. This indicates that the observed 
banding pattern is due to the reactivity of Cys20. If the reducing agent in the loading buffer is 
replaced with iodoacetamide (IAA), then clear bands are observed with RhoAWT and 
RhoAC16S. However, this result does not eliminate the possibility that Cys20 is oxidized, which 
would generate a reactive thiol during the denaturation step that could create a mixture of 
oxidized species during gel preparation. To verify that no oxidation was present on RhoA 
prior to SDS-PAGE analysis, we performed mass spectrometry of trypsin-digested peptides 
in the presence of IAA. In these samples, oxidation of Cys20 was not detected.  
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Figure 19. 2D NMR analyses of RhoA and RhoA variants. 
(A) HSQC of RhoAWT with the assigned residues highlighted. Assignments have been 
previously performed and the same conditions used previously were used herein. (B) Overlay of 
HSQC spectra of RhoAWT (black) and RhoAC16A/C20A (blue). Residues that showed chemical shifts 
are labeled in black based on the RhoA assignments. (C) Overlay of HSQC spectra of RhoAWT and 
RhoAC20S (red). (D) Overlay of HSQC spectra of RhoAWT and RhoAC20D (green). 
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Figure 20. Residues with chemical shifts plotted on pymol-generated structures. 
Residues that showed chemical shifts due to mutation are plotted on the structure of RhoA 
(pymol id 1FTN). (A) RhoAWT plotted with the p-loop in orange, switch I in cyan, and switch II in 
magenta for comparison of the structures. (B) All residues that showed a chemical shift by HSQC 
in RhoAC16A/C20A are plotted in blue. (C) Residues with a chemical shift in RhoAC20S are plotted in 
red. (D) Residues with a chemical shift in RhoAC20D are plotted in green. In black are all residues 
that are undefined in the NMR data. All residues showing no change are in grey. 
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Figure 21. SDS-PAGE of RhoA variants. 
The reactivity of Cys20 causes poor resolution by SDS-PAGE. On the left half of the gel, 
RhoA variants were denatured in the presence of iodoacetamide. In the right half of the gel, RhoA 
variants from the same sample were denatured in the presence of reducing agent. RhoAWT and 
RhoAC16S, which both contain Cys20, both showed poor resolution on the reducing gel. 
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In cell activation of RhoA variants 
It has previously been shown that RhoA is activated by peroxide in cells (81). However, 
this study used the RhoAC16A/C20A variant that displays altered nucleotide binding kinetics. 
The ABD-F modification study and the use of the RhoAC20S variant presented within suggest 
that mutation of RhoAC20S is sufficient to prevent RhoA oxidation. Thus, we generated a 
RhoAC20S variant and transfected this variant into Swiss3T3 cells (Figure 21). This 
variantshowed similar levels of activation compared to RhoAWT by the Rhotekin-RBD pull 
down assay, which suggests that this variant is a more reliable redox-insensitive variant than 
RhoAC16A/C20A.  
To mimic the effect of oxidation of RhoA in cells, we employed the RhoAC20D variant to 
determine the effect on GTP binding in cells. While the RhoAC20D variant cannot form the 
disulfide bond that has been previously observed between Cys16 and Cys20, it does mimic the 
primary oxidation step at Cys20. The RhoAC20D variant, like the RhoAC16A/C20A variant, showed 
significantly increased activation in the RBD-pull down experiments in Swiss3T3 cells 
(Figure 21). 
Discussion 
While numerous reports support modulation of RhoA activity by ROS and RNS, few 
have determined whether RhoA undergoes direct oxidation, and if so, the site(s) and type(s) 
of modification as well as the consequences on RhoA activity. Previously, RhoA has been 
shown to be form a disulfide between Cys16 and Cys20 after exposure to NO2• (173). In a 
separate study, NO•, which was generated using PAPA-NONOate, was shown to prevent 
nucleotide binding in RhoA in vitro and inactivate RhoA in aortic smooth muscle cells (167). 
Further, RhoA has been shown to be activated by peroxide in REF52 cells (81). In this study, 
a RhoAC16AC20A redox-insensitive variant was used to determine whether the effect of 
peroxide was due to direct thiol oxidation of RhoA. While this variant is insensitive to 
oxidation, we find that it possesses greatly enhanced rates of GDP dissociation relative to  
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Figure 22. RhoA regulation by peroxide and activation state of redox variants.  
(A) Endogenous RhoA was shown to be activated by peroxide in Swiss3T3 cells. Cells were 
serum starved and treated with 100 µM t-butyl peroxide for 15 min. Levels of GTP-bound RhoA 
and activated p38 and pErk1/2 were probed for. (B) Quantitation of GTP-bound RhoA from (A). 
(C) Endogenous RhoA was knocked down and RhoAWT, RhoAC20S, and RhoAC20D were 
exogenously expressed in Swiss3T3 cells. After stable transfection, the cells were probed for GTP-
bound RhoA. (D) Quantitation of GTP-bound RhoA from (C). Data in figure collected by Bingying 
Zhou. 
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RhoAWT. This observation is consistent with the increased activation observed in REF52 cells 
in the absence of oxidant. 
However, several studies have shown regulation of RhoA by activation of Rho effector 
proteins. In Chang et al, RhoA downregulation was observed after treatment with DETANO- 
NONOate in vascular smooth muscle cells. However, in this study, NO• was found to 
upregulate SHP-2, which caused downregulation of RhoA (168). Further, in Chandraet al, 
both NO• from SIN-1 as well as H2O2 were shown to activate Protein Kinase C, which in turn 
activated p115-Rho-GEF and RhoA in bovine aortic endothelial cells (162). In yet another 
study of RhoA and NO•, RhoA/Rho Kinase activity was shown to be downregulated by 
endogenously generated NO• and exogenously added sodium nitroprusside in rat aortic cells 
(174). However, in this study, the authors surmised that NO• led to the activation of cGK, 
which has been shown to inactivate RhoA (175, 176). Common to all of these studies, 
however, was the use of NO• donors, which have been shown to oxidize RhoA in vitro and 
directly regulate RhoA in cells, and these cellular-based studies did not look at direct RhoA 
oxidation. As RhoA has been shown to be directly regulated by these oxidants, we sought to 
biochemically characterize the oxidation events in RhoA and generate a redox-insensitive 
variant of RhoA, which would aid in studying the role of oxidants and RhoA function.  
Given the number of cellular studies that implicate functional alteration of RhoA 
activity by RNS and ROS, we sought to identify a redox inactive variant that retains the 
ability to bind and hydrolyze GTP similar to RhoAWT. Therefore, several Cys>Ser variants 
were generated and characterized to determine whether any retain RhoAWT properties. 
Redox inactive variants also served as controls for determining the sites of oxidation in 
response to thiol oxidizing agents in our in vitro studies. Further, we looked at the activation 
state of the redox-insensitive variants in cells as well as the oxidation mimetic RhoAC20D, 
which shows increased activation in Swiss3T3 cells and is agreement with our biochemical 
data. 
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Running SDS-PAGE of RhoAWT indicated that RhoA may be selectively oxidized at 
lower pH (<7.0). We verified RhoA cysteine reactivity by studying the modification of RhoA 
with ABD-F, which is a compound that selectively reacts with thiolates. The ABD-F data 
indicate that RhoA is oxidized primarily at Cys20 and Cys16 (Figure 12). Thus, the RhoAC16S 
variant shows greater reactivity to ABD-F than RhoAC16S/C20S. This indicates that Cys20, which 
is still present in the RhoAC16S variant, is being modified; however, in RhoAC20S, ABD-F 
reactivity was similar to the RhoAC16S/C20S variant, which suggests that Cys16 was not modified 
in RhoAC20S. The ABD-F reactivity observed in RhoAC16S/C20S was attributed to partial 
modification of Cys159, which is exposed when the protein undergoes nucleotide exchange, 
and partial modification of Cys105, which is on a face of RhoA that does not interact with 
effectors or interact with the nucleotide and is not expected to alter GTPase function. These 
data suggest that Cys20 is the central residue in RhoA regulation by oxidation. 
Due to the ABD-F results, we revisited the effects of oxidants on RhoA structure, 
stability and biochemical properties (+/- response to regulators), specifically oxidation at 
Cys20. Initially, we exposed RhoA to CysNO to determine the effect of S-nitrosation. 
Previously, RhoA was shown to have a significant increase in nucleotide dissociation after 
exposure to NO2• (79). While a subsequent study showed that a disulfide bond is generated 
between Cys16 and Cys20 (83), this study did not explore other potential oxidative 
modifications that could result. We selected CysNO to oxidize RhoA as this oxidant modifies 
exposed thiols with an NO group without radical formation. After exposing RhoA to CysNO, 
the rate of nucleotide dissociation of mantGDP-loaded RhoA was unaffected. This result is 
surprising as it suggests that nitrosation does not effect nucleotide binding and indicates 
that radical formation regulates RhoA nucleotide binding by nitric oxide oxidation.  
Oxidation by peroxide has been previously suggested to increase the rate of nucleotide 
dissociation by approximately 10-fold (79). However, RhoA was not oxidized by peroxide 
treatment before nucleotide dissociation was measured in this study, but rather peroxide 
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was added at the start of the assay. Results from this in vitro study indicate that peroxide 
addition to RhoA can increase nucleotide dissociation, but the sites and type of oxidation 
were not determined. The rate of thiol oxidation by peroxide can vary significantly as it is 
dependent on the accessibility and pKa of the cysteine (177). Further, the rate of cysteine 
oxidation on free cysteine has been shown to be approximately 20 M-1s-1. Therefore, we 
pretreated RhoA and RhoA variants with peroxide and observed nucleotide association. As 
RhoAWT showed a decrease in nucleotide binding after peroxide treatment, whereas 
RhoAC20S did not, this data indicates that oxidation is mediated through Cys20. Further, as a 
disulfide bond between Cys16 and Cys20 has been shown to inhibit nucleotide binding due to 
oxidation, it is likely that a disulfide bond between Cys16 and Cys20 has been formed, which 
explains the loss of binding that was observed. 
Another common 2e- modification common in cells is glutathiolation, which has been 
observed for Ras (77). As glutathiolation has been shown to be a possible outcome of 
activation by NO2• (120), which has been shown to generate a thiol radical in Ras (178), we 
tested the effect of glutathiolation on RhoA activity as this pathway of glutathiolation is 
likely for RhoA in cells. While we observed that glutathiolation of RhoA at Cys20 showed an 
increased nucleotide dissociation rate, we predict that oxidation at Cys20 can promote 
disulfide bond formation between Cys16 and Cys20 similar to peroxide. Therefore, we 
glutathiolated RhoAC16S to prevent intramolecular disulfides. This variant showed an 
increased nucleotide dissociation rate, indicating further destabilization of the nucleotide 
binding site.  
While we did not perform any experiments to explicitly determine the structure of the 
RhoA variants, we used CD spectroscopy and 2D NMR to indirectly observe the stability and 
structure of RhoAWT, RhoAC20S, RhoAC16A/C20A, and RhoAC20D. Thermal denaturation scans 
using CD (Figure 19) revealed that all of the redox-insensitive variants had similar thermal 
stability. However, the oxidation mimetic, RhoAC20D, showed decreased thermal stability. 
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The HSQC spectra show that the RhoAC20S variant is more similar to RhoAWT than 
RhoAC16S/C20S (Figure 20). While the RhoAC20S variant most closely resembled RhoAWT, the 
oxidation mimetic RhoAC20D had the largest number of chemical shifts. When the residues 
that showed a chemical shift are plotted on the crystal structure of RhoA, all variants at 
position 20 affected switch I and p-loop chemical shifts. However, RhoAC16AC20A and to a 
further degree, RhoAC20D, more altered chemical shifts in residues that are in switch I and p-
loop as well as in switch II. Thus, the NMR spectra suggest that RhoAC20S is a better redox-
insensitive variant than RhoAC16A/C20A as there are less chemical shift differences between 
RhoAC20S and RhoAWT. 
RhoA is initially oxidized at Cys20, which results in increasing the rate of nucleotide 
dissociation and was observed in glutathiolated RhoA and the RhoAC20D sulfinic acid mimic. 
However, as 2e- mediated oxidation is slow, it is likely that oxidants capable of generating a 
thiol radical play a bigger role in regulating RhoA activity. While the CysNO data suggests 
that nitrosation does not effect nucleotide dissociation, nitrosation is generally a free 
radical-mediated process in cells. Thus, NO2• has been shown to cause nucleotide 
degradation and dissociation (169) and likely leaves Cys20 as a thiol radical. This radical can 
react with Cys16, which results in RhoA inactivation due to the disulfide bond, or with other 
types of oxidants, such as glutathione or nitric oxide. Therefore, future studies that examine 
the oxidation properties of RhoA in cells should consider using the RhoAC20S variant to verify 
whether RhoA is being directly regulated by oxidants in cells. Taken together, our in vitro 
characterization of RhoA redox-insensitive variants shows that the RhoAC20S variant has the 
most similar kinetic rates, structure, and stability compared to RhoAWT, and importantly, is  
insensitive to thiol oxidation. As cellular based studies regarding oxidants have provided 
conflicting results in terms of RhoA regulation, the RhoAC20S variant will provide a new tool 
to determine whether RhoA is being directly oxidized and regulated, or whether the Rho 
effector proteins are being differentially regulated. 
88 
Chapter 5: Site-specific monoubiquitination activates Ras by 
impeding GTPase-activating protein function 
Introduction 
KRas has recently been shown to be activated by monoubiquitination (mUb). Similar 
to oncogenic mutations, mUb of Ras at position 147 activates Ras by causing a defect in 
GTPase activating protein (GAP) function. To characterize the mechanism by which mUb 
impairs GAP-mediated downregulation of Ras, we made various modifications at position 
147 of Ras and examined the impact on Ras sensitivity to GAP function. Whereas small 
modifications (iodoacetamide and glutathione) at position 147 of Ras do not affect GAP-
mediated hydrolysis, ligation of Ras to UbG76C (native linker), UbX77C (one residue longer), 
and PDZ2 (with a native ubiquitin linker) was defective in GAP-mediated GTP hydrolysis. 
However, restoration of GAP activity was observed for Ras modified with the similarly sized 
PDZ2 domain containing a shorter and stiffer linker region than ubiquitin. Therefore, the 
properties of the linker region dictate whether modification affects GAP-mediated 
hydrolysis, and our data indicate that the GAP defect requires a minimum linker length of 7 
to 8 residues.  
Commentary 
Ras GTPases regulate a variety of cellular functions, including gene expression, cell 
growth, and differentiation (179). Although Ras proteins are part of a larger superfamily of 
small guanine nucleotide binding proteins, Ras is the only family member that is frequently 
mutated in human cancer. Approximately 30% of all tumors contain Ras mutations. There 
are three isoforms of Ras (HRas, NRas, and KRas), which differ by their subcellular location. 
KRas is the most commonly mutated isoform of Ras in tumors (128). Ras GTPases cycle 
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between the GDP-bound ‘off’ state and GTP-bound ‘on’ state to regulate a plethora of 
signaling pathways that control cellular growth. As the intrinsic rates of nucleotide 
dissociation and GTP hydrolysis are too slow to function on the time scale of most cellular 
events, Ras activity is dictated by regulatory proteins. These regulatory proteins include 
guanine exchange factors (GEFs), which activate Ras by facilitating nucleotide exchange, 
and GTPase-activating proteins (GAPs), which downregulate Ras activity by increasing the 
rate of GTP hydrolysis. Oncogenic mutations lead to constitutive activation of Ras most 
commonly by causing a GAP defect. Recent work by Sasaki et al (16) demonstrated that post-
translational modification of KRas at position 147 by monoubiquitination (mUb) is another, 
yet novel, mechanism of Ras activation. While mUb has been shown to regulate a number of 
cell functions, including DNA repair, gene expression, endocytosis, and nuclear export (180), 
the regulation of protein activity by mUb is emerging as another functional role (181). 
Furthermore, mUb is highly regulated and can be reversed by deubiquitinating enzymes 
(182). KRas is predominately monoubiquitinated at Lys147. Sasaki et al showed that mUb of 
KRas (mUbRas) resulted in an increased fraction of GTP-bound Ras, altered effector 
specificity, and increased tumorigenicity. Lysine147 is part of the highly conserved motif 
(SAx) in Ras superfamily GTPases and forms critical interactions with the guanine 
nucleotide base. Within the SAx motif in the Ras subfamily, Lys147 is less conserved (67%) 
relative to Ser145 (97%) and Ala146 (89%) (183). Mutation of Ala146 to valine results in 
oncogenic transformation of Ras due to increased nucleotide exchange, which populates Ras 
in the GTP-bound form (184). Thus, Sasaki et al hypothesized that mUb of Ras at Lys147 
activates Ras by enhancing nucleotide exchange and populating Ras in its active GTP-bound 
state.  
While mutation of the site of KRas mUb (K147L) reduced tumorigenesis in 3T3 cells 
injected into mice (16), it is unclear whether altered levels of Ras mUb occur in primary 
tumors as most studies probe for Ras mutations and not upregulation of Ras activity. 
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Moreover, the levels of mUb Ras are controlled by enzymes responsible for ubiquitination 
and deubiquitination, which can become altered in many cancers (185). Aside from 
elucidating how ubiquitin alters Ras properties, determining the enzymes necessary for Ras-
mediated ubiquitination is a critical future direction in understanding the role of this 
modification in healthy and diseased states. Sasaki et al found that mUbRasG12V was more 
oncogenic than RasG12V (16). This is an interesting result as KRas mUb may contribute to 
tumorigenicity in the context of a GAP-defective oncogenic mutation (G12V), possibly 
because of enhanced association with select effectors (16). Thus, more studies probing Ras 
oncogenicity should be performed in cell lines with and without Ras mutation-driven 
tumors. In addition, the role of mUbRas in regulating effector specificity should be 
investigated. Understanding the functional consequences underlying this post-translational 
modification will be critical to understanding the role of mUbRas under normal and 
oncogenic conditions. 
Towards this goal, Baker et al recently elucidated how mUb of KRas at 147 upregulates 
Ras activity in vitro. Moreover, they were able to verify the GAP-deficient defect of mUb 
KRas immunoprecipitated from HEK293T cells (15). First, it was shown that mutating Lys147 
to less conservative substitutions, such as K147A and K147L, had only a modest effect on 
intrinsic and regulator (GEF/GAP)-mediated GTP hydrolysis and nucleotide exchange. This 
finding indicates that Lys147 does not play a critical role in nucleotide binding, but rather, 
Lys147 may be conserved in Ras GTPases for regulation by ubiquitin modification. Baker et al 
developed a method to chemically modify Ras in vitro with ubiquitin using variants 
containing a cysteine substituted at the site of ubiquitination (RasK147C and ubiquitinG76C) 
(15). The studies were conducted in the context of the RasC118S substitution, which does not 
alter Ras structure or biochemical properties (66, 131), so that position 147 was specifically 
modified. The intrinsic and regulator-mediated rates of nucleotide dissociation and GTP 
hydrolysis on RasC118S/K147C (hereafter called RasCSKC) were measured. While mUb of Ras did 
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not alter the intrinsic rates of nucleotide dissociation or GTP hydrolysis, mUbRas impaired 
GAP-mediated GTP hydrolysis. This finding explains the observed increase in active GTP-
loaded Ras observed for the mUbRas pool in vivo (16). Baker et al verified these in vitro 
findings in HEK293T cells as immunoprecipitated mUbRas, but not unmodified KRas, was 
GAP defective. Thus, increased Ras activation upon mUb results from the loss of GAP 
activity and not an increase in intrinsic nucleotide exchange (15). Monoubiquitination of Ras 
may be activated in a similar manner to common GAP-defective oncogenic Ras mutations at 
positions 12, 13, and 61 (128). 
It is unclear how mUb of Ras impairs GAP-mediated hydrolysis while retaining the 
intrinsic rate of GTP hydrolysis. One possibility is that mUbRas is not responsive to GAP-
mediated hydrolysis because GAPs cannot bind to the transition state of mUbRas, similar to 
many oncogenic mutations at position 12 and 13 (186). Using the transition state analog that 
consists of AlF3 and GDP, Baker et al determined that mUbRas could still bind GAPs while in 
the transition state, albeit with decreased binding (15). However, binding to the transition 
state is not necessarily indicative of GAP sensitivity because the RasG12A mutant is 
unresponsive to GAP-mediated hydrolysis but can still bind to GAPs in the presence of the 
transition-state analogs (186). It is currently postulated that GAPs enhance the rate of GTP 
hydrolysis by stabilizing the switch regions around position Gln61 for in-line nucleophilic 
attack on the γ phosphate as well as to move Tyr32 to an open position, which provides space 
for the GAP arginine ‘finger’ to insert into the binding pocket and catalyze phosphate 
hydrolysis (187). The data from Baker et al indicate that ubiquitin ligation to Ras impairs 
GAP-mediated hydrolysis without forming a high-affinity interaction with a particular 
surface of Ras. Using nuclear magnetic resonance (NMR) spectroscopy and Rosetta-based 
computer simulations, Baker et al demonstrated that ubiquitin does not specifically interact 
with Ras but that ubiquitin ligation to Ras affects the dynamics of the switch regions and 
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phosphoryl-binding loop (p-loop) (15). This finding suggests that mUbRas may alter the 
conformational dynamics of regions critical for GAP-mediated GTP hydrolysis.  
While Ras has not been shown to directly interact with ubiquitin, it is unclear if there 
are transient or low affinity interactions between Ras and ubiquitin that alter the ability of 
GAP proteins to facilitate the rate of GTP hydrolysis. To simplify this post-translational 
modification, mUb may be viewed as two components: a ball, which consists of the core 
ubiquitin domain, and a chain (tether), which consists of the 7-residue linker from the core 
ubiquitin domain to the carboxy-terminus. To confirm that the deficiency in GAP-mediated 
GTP hydrolysis was not due to specific interactions formed between Ras and ubiquitin, we 
ligated RasCSKC to a modified PDZ2 domain (PDZ2UL; with the same carboxy-terminal linker 
as ubiquitin), which is a protein with a similar size and fold as ubiquitin. We found that Ras 
ligated to PDZ2UL was also defective in GAP-mediated GTP hydrolysis, which supports 
earlier NMR and modeling studies (15) that indicate that ubiquitin does not specifically 
interact with Ras but samples a range of conformations on the surface of Ras to render Ras 
insensitive to GAP-mediated GTP hydrolysis. To address whether the size of the 
modification (ball) or length of the tether (chain) at position 147 significantly contributes to 
the loss of GAP-mediated hydrolysis, we expanded on our earlier work by modifying Ras 
with various modifications. These modifications include iodoacetamide (IAA), glutathione, 
PDZ2 with a shortened linker region (PDZ2SL; the chain was truncated to 6 residues), and 
ubiquitin with a slightly longer linker UbX77C (chain length was increased to 8 amino acids) 
and measured the intrinsic and GAP-mediated rates of GTP hydrolysis.  
Although mutation of Ras at Lys147 does not significantly alter nucleotide hydrolysis 
(15), it is possible that small modifications of Ras at Lys147 could affect GAP-mediated GTP 
hydrolysis. Thus, we first modified purified KRasCSKC with IAA. This modification was 
selected because IAA is small, uncharged, and the chemistry of cysteine oxidation has been 
sufficiently documented (188, 189). Using a fluorescence-based GTP hydrolysis assay (15, 
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131), we found that iodoacetylation of KRasCSKC did not affect either the intrinsic or GAP-
mediated rates of GTP hydrolysis when using the p120 RasGAP catalytic domain (GAP334) 
compared to unmodified KRasCSKC (Figure 24A). We also modified KRasCSKC with 
glutathione. Glutathione was selected because it is larger than IAA (305 Daltons compared 
to 58, respectively) and has a negative charge. Furthermore, the cysteine in glutathione 
allows for disulfide bond formation between KRasCSKC and glutathione, which is similar to 
the ubiquitin ligation technique presented in Baker et al (15). We verified that KRasCSKC was 
100% glutathiolated at position 147 using mass spectrometry (Figure 24B, C), and similar 
to our findings with iodoacetylated RasCSKC, we find that glutathiolated RasCSKC possesses 
similar rates of intrinsic and GAP-mediated GTP hydrolysis compared to unmodified 
KRasCSKC. These in vitro results indicate that perturbations at position 147 of Ras, by 
mutation or small molecule modifications (up to ~300 Da), do not affect GAP-mediated 
hydrolysis.  
We next asked whether the linker length associated with either PDZ2 or ubiquitin 
ligation to Ras was important for GAP-mediated GTP hydrolysis. We have previously shown 
that a ~2 kDa larger ball (PDZ2UL instead of ubiquitin) ligated to position 147 of Ras retained 
the GAP defect observed with mUb (15); however, it was unclear how different chain lengths 
associated with the ligation affect GAP-mediated GTP hydrolysis. Toward this end, we 
altered the properties of the linker between Ras to either ubiquitin or PDZ2. We first 
increased the linker length by 1 residue by ligating Ras to a ubiquitin variant (UbX77C; Figure 
25C) and observed a similar GAP defect to that of mUbRas. However, when we shortened 
the chain length by 1 residue, by modifying Ras with PDZ2 with the native PDZ2 carboxy-
terminus (PDZ2SL; 6 residue linker), we observed that ligation of PDZ2SL to Ras restored 
sensitivity to GAP-mediated GTP hydrolysis. While the linker length for this ligation is 1 
residue shorter, the composition of the linker differs from that found in ubiquitin and is 
predicted to be less flexible by FlexServ (190). Taken together, these data indicate that the  
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Figure 23. Characterization of GTP hydrolysis of oxidized RasCSKC. 
(A) Rates of intrinsic and GAP-mediated hydrolysis of KRas with various modifications. 
The minimal catalytic domain of p120 RasGAP, residues 1-334, was used. The relative rates of 
hydrolysis are presented using the phosphate detection protein FlipPi, as previously reported (10, 
11). All reactions were performed in triplicate and fit to a single exponential dissociation curve 
using GraphPad Prism. The error is reported as the standard deviation of the replicates. (B) MS3 
product ion showing c- and z-type product ions resulting from the dissociation of the N-C (alpha) 
bonds due to electron transfer dissociation (ETD) of a 6+ charge of collision-induced dissociation 
(CID)-derived [Y30+G] product ions. The [Y30+G] product ions were generated by CID-MS/MS, 
which generated b- and y-type fragment ions from the dissociation of the backbone amide bonds 
of a 20+ product ion from intact KRasCSKC modified with a single glutathione. (C) MS4 product ion 
spectrum derived from CID-MS3 of the singly charged glutathione product ion (G+). Note that the 
glutathione moiety was confidently localized to cysteine 147 of KRasCSKC by tandem mass 
spectrometry. Mass spectrometry data collected in collaboration with Harsha Gunawardena. 
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linker length and/or flexibility are critical for the GAP defect upon ligation to position 147 of 
Ras and suggest that conformational sampling or accessibility to a particular surface(s) of 
Ras may play an important role in the ability of mUb at position 147 of Ras to impede GAP-
mediated GTP hydrolysis.  
By comparing the findings in Baker et al to the present results, the composition and 
length of the linker (chain) associated with either PDZ2 or ubiquitin ligation to position 147 
of Ras appear critical for inhibition of GAP-mediated GTP hydrolysis. Although we find that 
a ball size between 8-10 kDa attached to a ubiquitin linker of at least 7 residues can impede 
GAP-mediated hydrolysis, we have not determined whether there is a minimum ball or 
maximum chain size associated with the inhibition of GAP function. However, we have 
shown that there is a minimal chain length for effective inhibition. We modified Ras at 
position 147 with UbX77C, which is 1 C-C bond length longer than the native ubiquitin 
modification as well as UbG76C, which is 2 C-C bond lengths shorter than the native 
modification, and both of these modifications fully inhibit GAP-mediated GTP hydrolysis in 
our assays. Further, when using the PDZ2SL modification, which is 5 C-C bond lengths 
shorter than the native modification, Ras was responsive to GAP-mediated GTP hydrolysis 
(see Figure 25 for chain length depictions and Figure 26 for a structural representation of 
the modifications). These results suggest that there is a minimum chain length for the 
ubiquitin modification to inhibit GAP-mediated GTP hydrolysis of Ras. However, as 
ubiquitin does not appear to specifically interact with Ras, we reviewed proposed 
mechanisms of GAP-mediated hydrolysis to generate a hypothesis as to why mUbRas 
displays a GAP defect. 
GAP proteins interact with Ras and greatly facilitate GTP hydrolysis rates via three 
primary steps, according to a report by Kötting et al (191, 192). Using Fourier-transformed 
infrared (FTIR) spectroscopy and photo-caged GTP-bound Ras complexed with p120 
RasGAP, the authors first observed movement of switch I from an ordered ‘off’ state to an  
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Figure 24. Depiction of the protein:protein ligations in this study.  
Ras is indicated in red and the attached modifications are in black. The single letter amino acid 
code associated with the tether of ubiquitin and PDZ2 are highlighted in bold font. (A) The native 
ubiquitin modification of Lys147 of Ras. (B) The chemical ubiquitination by disulfide formation 
between RasK147C and UbG76C. (C) The chemical ubiquitination of RasK147C by UbX77C. Gly76 is 
highlighted by a black box to show the increased size of the UbX77C modification compared to the 
native modification. (D) The chemical ubiquitination of RasK147C to PDZ2UL. (E) The chemical 
ubiquitination of RasK147C to PDZ2SL. The linker region of PDZ2SL is outlined to highlight the 
differences within the linker region. The core domain of each ligated protein is also shown. 
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Figure 25. Pymol-generated images of the small molecule modifications as well as PDZ2 
and mUb.  
(A) KRas (PDB 3GFT) with the K147C mutation modified with iodoacetamide. (B) KRas (PDB 
3GFT) with the K147C mutation modified with glutathione. (C) HRas (PDB 1CRR) with the K147C 
mutation ligated to ubiquitin, which is ligated to Ras by a disulfide bond through a cysteine at 
K147C and a C-terminal cysteine in ubiquitin (G76C). (D) HRas (1CRR) with the K147C mutation 
ligated to PDZ2SL with a C-terminal cysteine by a disulfide bond. Structural depictions on (A) and 
(B) were generated in pymol and are presented for comparison of size. Depictions in (C) and (D) 
were generated using Rosetta and are depictions of low-energy models of the complex. Ras is 
shown in teal in all images, switch I (residues 25-40) is in red, switch II (residues 57-75) is in 
green, and each modification is in magenta. The nucleotide has been removed from (B), (C), and 
(D) for clarity. 
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ordered ‘on’ state. The second step of GAP-mediated hydrolysis involves the movement of 
the arginine finger of the GAP into the catalytically active position, and the third step is 
cleavage of the γ phosphate. Recently, Rudack et al used FTIR and biomolecular simulations 
to study the mechanism of GAP-mediated GTP hydrolysis in Ras in more detail (193). In this 
study, the authors suggest that GTP hydrolysis is a result of the α, β, and γ phosphates being 
pulled into an eclipsed conformation by GAP binding, which results in the γ phosphate 
becoming more electro-positive; this allows the catalytic water to hydrogen bond with the γ 
phosphate and accelerate hydrolysis by nucleophilic attack. Further, Rudack et al used FTIR 
to show that the GAP-arginine finger forms hydrogen bonds with the α and γ phosphates of 
GTP (193, 194). Molecular dynamics simulations performed by Kötting et al (191, 192) 
indicate that when the arginine finger inserts into the active site of Ras, it displaces 5 water 
molecules and increases the negative charge on the β phosphate and imparts partial positive 
charge to the γ phosphate of GTP. The removal of the water molecules has been theorized to 
provide the thermodynamic (entropic) energy necessary for GAP-mediated hydrolysis (191). 
Furthermore, Grigorenko et al (195) suggested that the placement of the arginine finger 
locks a conformation of the GTP binding pocket that decreases the free energy necessary for 
γ phosphate cleavage. In the GAP-bound state, Grigorenko et al determined that Gln61 of Ras 
and Arg789 of p120 RasGAP, as well as Thr35 (switch I), Mg2+, Gly60 (switch II) and Lys16 (p-
loop), provide further orientation of the phosphates of GTP and facilitates hydrolysis. 
However, in intrinsic Ras-mediated GTP hydrolysis, only Thr35, Mg2+, Gly60, Lys16, and water 
molecules are directly involved in GTP hydrolysis, which results in an increased activation 
energy (195). The primary factors proposed for driving increased nucleotide hydrolysis of 
Ras by GAPs include reorientation of the γ phosphate, Gln61, and catalytic water of Ras as 
well as the placement of the arginine finger from the GAP.  
These mechanistic studies of GAP-mediated hydrolysis can be used to generate a 
hypothesis for the results observed by Baker et al (15). Although Baker et al showed that 
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GAPs still bind to the transition state of mUbRas, the binding affinity and whether the GAP 
favors the proper conformation of Ras for GTPase activity was not determined. The data by 
Kötting et al imply a structural rearrangement by insertion of the arginine finger by the GAP 
after binding to Ras, and it is unclear whether this structural rearrangement by the GAP is 
impeded in mUbRas. NMR and Rosetta simulations indicate that when Ras147 is ligated to 
ubiquitin, ubiquitin samples a large surface area of Ras, including parts of the p-loop and 
switch regions. As GAP binding has been shown to restrict the motions of the phosphate 
moieties of GTP and switch regions (193), these regions in mUbRas may not conducive for 
GAP-mediated hydrolysis (15). Specifically, the NMR data suggest that conformational 
dynamics of the p-loop and switch regions are altered by ubiquitin ligation at position 147, 
which could change either the rates or population of the conformers associated with these 
regions. However, it will be important to better characterize the conformational dynamics 
associated with GTP-bound mUbRas as only the GDP-bound form of mUbRas was studied 
by NMR (15). The inability to populate the correct orientation of the active site, specifically 
the region near the p-loop, could prevent stabilization of the switch regions in Ras as well as 
the eclipsed conformation of GTP, which would likely prevent GAP-mediated hydrolysis. 
This hypothesis is consistent with the simulations performed by Rudack et al, who proposed 
that the eclipsed phosphate conformation is necessary for hydrolysis. Thus, modification 
alone at position 147 is not enough to prevent hydrolysis-competent conformations; 
however, the ability of tethered ubiquitin to sample regions associated with the catalytic site 
(p-loop and switch regions) is necessary to interfere with GAP function. In this case, other 
modifications of Ras, such as PDZ2SL, that possess a shorter tether may not alter the 
conformational dynamics of the Ras switch regions and p-loop, and thus retain the ability to 
be downregulated by GAPs, which is likely why the smaller modifications (IAA and 
glutathione) and PDZ2SL do not affect GAP-mediated hydrolysis.  
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In summary, we present additional data that provide further insight into how ligation 
of ubiquitin to Ras147 results in a GAP-deficient phenotype. Using the KRasCSKC variant, we 
were able to build on the recent publication by Baker et al and show that smaller 
modifications of Ras at position 147 (IAA and glutathione) do not affect GAP-mediated 
hydrolysis. However, as both the PDZ and ubiquitin modifications result in a GAP defect, the 
minimum size of the modification necessary to generate the GAP defect is not known. 
Rather, by changing the tether length of the PDZ2 domain, we were able to show that there 
is a critical tether length needed to produce a GAP defect. Thus, with the PDZ2SL 
modification, no loss of GAP function was observed; however, with the longer tether, 
PDZ2UL, a complete loss of GAP function was observed. The ability of ubiquitin ligation to 
Ras at position 147 to impede GAP-mediated GTP hydrolysis appears to be dependent on the 
length and composition of the linker, which we speculate to be important for the 
conformational sampling of a surface(s) on Ras that prevents GAPs from catalyzing GTP 
hydrolysis, and downregulation of Ras activity. As mUbRas appears to mediate Ras-induced 
tumorigenesis in HEK293T cells, understanding how this modification alters Ras function 
could aid in providing a new direction for inhibiting Ras-driven tumors. 
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Chapter 6: Biophysical and Proteomic Characterization Strategies for 
Cysteine Modifications in Ras GTPases 
Introduction 
One of the most reactive amino acids in proteins is cysteine, which can undergo a 
variety of different post-translational modifications and several different types of oxidative 
reactions (196). In fact, thiol oxidation plays a key role in regulating redox homeostasis and 
protecting the cell during oxidative stress (197-199). Moreover, many genes that respond to 
redox stress show altered regulation by reactive oxygen and nitrogen species (ROS and RNS) 
(200). Some of the common end products of cysteine oxidation are disulfide bond 
formation, mixed disulfide bond formation with glutathione (glutathiolation), and 
nitrosation as well as sulfenic, sulfinic, and sulfonic acid (201). Many redox-sensitive 
proteins contain cysteine residue(s) that have an altered pKa. The microenvironment 
surrounding the cysteine determines the pKa of the thiol side chain. However, cysteine pKa 
values are difficult to reliably predict as several factors influence pKa, including solvent 
exposure, hydrogen bond formation, and charge-charge interactions (202). The pKa of L-
cysteine in water has been measured to be ~8.5-9, and the thiolate form (RS-) is 
approximately tenfold more reactive than the thiol form (RSH) (203). Thus, redox-regulated 
proteins often contain reactive cysteines with altered pKa values that are close to or lower 
than physiological pH.  
Critical cellular enzymes that regulate redox homeostasis include peroxiredoxins 
(reduce peroxide), thioredoxins (reduce oxidized peroxiredoxin), and glutathione 
peroxidases (reduce peroxide using the cellular glutathione pool), which act through 
mechanisms involving cysteine oxidation. The pKa of the active-site cysteines have been 
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shown to be markedly reduced in each of these classes of enzymes; for example, the active-
site cysteine pKa has been shown to be approximately 5-6 in 2-Cys peroxiredoxins (204), the 
active-site cysteine in Escherichia coli thioredoxin was measured to be between 7.1 (205) 
and 7.5 (206), and the pKa of the active-site cysteine in glutathione peroxidase has been 
estimated to be 7.2 (207).  
The work in our lab is centered on the redox regulation of Ras superfamily GTPases. 
We have shown that the activity of a subset of Ras and Rho GTPases can be regulated 
through redox-sensitive cysteines (21, 57, 164). Ras GTPases, in particular, have received a 
great deal of interest in the field of redox biology. There are four distinct Ras genes in the 
human genome, H-, K- (1A and 1B) and N-Ras, which differ primarily in their carboxyl-
terminal regions. They encode small, 21-kDa guanine nucleotide binding proteins that 
function as molecular switches to modulate signaling pathways that control cell growth, 
differentiation, and apoptosis (86). This is achieved by cycling between the inactive (‘off’) 
GDP-bound and active (‘on’) GTP-bound states. Given the high affinity interaction between 
Ras and its nucleotide ligands (GDP and GTP) as well as the slow intrinsic rate of GDP 
dissociation and GTP hydrolysis, two classes of modulatory proteins regulate the activation 
state of Ras proteins. One class of proteins that activate Ras is guanine nucleotide exchange 
factors (GEFs), which promote exchange of GDP for GTP. Analogous to guanine nucleotide 
exchange factors, redox agents have been shown to stimulate nucleotide exchange and alter 
the activity of Ras proteins through reaction with cysteine 118 (Cys118), which is located in a 
conserved guanine nucleotide-binding motif (94). We have found that only redox agents 
capable of thiyl radical formation, such as NO2•, can modulate Ras activity (69). Thiyl radical 
formation at Cys118 facilitates guanine nucleotide exchange in Ras by promoting oxidation 
and the subsequent dissociation of the bound guanine base (62). In cells, where the 
GTP/GDP ratio is in excess, this can lead to exchange of GDP for GTP and result in Ras 
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activation. Importantly, this mechanism of Ras regulation has been shown to play a role in 
Ras-mediated tumorigenesis and tumor maintenance (63).  
Rho GTPases are members of the Ras superfamily, and like Ras GTPases, function as 
molecular switches to regulate cellular growth. However, they also regulate cell motility and 
oxidant regulation (4). We have previously shown that a subset of Rho GTPases can be 
regulated through redox modification (80). These GTPases contain a distinct, reactive 
cysteine that is conserved in ~40% of Rho GTPases and renders them sensitive to oxidation 
and oxidative modification in cells (81).  
Although several methods to determine cysteine pKa values have been employed in the 
field (202), we have recently developed a fluorescence-based method to measure cysteine 
pKa values (208). Using 4-fluoro-7-aminosulfonylbenzofurazan (ABD-F), a compound that 
specifically reacts with the thiolate form of the cysteine side chain, we have been able to 
measure the pKa of reactive thiols in Ras and Rho family GTPases. In Ras, Cys118 is the only 
solvent accessible cysteine in the core catalytic domain (Ras residues 1-166). Thus, Ras 
provides an excellent system to demonstrate the use of the ABD-F strategy for measuring 
pKa values of cysteine thiol side chains. 
When coupled with mass spectrometry (MS), this method provides an analytical 
platform for the detection and quantification of redox modifications in Ras family GTPases 
and other proteins. The bottom-up MS method we’ve employed (209) requires proteolytic 
digestion with trypsin followed by LC-MS analysis by electrospray ionization (ESI). The 
accurate identification of peptides has become a routine practice with the availability of a 
vast number of programs and search engines that assist in assigning peptide sequences to 
mass spectra using probabilistic prediction algorithms (210). In addition, the intensity, or 
spectral count information, can be used for the relative or absolute quantification of peptides 
associated with site-specific protein modifications.  
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Herein, we describe in detail a new method for determining the pKa of cysteine thiols 
in proteins as well as the use of MS approaches to quantify the level of modification, 
including (1.1: Cysteine pKa determination using 4-fluoro-7-aminosulfonylbenzofurazan), 
the preparation and handling of several ROS and RNS (1.2: Generation of cysteine-
modifying redox-active compounds and 1.3: NO2• generation and NONOates), and mass 
spectrometry-based methods for determining the type and site of cysteine oxidation (1.4: 
Quantitative mass spectrometry), including 1.4.1: Isotope-coded affinity tag-labeling for 
relative cysteine quantification, 1.4.2: Quantification of the cysteine oxidation, 1.4.3: 
Differential quantification of cysteine oxidation, 1.4.4 Differential thiol trapping to 
determine reversible oxidation of cysteine residues, and 1.4.5 Filter-aided sample 
preparation.  
Materials 
2.1 ABD-F buffers and reagents 
1. Components: 4-fluoro-7-aminosulfonylbenzofurazan (ABD-F), black, flat-bottom, 
non-coated plates, and protein spin concentrators.  
2. Reducing Buffer: 15 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(Hepes), pH 8.0, 5 mM MgCl2, 30 mM NaCl, 200 μM diethylene triamine 
pentaacetic acid (DTPA), 5 mM dithiothreitol (DTT; added day of use). 
3. ABD-F modification buffer: 15 mM 2-(N-morpholino)ethanesulfonic acid (MES), 
pH 6.5; see note 1), 5 mM MgCl2, 30 mM NaCl, 200 μM DTPA. 
4. pH screen buffer (for a pH range between 5.5 to 8.5): 100 mM MES, 100 mM 
Hepes, 5 mM MgCl2, 200 μM DTPA (titrate each pH value individually). 
2.2 Nitrosation reagent (CysNO/GSNO) generation 
1. Solution I: 50 mM L-cysteine (or reduced glutathione) in 120 mM HCl 
2. Solution II: 50 mM NaNO2  
105 
3. Solution III: 40 mM Ammonium Sulfamate 
4. CysNO dilution buffer: 100 mM Hepes, pH 7.5, 5 mM MgCl2, 1 mM DTPA 
2.3 Nitric oxide releasing agents (NONOates) 
1. All NONOate compounds (available from Cayman Chemicals) 
2. 4,5-diaminofluorescein (DAF-2)  
2.4 Mass Spectrometry techniques 
2.4.1.  Isotope-coded affinity tag (ICAT)-labeling for relative cysteine quantification 
1. Strong cation-exchange (SCX) PolySulfoethyl A column; Isotope-coded affinity tag 
(ICAT) reagents (AB Sciex; Framingham, Ma), kit includes a cation-exchange 
cartridge and Avidin affinity cartridge; micro-concentrator/spin filter device; C18 
spin column. 
2.4.2  Quantification of the cysteine oxidation  
1. Ammonium Bicarbonate (ABC) Buffer: 200 mM NH4HCO3 
2. ABC + Iodoacetamide (IAM): 200 mM NH4HCO3, 5 mM IAM 
3. Phosphate buffer: 100 mM Na2HPO4, pH 7.4, 50 mM NaCl, 5 mM MgCl2 
4. Phosphate-buffered saline (PBS): 10 mM Na2HPO4, 2 mM KH2PO4, 137 mM NaCl, 
2.7 mM KCl 
5. BIAM-elution buffer: 50 Na2HPO4, pH 7.2, 2 mM D-biotin, 150 mM sodium 
chloride  
2.4.3  Differential quantification of cysteine oxidation  
1. Tris Buffer: 50 mM Tris, pH 8.5, 25 mM NaCl, 5 mM MgCl2  
2. SCX Buffer A: 10 mM KH2PO4, pH 3.0, 20% (vol/vol) acetonitrile (ACN) 
3. SCX Buffer A: 10 mM KH2PO4, pH 3.0, 350 mM KCl, 20% (vol/vol) ACN 
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2.4.4  Differential thiol trapping to determine reversible oxidation of cysteine residues 
1. Denaturing alkylation buffer (DAB): 200 mM Tris, pH 8.5, 8 M urea, 0.5% (wt/vol) 
SDS, 10 mM EDTA 
2.4.5  Filter-aided sample preparation (FASP) 
1. Denaturing buffer: 0.1 M Tris, pH 8.5, 8 M Urea 
2. Iodoacetamide (IAM) buffer (should be made day of use): 0.1 M Tris, pH 8.5, 50 
mM IAM, 8 M urea 
Methods 
3.1: Cysteine pKa determination using 4-fluoro-7-aminosulfonylbenzofurazan 
(ABD-F)  
1: Determine the amount (in moles) of protein that will be required to perform the 
assay. The assay as described is performed in a 96-well plate and requires fluorescence 
detection at 513 nm (excitation at 389 nm). Each well should contain approximately 5 or 10 
μM protein and be performed in triplicate at each pH value (technical repeats). To 
determine the pKa accurately, a pH range must be performed with adequate coverage. As 
ABD-F fluorescence intensity is sensitive to the site of modification, it is important to ensure 
similar buffer conditions across the pH range selected. 
2: Calculate the quantity of protein required; for example, 12 pH values performed in 
triplicate requires approximately 72 nmol of protein to perform the assay (200 μl/well; 10 
μM/well * (36 wells * 200 μl) = 72 nmol required). 
3: Reduce the protein with dithiothreitol (DTT) or dithiobutylamine (DTBA) (see note 
2) to increase the yield of protein that can react with ABD-F. For adequate reduction, 
exchange the protein into a buffer containing 5 mM (or greater) DTT. Prepare the reducing 
buffer (minimum pH of 8.0) and exchange the protein into the buffer. As a subset of 
oxidative reactions (sulfenic and sulfonic acid) will not be reversed by DTT (see note 3), this 
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step serves to increase the percentage of protein that can be modified by ABD-F and 
enhances the signal-to-noise ratio of the assay.  
4: While the protein is being buffer exchanged, prepare the ABD-F modification 
buffer. To remove dissolved oxygen (see note 4), sparge the ABD-F modification buffer with 
an inert gas, such as N2, for 30 minutes.  
5: Incubate the protein in reducing buffer for at least 60 minutes on ice for complete 
reduction. 
6: Buffer exchange the protein into the sparged ABD-F modification buffer using spin 
concentrators (use appropriately sized membrane pores). This step removes reducing agents 
from the sample. It is critical that at least three rounds of exchange are performed to 
efficiently remove the reducing agent from the sample (see note 5).  
7: Determine the protein concentration. 
8: Set up the 96-well plates. The excitation wavelength for ABD-F is 389 nm and 
emission wavelength is 513 nm. Set up a ‘dummy tray’ that contains half of the volume of the 
final reaction (100 μl). In the ‘dummy tray’, add ABD-F to a final concentration that is 
double the intended concentration (add 2 mM ABD-F in 100 μl). As the reaction proceeds 
through second-order kinetics, it is critical that all wells contain exactly the same amount of 
protein and ABD-F; therefore, the rate of modification is related to the thiol/thiolate state of 
the cysteine. In a separate 96-well plate, replicate the pH screen of the ‘dummy tray’, but add 
20 µM protein in 100 μl to each well (see note 6). 
9: Using a multi-channel pipette, quickly remove the solution from the ‘dummy tray’ 
and place the solution into the respective wells of the test plate to initiate the ABD-F 
reaction. Quickly start the plate reader for data collection. 
10: Data analysis (see note 7). Use the linear portion of the initial slopes to calculate 
the rate of fluorescence generation over time (Figure 27 A, B). Plot the determined rates of 
fluorescence generation vs. pH and fit the resulting sigmoidal curve to a Boltzman sigmoidal  
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Figure 26. ABD-F modification of H-RasWT over a selected pH range.  
(A) H-RasWT (10 µM) was reacted with ABD-F (1 mM) over 6 h at the indicated pH values. 
Each reaction was performed in triplicate (error bars removed for clarity). Absolute fluorescence 
values are presented. In systems containing one modifiable cysteine, the total fluorescence values 
will plateau at a similar value if given sufficient time. The inset shows the relative reactivity of H-
RasC118S, which was performed under identical conditions as H-RasWT. (B) The initial rates of 
ABD-F modification are used for pKa determination. Here, the initial data are presented (zoomed 
in from Fig 1A), and the initial rate was determined using GraphPad Prism; linear curve fitting 
was performed. Error bars are removed for clarity. (C) The observed rates of modification are 
plotted against pH. Each data point represents the rate of modification determined from the curve 
fitting in (B). The data were fit to a Boltzmann Sigmoidal distribution to determine the pKa. 
Control data (see inset in figure 27A) show that only Ras Cys118 is modified by ABD-F as the 
RasC118S control shows no reactivity. However, RasCys118 does not have an altered pKa. Hence, the 
maximal rate of modification could not be obtained as Ras becomes unstable at high pH values. 
Therefore, the pKa is an estimate. 
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equation. This equation is used to calculate the pKa for a single site-specific modification 
(see note 8; Figure 27C). 
11: After the fluorescence data has been collected, determine the site(s) modified by 
ABD-F (see note 9). A straightforward method is to employ liquid chromatography-mass 
spectrometry (LC-MS) on trypsin-digested samples. We have also found that cysteine-to-
serine mutants can be used to confirm modification sites if the mutation does not alter the 
protein structure and/or ABD-F reactivity. 
3.2: Generation of cysteine-modifying redox-active compounds (CysNO/GSNO 
generation) 
As the reactions of ROS and RNS with proteins are diverse and often complex, this 
section will focus on the generation and quantification of various redox-active compounds. 
Chapter 3.4 describes mass spectrometry (MS) approaches to quantify and determine the 
sites of modification. 
1: Prepare solution I and solution II on the day of use (see note 10), as detailed in 
Section 2.2 (see note 11).  
2: Mix 100 μl of solution I with 100 μl of solution II and place into a foil-covered 1.5-
ml eppendorf tube. Allow the reaction mixture to sit in the dark for 10 min. These reactions 
are highly light sensitive; therefore, care should be maintained to keep all reactions in the 
dark. 
3: Add 20 uL of 40 mM ammonium sulfamate to remove unreacted nitrate and allow 
the reaction to proceed in the dark for an additional 2 min. This protocol assumes an ~85% 
efficiency of the reaction (although published reports suggest an efficiency as high as ~90% 
(211)) and adds a sufficient concentration of sulfamate to remove all remaining NO2.  
4: Dilute the thiol-NO (i.e., CysNO or GSNO) with 880 μl (4-fold) of a CysNO dilution 
buffer (see Materials). While this buffer can be altered to fit the needs of the individual 
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researcher, the high concentration of the buffer component prevents changes in pH, reduces 
metal contaminants, and increases the half-life of the thiol-NO in solution (132, 212). 
5: Concentration determination. The easiest way to measure the concentration of the 
generated thiol-NO is to measure absorbance at 336 nm. The molar absorptivity for CysNO 
and GSNO is 900 M-1cm-1. Alternatively, the molar absorptivity of 16.8 M-1cm-1 at 543 nm 
can be used for concentration determination (see note 12).  
3.3 NO2• generation and NONOates  
While CysNO represents a good nitrosation agent that can modify protein thiols 
through non-radical oxidative (two-electron) chemistry, the activity of Ras GTPases are 
uniquely sensitive to free radical oxidation. Free radical agents, such as NO2•, can react with 
a solvent accessible thiol in Ras to produce a thiyl radical. Through electron transfer, the 
bound guanine nucleotide becomes oxidized, which results in enhanced guanine nucleotide 
dissociation and exchange (activation) (57). Thus, Ras activity is modulated by free radical 
agents capable of thiyl radical formation but not through non-radical oxidation. However, 
this radical-mediated mechanism may not be unique to Ras GTPases. Increasing evidence 
suggests that in many cases, non-radical-mediated thiol oxidation reactions may be too slow 
to be biologically relevant (213). Thus, in this section, we describe the preparation and 
handling of NO2• for use in radical-mediated protein modification.  
3.3.1 NO2• gas generation 
1: NO2• gas can be purchased from various companies; however, it can just as easily be 
generated. Obtain a small reaction vial and add a small piece of copper wire (~100 mg or 
less) and cover the vial with a rubber stopper that is airtight.  
2: Deplete the oxygen from the vial using an inert gas, such as N2.  
3: Inject in a small volume of nitric acid. Allow the reaction to proceed for 5 to 10 min. 
Nitrogen dioxide radicals are formed by the following equation: 
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Cu + 4HNO3  Cu(NO3)2 + 2NO2• + 2H2O    Reaction 1 
 
The reaction proceeds by the above reaction pathway if a brown gas is generated. This 
reaction should be performed in a hood as NO2• gas is highly toxic.  
4: Estimate the concentration of NO2• gas that will dissolve in solution using Henry’s 
Law. Henry’s Law states that the amount of a gas that will dissolve in solution is directly 
proportional to the partial pressure of the gas in equilibrium with the liquid. The coefficient 
(k) for NO2• is needed for these calculations. From a table containing these coefficients, a 
range of 1800-2500 mol/L/atm can be obtained (214). As the density for NO2• gas (2.62 
g/cm3) is heavier than N2 gas (0.808 g/cm3), one can assume that the relative gas 
concentration is 100% NO2• at the bottom of the vial. The coefficient needs to be converted 
to units of atm/mol/L by taking the reciprocal of the coefficient. Thus, a range of 1.2-3.4×10-
2 atm/mol/L is obtained.  
5: Prepare a reaction vial with the protein. Seal the reaction vial and deplete the 
oxygen using N2 or another inert gas. The headspace remaining will be critical; thus, the 
volume remaining in the reaction vial after the addition of the protein sample needs to be 
determined. 
6: Add NO2• gas to the reaction vial. The amount of gas added to the sealed reaction 
vial will not likely affect the pressure in the reaction vial significantly; therefore, the pressure 
is estimated to be 1 atm. However, the percent of NO2• added to the vial relative to the 
remaining headspace must be calculated to determine the percent of NO2• gas in the gas 
mixture. Thus, if 100 μl of pure NO2• gas is added to a reaction vial with 1 ml headspace 
(inert N2 gas), then the total concentration of NO2• gas will be 10% (thus, 0.10*1.00 atm = 
0.10 atm NO2• gas in this example). 
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7: Using the equation c = p/k, where c is the concentration, p is the partial pressure 
(from Step 8, 0.10 atm), and k is the inverse of Henry’s Law coefficient (from Step 4, using 
an average of 2.3×10-2 atm/mol/L), approximately 4.35 mol/L NO2• gas will dissolve in 
liquid in a sealed reaction vial, according to the example presented.  
3.3.2 NONOates 
NONOates, such as the compounds listed in Table 4, are compounds that release NO• 
in solution in a pH and time-dependent manner over seconds, minutes, or hours. There are 
8 NONOate compounds available. All NONOates are relatively stable at alkaline pH 
(approximately 24 hours at 0°C) and are water-soluble. However, at pH 5, the release of NO• 
is nearly instantaneous. In addition, each NONOate has a characteristic UV absorbance 
value. Relevant information on NONOates is listed in Table 4.  
1: Suspend the desired amount of NONOate in 10 mM NaOH to minimize NO• release 
(see note 13 and Figure 28).  
2: To measure NO• release in the selected buffer, 4,5-diaminofluorescein (DAF-2) can 
be used. DAF-2 specifically binds to NO• and undergoes a change in fluorescence upon 
reaction. DAF-2 has excitation and emission wavelengths of 485 and 538 nM, respectively. 
Approximately 10 μM DAF-2 is recommended. DAF-2 has a detection limit of 5 nM at 
neutral pH (see note 14).  
3.4 Quantitative mass spectrometry  
The cysteine labeling procedure known as isotope-coded affinity tag (ICAT) (215) was 
the first stable isotope labeling method used in quantitative proteomics. The ICAT approach 
was designed primarily for the semi-quantitation of proteins expressed in two cellular states 
by labeling proteins with heavy and light cysteine-reactive tags. The trypsin-digested 
peptides that correspond to the differential labels are identified using MS, and the relative 
signal intensities are used for quantitative comparison (see Figure 29).  
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  Table 4. Specifications and use of NONOate compounds 
Name Cas# 
Efficiency  
(mol NO per 
NONOate) 
Half-life at 37˚C; 
22-25˚C 
λmax 
(nm) 
ε (M-1cm
DETA NONOate 146724-94-9 2 20 h; 56 h 252 7640
Spermine NONOate 136587-13-8 2 39 min; 230 min 252 8500
Proli NONOate N/A 2 1.8 sec; N/A 252 8400
DPTA NONOate 146724-95-0 2 3 h; 5 h 252 7860
DEA NONOate 372965-00-9 1.5 2 min; 16 min 250 6500
PAPA NONOate 146672-58-4 2 15 min; 77 min 252 8100
MAHMA NONOate 146724-86-9 2 1 min; 2.7 min 250 7250
Sulpho NONOate 61142-90-3 0 7 min; 77 min 252 8100
(1-3)     
All NONOate compounds currently available and the CAS# (Proli NONOate currently has 
no CAS#) are listed. The efficiency represents the number of moles NO released per mol of 
NONOate compound. The half-life information is provided at both temperatures. The λmax is the 
wavelength where concentration of the compounds can be taken using a UV spectrophotometer 
and ε is the corresponding extinction coefficient. 
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Figure 27. The reaction profile of NO• generated from NONOates.  
The two most important reactions with NO2• are with free thiols (black pathway) and free 
NO• (red pathway). The rate for NO2• with free thiol (RSH) is ≥2×107 M-1s-1 [50,51]. For the 
reaction of NO2• with NO• to form N2O3, the rate is 1.1×109 M-1s-1 [52,50]. While this reaction is 
readily reversible, the reaction kinetics in vitro will favor the nitrosation of thiols through the 
reaction N2O3 + RSH  RSNO (in red, rate of 1.2×107 M-1s-1, and an autohydrolysis rate with 
water of 4.75×107 s-1). However, in an in vivo system, the pathway in black will likely be the major 
route of protein oxidation [13]. While the product of the pathway in red is identical to the pathway 
in black (free radical-mediated), the reactions involving thiyl radical species result in unique 
regulation in Ras family GTPase activity. The gray reaction pathway is less likely to occur because 
it relies on three bimolecular reactions (2(NO• + NO•  NO2•) and NO2• + NO2 N2O4), whereas 
the red and black pathways require only two bimolecular reactions. 
115 
Proteomics-based methodologies have recently been developed to study redox regulation in 
proteins, also known as the redoxome (216, 217). A number of stable isotope-labeling 
methods exist for measuring cysteine oxidation by MS. The majority of these methods fall 
into two main categories: 1) cysteine oxidation measured directly by comparing the loss of 
oxidized peptide as a function of oxidants by the relative signal intensities of cysteine-
containing peptides labeled with light and heavy stable isotope reagents, such as ICAT, 
biotinylated-ICAT (96, 218), or biotinylated iodoactamide (BIAM) (217); 2) cysteine 
oxidation measured indirectly by thiol-blocking, selective reduction, and reversible 
modification using thiol probes that detect a gain in signal due to thiol oxidation (defined as 
oxICAT; see Figure 30) (219). In the context of measuring redox modifications, ICAT and 
other types of cysteine-reactive tags allow for the accurate quantification of cysteine-
containing peptides (220). Here, we describe new techniques for detecting and quantifying 
cysteine oxidation using mass spectrometry-based methods, including 3.4.1: Isotope-coded 
affinity tag-labeling for relative cysteine quantification, 3.4.2: Quantification of the cysteine 
oxidation, 3.4.3: Differential quantification of cysteine oxidation, 3.4.4 Differential thiol 
trapping to  
determine reversible oxidation of cysteine residues, and 3.4.5 Filter-aided sample 
preparation (see note 15). 
3.4.1. Isotope-coded affinity tag (ICAT)-labeling for relative cysteine quantification  
1: Generate proteins from cellular extracts and measure total protein using the 
bicinchoninic acid (BCA) assay. 
2: Supplement the buffer with 0.1% sodium dodecyl sulfate (SDS) before modification 
with the ICAT reagents (see note 16).  
3: Incubate the modified and unmodified samples at 37°C with the acid-cleavable 12C 
(light) or 13C (heavy) ICAT reagents in the absence of reducing agent using the protocol 
supplied by the manufacturer. 
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Figure 28. Generalized ICAT-based relative quantification schematic for measuring 
cysteine peptides. 
ICAT allows for the relative quantification of samples from two separate conditions, such 
as quantification of protein expression levels under different cellular conditions. However, if one 
omits the reducing steps and adds an oxidation step to one of the conditions, then this approach 
can be adapted to study oxidation of proteins in cellular tissue (described in detail in the acid-
cleavable ICAT with H2O2 approach). Each sample can be subjected to a technical replicate by 
reverse labeling to ensure reproducibility. Furthermore, ICAT reagents can be swapped out for 
other stable isotope labeled tags, such as BIAM or Cys-tandem mass tag reagents. Figure 
generated by Harsha Gunawardena. 
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4: After 2 h of incubation, mix the light and heavy ICAT-labeled protein samples at a 
stoichiometric ratio of 1:1, and trypsin digest the mixture by incubating at 37°C overnight in 
ABC buffer.  
5: Purify the trypsin-digested peptides using a cation-exchange cartridge to remove 
excess labeling reagent. The desalted peptides are affinity purified using the avidin affinity 
cartridge. Dry the peptides and suspend in the cleavage reagent to release the peptides from 
the acid-cleavable linker by incubating at 37°C for 2 h. Dry the acid-cleaved peptides and 
suspend in 0.1% formic acid for LC-MS analysis (see note 17, see note 18 for data analysis, 
see notes 19 and 20 for alternative approaches). 
3.4.2 Quantification of the cysteine oxidation  
The biotinylated iodoacetamide (BIAM) approach can be used to study oxidation of 
exposed cysteines under controlled redox conditions by quantifying differential BIAM 
labeling. The redox chemistry includes the reversible oxidation of cysteine residues by the 
addition of H2O2 or other oxidants as well as reduction with reducing agents to reduce 
oxidized cysteines. 
1: Generate oxidized proteins. 
2: Dissolve the proteins in ABC buffer containing 5 mM iodoacetamide (IAM) and 
incubate at room temperature in the dark for 30 min to complete the modification of 
accessible Cys residues with IAM.  
3: Centrifuge the samples at 15,000×g for 1 h, dialyze the supernatant against 
phosphate buffer and divide the sample into two equal parts. 
4: Dilute the two equal samples to 5 ml with phosphate buffer.  
5: Add 250 μl of 100 mM DTT. Similarly, incubate the second control sample with 250 
μl phosphate buffer. 
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Figure 29. The oxICAT schematic for measuring cysteine oxidation.  
This method measures reversible cysteine oxidation. Here, the protein is denatured and 
labeled in one step, which labels all non-oxidized and buried cysteines with the heavy label, and is 
completed by reducing the oxidized species and labeling with the light isotope. Thus, if several 
experiments are performed by varying levels of oxidant exposure, one can estimate the level of 
oxidation (relative reactivity) of cysteines in a protein. A gain in signal intensity of the light-
isotope labeled signal is an indirect measure of reversible thiol oxidation. Note that a technical or 
biological replicate analysis can be performed by reversing the order of the ICAT labels with the 
heavy isotope representing the oxidized species. Figure generated by Harsha Gunwardena. 
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6: Incubate both samples at room temperature for 30 min and treat with 275 μl of 10 
mM BIAM for 30 min in the dark at room temperature. Remove excess BIAM by overnight 
dialysis against ABC buffer.  
7: Load the sample on an avidin affinity cartridge followed by incubation for 20 min at 
room temperature.  
8: Wash the column with 1-4 volumes of PBS, collect the flow-through, and wash the 
column further with PBS until the absorbance at 280 nm returns to baseline.  
9: Elute the BIAM-modified proteins with four bed volumes of BIAM-elution buffer. 
10: Trypsin-digest the proteins overnight at 37°C. Purify peptides using a PepClean 
desalting column according to the manufacturer’s protocol and analyze the peptides by LC-
MS analysis.  
3.4.3 Differential quantification of cysteine oxidation  
1: Incubate oxidized and reduced protein samples (200 μg) in 100 μL of Tris buffer 
with light and heavy acid-cleavable ICAT reagents, respectively, at 37°C for 3 h in the 
absence of reducing agents. 
2: Volumetrically mix the light and heavy labeled proteins at a 1:1 ratio and buffer 
exchange the samples against ABC buffer.  
3: Digest the samples with trypsin by overnight incubation at 37°C.  
4: Lyophilize the digested peptides and suspend in either affinity loading buffer for 
direct avidin affinity purification or fractionate by reconstituting the dried peptides in SCX 
Buffer A.  
5: Fractionate the peptides using HPLC and a strong cation-exchange (SCX) 
PolySulfoethyl A column with a step gradient of SCX Buffer A to SCX Buffer B.  
6: Mix the individual fractions from SCX with equivalent amounts of affinity loading 
buffer and load onto an avidin affinity cartridge. Dry the avidin-affinity purified peptides 
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using a lyophilizer and suspend in the cleavage reagent to release the ICAT-labeled peptides 
from the acid-cleavable linker by incubating at 37°C for 2 h.  
7: Dry the peptides obtained by acid cleavage and suspend in 0.1% formic acid for LC-
MS/MS analyses. 
3.4.4 Differential thiol trapping to determine reversible oxidation of cysteine residues 
1: After purifying the oxidized protein sample, precipitate the protein with 10% 
trichloroacetic acid (TCA). 
2: Centrifuge the TCA precipitates (13,000×g, 4°C, 30 min) and wash the pellet with 
500 μL of ice-cold 10% TCA and 200 μL of ice-cold 5% TCA.  
3: Dissolve the pellet in 80 μL of denaturing alkylation buffer (DAB) and the contents 
of one vial of cleavable heavy ICAT reagent dissolved in 20 ul of ACN. 
4: Incubate the sample at 900 rpm for 1 h at 37°C in the dark. To remove the light 
ICAT reagent, precipitate the proteins with 400 μL of chilled (20°C) acetone for 4 h at 20°C. 
After centrifugation (13,000×g, 4°C, 30 min), wash the pellet twice with 500 μL of chilled 
acetone. 
5: Dissolve the protein pellet in a mixture of 80 μL of DAB, 1 μL of 100 mM DTT, or 
other selected reducing agents. 
6: Add the contents of one vial of cleavable light ICAT reagent dissolved in 20 μL of 
ACN. 
7: Incubate the sample at 900 rpm for 1 h at 37°C in the dark. 
8: Perform trypsin-digestion of the ICAT-labeled peptides, enrichment on streptavidin 
columns, and cleavage of the biotin tag according to the description in Sections 3.4.1 and 
3.4.2. 
9: Subject the sample to LC-MS/MS analysis. 
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3.4.5 Filter-aided sample preparation (FASP) 
There are two major strategies for converting proteins extracted from biological 
material to generating peptides suitable for MS-based proteome analysis: SDS-PAGE 
separation and in-gel digestion, or in-solution digestion. The SDS-PAGE separation method 
reduces sample complexity by removing sample contaminants, such as detergents, salts, 
DNA, and other non-protein compounds. The in-gel digestion approach is generally less 
efficient compared to in-solution digestion; however, when sample amounts are not limiting, 
this technique has shown wider usage amongst biologists for generating peptides. More 
recently, the filter-aided sample preparation (FASP) method, has been introduced as it 
removes high levels of salts, SDS, and other contaminants prior to in-solution digestion 
(221-224). In the FASP protocol, all protein clean-up steps, enrichment, and tryptic 
digestions are performed in a single micro-concentrator/spin-filter device. The technique 
can be quite useful for performing fast sample clean-up of in vitro-purified proteins where 
no further separation is required.  
1: Mix 30 μl of sample with 200 μl of denaturing buffer in a YM10 or YM30 
(depending on protein size) spin column and centrifuge for 15 min at 14,000×g.  
2: Add an additional 200 μl of denaturing buffer to a YM10 or YM30 spin column and 
centrifuge for 15 min at 14,000×g (see note 21).  
3: Discard the flow-through.  
4: Add 100 μl of IAM buffer and mix on a shaker at 600 rpm for 1 min.  
5: Incubate for 20 min at 25°C (see note 22).  
6: Centrifuge for 10 min at 14,000×g.  
7: Add 100 μl of denaturing buffer to the spin column and spin for 15 min at 14,000×g. 
Repeat this step two additional times.  
8: Add 100 μl of ABC buffer and spin as in step 7. Repeat this step two additional 
times.  
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9: Add 16 μl of 0.1 μg/μl trypsin solution (trypsin should be diluted with ABC buffer) to 
the micro-concentrator/spin-filter device (see note 23 for an alternative approach).  
10: Remove old collection tubes from the spin column and replace with fresh collection 
tubes before centrifuging for 10 min at 14,000×g.  
11: Add 40 μl of ABC buffer and centrifuge for 10 min at 14,000×g to collect peptides. 
Notes 
Note 1: pH 6.5 was selected because low pH values help maintain cysteine residues in 
the thiol (RSH) state. Higher pH buffers (> 8.0) allow cysteines to populate the thiolate (RS-) 
state, which makes them more susceptible to air oxidation.  
Note 2: To modify proteins with redox-active reagents, it is important that the thiol 
moieties of the protein be in the reduced state. ABD-F will not react with oxidized cysteines 
and will result in reduced fluorescence yield. Further, oxidation of a thiol to sulfenic acid 
(RSOH) can result in disulfide bond formation. Thus, disulfide bonds and further oxidation 
states can readily occur when the protein is in the sulfenic acid state regardless of the thiol 
pKa. If the protein is in the sulfinic (RSO2H) or sulfonic (RSO3H) state, the protein cannot be 
reduced and will be less reactive to ROS and RNS. By maintaining the protein in a reduced 
state, the reactivity will be dependent on the thiol/thiolate state of the protein. 
Note 3: DTT works most efficiently at pH values greater than 8.0. This is because the 
reducing agent is effective when one of the thiol moieties is in the thiolate form. The pKa of 
the DTT thiols are ~9.2 and 10.1 (225). Mercaptoethanol (β-ME) is not optimal as it can 
stably modify thiols, which will reduce reactivity with ABD-F. Tris(2-
carboxyethyl)phosphine (TCEP), which is a phosphine reducing agent, appears to be 
efficient at reducing disulfides; however, other oxidation states, such as sulfenic acid 
(RSOH), are not efficiently reduced by TCEP according to our observations. A new reducing 
agent, dithiobutylamine (DTBA), functions similarly to DTT and has a thiol pKa that is 
approximately one unit lower (226), which increases the reactivity of DTBA at physiological 
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pH values. However, this reducing agent needs to be generated in house and is currently 
unavailable for purchase.  
Note 4: The buffer should have all oxygen removed as this will aid in preventing air 
oxidation over time, especially when studying thiols with altered pKa values, as the thiolate 
(RS-) is more reactive than a thiol (RSH).  
Note 5: ABD-F reacts with free thiols in solution. Thus, reducing agents that act 
through a free thiol (e.g., DTT, β-ME, and DTBA) will generate fluorescence signal (false 
reactivity) and interfere with pKa measurements. Therefore, these reagents cannot be 
present during data collection. 
Note 6: A final concentration of 10 μM protein is sufficient to give a good signal-to-
noise ratio for most proteins. In general, a 100:1 ABD-F:protein ratio is sufficient. 
Note 7: Although the curve fitting approach outlined quantifies the initial linear slopes, 
collecting data at longer times will aid in verifying whether equivalent amounts of protein 
and ABD-F were added to each well. See Figure 27A. 
Note 8: This method is most effective when using a protein that only has one solvent 
accessible cysteine because the reactivity of other cysteines will complicate data analysis.  
Note 9: If the protein of interest contains multiple solvent accessible cysteines, the 
assay can be modified to determine whether the protein has a cysteine with an altered pKa. 
Using a substitution mutant of the suspected redox-sensitive cysteine (Cys-to-Ser (or Ala) 
mutation), perform the assay essentially as described but at one pH value (pH 6.5 is 
recommended such that non-redox-sensitive cysteines that do not have altered pKa values do 
not result in high background signal). Thus, the cysteine mutant serves as a control and 
provides the background level of ABD-F modification in the protein.  
Note 10: As reported in Grossi et al (211), the pH of the reaction is critical for 
generating optimum nitroso-thiol content; therefore, after solution I and II are mixed, the 
solution pH should be approximately 1.7 to 2.0. 
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Note 11: In general, any volume and concentration of nitroso-thiol is possible. The 
protocol explained in detail here is scaled to meet the needs of our experiments. Thus, this 
protocol will yield approximately 1100 μl of 8 mM thiol-NO. 
Note 12: An alternative is to use the Saville Assay (227) to measure thiol-NO 
concentration. However, this assay detects NO2- as well as the thiol-NO, which could lead to 
error if the free NO2- in solution has not been reacted with the thiol or sulfamate. In our 
experience, the absorbance at 336 nm is reliable.  
Note 13: An inherent disadvantage to using NONOates is that they generate NO•. In 
the case of Ras, NO2• is required for thiyl radical production. However, NO• can react with O2 
to form NO2• as well as other reaction products. A further disadvantage is that once NO2• is 
generated, it can react with NO• released by the NONOate to produce other reaction 
products. A common reaction product is N2O3, which can nitrosate cysteines at an 
approximate rate of 1.2×107 M-1s-1 (Figure 28) (228). In Ras reactions with DEA NONOate, 
we observed that only a fraction of Ras reacts with NO2• to induce nucleotide dissociation, 
and a sizable fraction of Ras can be nitrostated by N2O3. However, nitrosation of Ras 
through a non-radical pathway does not alter Ras activity (66, 229). Modification by N2O3 is 
only likely under the reaction conditions used in vitro with purified proteins; however, in 
cells, this oxidation pathway is not favored. 
Note 14: One can verify the dependence of the NO• species generated on protein 
activity when using NONOates by adding in PTIO (2-Phenyl-4,4,5,5-tetramethylimidazoline-
1-oxyl 3-oxide), which is a selective NO• scavenger. This control will allow the user to verify 
whether free radical byproducts cause the observed effects, as opposed to a competing 
reaction with the NONOate breakdown products.  
Note 15: All of the strategies described in 3.4 rely on the loss of the analytical signal 
upon cysteine modification (oxidation). Most cysteine residues are maintained in their 
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reduced state in cells, measuring glutathiolation directly using chemical labeling 
significantly impacts the sensitivity and dynamic range of (oxidation) detection. 
Note 16: Buffers with low concentrations of SDS or urea allow for more complete 
labeling of the unfolded protein by the ICAT reagents. 
Note 17: All buffers should be prepared in HPLC grade water for optimum 
performance. All reversed-phase LC-MS buffers should be prepared in LC-MS grade water. 
Note 18: All peptides containing cysteine residues will contain heavy and light pairs of 
ICAT labels, and their relative intensities are measured using a full MS scan. The relative 
intensity, ratio = [Lint/Hint], is used to determine the relative levels of modification. 
Note 19: A similar strategy to ICAT has been demonstrated to measure cysteine 
oxidation due to NO• through the use of light and heavy n-ethyldmaleimide (NEM) reagents 
that are generally used to protect sulfhydryls. We believe that this strategy could be adapted 
to study glutathiolation as well because the ICAT reagents can be easily replaced by NEM 
and d5-NEM. More recently, other stable isotope labeling reagents have become available, 
such as Cys-TMT. The use of Cys-TMT allows for an analytical workflow to quantitatively 
assay free cysteine residues and determine the extent of modification using six biologically 
distinct conditions in a single mass spectrometry experiment. The multiplexing is 
particularly useful for studies involving time-course measurements. 
Note 20: An alternative strategy compared to the methods described in Section 3.4 is 
to introduce a reduction step to remove reversible cysteine modifications. Protein 
modifications can be measured indirectly by the following steps: 1) Alkylation of free 
sulfhydryl groups on cysteine residues. 2) Reduction of glutathione adducts by glutaredoxin 
(Grx), which does not affect other cysteine modifications. 3) Blocking all nascent sulfhydryl 
groups with an irreversible labeling reagent, such as IAM or NEM. The advantage of this 
method is that glutathione-specific cysteines will be quantitatively assayed. This 
methodology is more sensitive due to a net increase in the analytical signal for measuring 
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glutathiolation, which is advantageous because most cysteine residues have low levels of 
glutathiolation in cells. 
Note 21: A YM30 filter (MW cut-off of 30 kDa) is used to improve filtration speeds, 
whereas denaturants assist on-filter retention of proteins less than 30 kDa. However, the use 
of YM10 filters would be a conservative approach for ensuring the retention of lower 
molecular weight proteins/polypeptides (approximately 5-8 kDa range).  
Note 22: As we are studying cysteine oxidation in the sample prior to alkylation, the 
reducing step is omitted. Alkylation is performed to prevent disulfide exchange from 
scrambling the oxidative modifications to other cysteine residues that are exposed upon 
trypsin digest.  
Note 23: Incubate overnight at 37°C or incubate for 1-5 minutes using microwave 
irradiation as described in the GOFAST method (230). An alternative approach uses 
endoprotease Lys-C (1:100 enzyme:protein ratio) for 4 h at 37°C prior to trypsin digestion to 
improve the overall peptide digestion efficiency. 
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Chapter 7: Magnesium coordination of RhoG 
Introduction 
The Ras superfamily of GTPases consists of over 200 members and are categorized 
into five subclasses on the basis of sequence: Ras, Rho, Rab, Sar1/Arf, and Ran (86, 145-147, 
150). These GTPases are present in all eukaryotes and possess 30-55% sequence homology 
within the family (84). Ras superfamily GTPases serve as molecular switches that regulate 
cellular processes by cycling between the inactive GDP-bound and active GTP-bound 
conformers (65, 89, 145, 149, 150). The structural changes that result from GDP/GTP cycling 
are localized within two regions, switch I (residues 30-38) and switch II (residues 59-67), 
with the GTP-bound conformer binding to its downstream effectors with higher affinity (231, 
232). The rate limiting step in guanine nucleotide cycling is nucleotide hydrolysis.  
Rho GTPases regulate pathways involved in cell growth, differentiation, cell death, cell 
morphology, and cell motility (145, 147, 158, 161, 233, 234). Most studies to date have 
focused on Rac1, RhoA, and Cdc42. Protein modulatory factors regulate the activity of 
GTPases, including guanine nucleotide exchange factors (GEFs) that induce nucleotide 
dissociation by disrupting Mg2+ and guanine nucleotide coordination (87, 235, 236) and 
GTPase activating proteins (GAPs) that inactivate the GTPases by catalyzing the hydrolysis 
of the γ-phosphate of GTP.  
Rho GTPase activity has been shown to be deregulated in human cancer. However, 
unlike Ras, which is frequently mutated in human cancers, deregulation of Rho GTPases 
occurs through changes in the expression levels of the GTPases, GEFs, GAPs, and guanine 
dissociation inhibitors (GDIs). Furthermore, overexpression of RhoG and Rac1 has been 
observed in malignant breast cancers (237). GEFs, which activate Rho GTPases, are often 
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upregulated, whereas GAPs, which negatively regulate GTPase activity, are often 
downregulated in invasive tumors. In addition, GDIs, which sequester Rho GTPases and 
prevent their activation, have been shown to be deregulated in many cancers, which leads to 
GTPase upregulation (238). 
Magnesium levels have also been shown to regulate cell proliferation and apoptosis. 
Mg2+ serves two important roles in GTPases, it is a cofactor with guanine nucleotides that 
helps to stabilize the negative charge of the phosphates of GTP/GDP in the binding pocket 
and plays a role in GTP hydrolysis. Notably, Mg2+ depletion has been linked to 
carcinogenesis and increased metastasis in cancer (239).  
Interestingly, RhoG has been shown to signal both in a series or in parallel (240, 241) 
with Rac1. Thus, these studies have shown that RhoG activates Rac1 (in series) or can 
activate Rac1-specific pathways in the absence of Rac1 (in parallel). Our data suggest that 
Lys30 of RhoG (Gly30 in Rac1) may play a critical role in determining how RhoG signals. 
Depending on the orientation of Lys30 in RhoG, it may be possible for RhoG to ‘switch’ 
between its known effectors and Rac1 effectors simply by burying the lysine in the absence of 
bound Mg2+. 
This hypothesis is supported by in-cell data where the constitutively active Rac1 
mutant, Rac1Q61L, induced transformation in NIH3T3 cells (242); however, the constitutively 
active RhoGQ61L mutant did not lead to transformation. Furthermore, Rac1G30K in NIH3T3 
cells reduced the transforming ability of Rac1 by 15-fold, and the RhoGK30G/Q61L variant 
increased the transforming potential of RhoG in NIH3T3 cells to similar levels as Rac1Q61L 
(242). These data indicate that residue 30 plays a key role in the recognition of regulatory 
factors and/or effectors. Thus, we have preliminary data that examines the role of Lys30 in 
RhoG in nucleotide exchange and have compared our data to Rac1WT. Here, we have shown 
that Lys30 plays a unique role in nucleotide binding in RhoG and may stabilize nucleotide 
binding in the absence of Mg2+. 
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Methods 
Protein purification of RhoG 
The truncated form of the human RhoG gene (RhoG1-177) was cloned into the pQlinkH 
vector. The hyper-variable region of RhoG, including the C-terminal CAAX box, was 
removed as this region does not undergo post-translational lipid modification in bacteria, is 
unstructured, and its removal does not affect nucleotide binding or GTP hydrolysis (243). All 
proteins were expressed in BL21 Rosetta 2 cells and purified following the Qiagen Nickel 
NTA purification protocol (Germantown, MD). RhoG was further purified by size exclusion 
chromatography (Superdex-75 10/300 GL column; GE Life Sciences; Piscataway, NJ) and 
judged greater than 95% pure by SDS-PAGE analysis.  
Nucleotide exchange assays  
The rate of GDP dissociation from Ras was measured using 2'-/3'-O-(N'-
methylanthraniloyl)guanosine-5'-O-diphosphate (mantGDP) as previously reported (108, 
109). One micromolar RhoG or RhoG variant loaded with mantGDP (BioLog; San Diego, CA) 
was added to 1 mL of degassed assay buffer (50 mM Tris pH 7.4, 50 mM NaCl, 5 mM MgCl2, 
2 mM GDP, and 100 μM diethylenetriaminepentaacetic dianhydride; DTPA), and the rate of 
guanine nucleotide dissociation was measured by monitoring the change in fluorescence 
(excitation: 365 nm; emission: 435 nm; 25˚C) over time using a Perkin Elmer LS50B 
fluorimeter (Waltham, MA). All experiments were performed in triplicate. Fluorescent 
nucleotide dissociation curves were fit to a one-phase exponential decay equation using 
GraphPad Prism version 3.03 (GraphPad Software; San Diego, CA). For GEF-induced RhoG-
GDP dissociation assays, the minimal catalytic domain of Vav2 was used at a 1:1 ratio (244). 
This concentration of Vav2 was selected as the rate enhancement of nucleotide exchange was 
easy to measure using fluorimetric assays and other labs have published using the GEF at 
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this concentration. EDTA-induced nucleotide dissociation was performed by adding 25 mM 
EDTA to the reaction cuvette at the indicated time point. 
Results 
We have conducted fluorescence-based nucleotide dissociation assays with Rac1, 
RhoG, and RhoG variants. Our preliminary data, shown in Figure 31, reveals that the 
RhoGWT (red curve) nucleotide dissociation rate is much slower compared to the rate of Rac1 
(blue curve) nucleotide exchange.  
To determine the role of Lys30 in guanine nucleotide exchange and GEF specificity, we 
have employed nucleotide exchange assays for the direct measurement of nucleotide 
dissociation in the presence and absence of a catalytic fragment from the GEF Vav2, which is 
shown in Figure 31B. We observed that by making a single mutation in RhoG, RhoGK30G 
(green curve), we were able to increase the activation of RhoG by Vav2 (Figure 31B).  
The RhoGK30G mutation, which makes RhoG more Rac1-like, was constructed and 
nucleotide exchange was measured. The results (Figure 31B and C) indicated that 
RhoGK30G reacted nearly identically to Rac1 GEF-mediated nucleotide exchange with Vav2, a 
Rac1-specific GEF, and in EDTA-mediated nucleotide exchange. This data suggests that 
residue 30 in Rho family GTPases plays a role in modulating Vav2 specificity and activity.  
EDTA was used to remove Mg2+ from RhoG. Most GTPases show nucleotide 
dissociation on the addition of EDTA, which reflects a reduction in the nucleotide binding 
affinity. However, on the addition of EDTA to RhoG, we observed a transient increase in 
fluorescence, followed by slow nucleotide dissociation. The results, shown in Figure 31C, 
suggest that there was a change in the chemical environment around the MANT moiety on 
nucleotide binding, which was indicated by the transient fluorescence increase, and that 
RhoG binds nucleotide even in Mg2+-null situations. However, this effect was ablated when  
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Figure 30. Nucleotide dissociation of RhoG and Rac1.  
The nucleotide dissociation studies were performed by preloading the GTPase with the 
fluorescent GDP analog, mantGDP, which has a greater fluorescence when bound to a protein than 
when free in solution, and the rate of dissociation was measured by detecting the loss of signal 
intensity as mantGDP dissociates. Fluorescent nucleotide dissociation studies were performed on 
RhoG, RhoG variants, and Rac1 as shown by the figure legend. (A) Intrinsic nucleotide 
dissociation was determined in a buffer containing 5 mM MgCl2, 2 mM non-labeled GDP, and 1 
µM protein. (B) Vav2 mediated dissociation was performed similarly to intrinsic, but with 1 µM 
Vav2 present. (C) EDTA data was collected in the same manner as (A), but with 25 mM EDTA 
present. All data was normalized to the maximal value and performed in quadruplicate. Note the 
change in time scale for (C). 
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we used the RhoGK30G variant, suggesting that Lys30 plays a role in nucleotide binding under 
specific situations. 
Discussion 
RhoG shares the closest sequence homology (72% identity) with Rac1. However, while 
Rac1 induces the formation of lamellopodia, RhoG has been shown to promote dorsal ruffles 
(240, 245). In addition, Ellerbroek et al has observed that RhoG is activated by the GEF, 
SGEF, whereas Rac1 is not (246). In addition, RhoG has been shown to activate Rac1 
through interaction with the GEF Dock/ELMO (245). In contrast to these studies that have 
suggested independent pathways for RhoG and Rac1, RhoG has also been shown to activate 
Rac1-specific pathways in cells where Rac1 expression has been silenced. Our data suggest 
that RhoG may be able to perform these functions by regulating Mg2+ coordination and the 
position of Lys30.  
Recent studies have indicated that RhoG recognizes its unique modulatory proteins in 
part through Lys30 of switch I (242, 247). Sequence alignments of RhoG and Rac1 show that 
there are two residues in the p-loop and switch I regions of RhoG and Rac1 that are different, 
Cys22 and Lys30 (RhoG numbering). Therefore, we mutated these two residues to match the 
Rac1 sequence (RhoGC22S and RhoGK30G) individually and together and observed that the 
response to Vav2 of RhoG increased to match the rates observed for Rac1. By preloading 
RhoG and RhoG variants with MANTGDP, we observed that RhoG had a slower nucleotide 
dissociation rate compared to Rac1 (Figure 31A). Further, we noticed differential reactivity 
to the Rho GEF Vav2 (Figure 31B). In addition, the observed effects were primarily 
mediated through Lys30. Thus, as lysine has a positive charge, we postulated that Mg2+ 
binding may be altered. To determine the role of Mg2+ binding and nucleotide dissociation, 
we preloaded RhoG with MANTGDP and measured nucleotide dissociation in the presence of 
EDTA (Figure 31C). We observed that Lys30 altered the effect of sequestering Mg2+ with 
EDTA. Thus, with RhoG, we observed a transient increase in fluorescence before a slow rate 
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of nucleotide dissociation; however, in the RhoGK30G variant, we observed no increase in 
fluorescence and a rate of nucleotide dissociation that mirrored Rac1. Therefore, this data 
suggests that Lys30 of RhoG plays a unique role in nucleotide binding, and the altered 
position of this residue upon loss of Mg2+ binding may result in RhoG interacting with Rac1-
specific effectors. 
A structural comparison of Rac1GTP and Rac1GDP is presented in Figure 32A. 
Differences between active GTP-bound and inactive GDP-bound Rac1 are primarily located 
within switch I and II. These structural changes underlie differences in recognition of 
downstream effectors and GAPs, which bind with preferential affinity to the GTP-bound 
form. RhoG is the only Rho family GTPase that contains a lysine in switch I (248). The 
homologous residue in Rac1, Gly30, is important for binding to the Rac1-specific effector, p67 
of NADPH oxidase, through a backbone hydrogen bond (Figure 32B) (249). Glycine30 
interacts with p67 through a backbone amide. As RhoG contains a lysine at this position, 
RhoG likely has a reduced affinity for p67 oxidase. However, in the absence of bound Mg2+, 
the lysine side chain may reorient towards the p-loop and promote an interaction between 
RhoG and p67. Therefore, Lys30 may contribute to the different specificity of GEFs, GAPs, 
and effectors that interact with RhoG and Rac1. 
In addition, reactive oxygen species (ROS) are also involved in oncogenesis (250). 
Intriguingly, a subset of Ras superfamily GTPases have been shown to be activated by ROS 
and RNS (69, 80). RhoG has been connected to the production of ROS through the 
activation of Rac1 (240, 246, 247, 251), which regulates NADPH oxidase activity (252, 253). 
RhoG has also been shown to regulate NADPH oxidase activation in neutrophils (254). Thus, 
RhoG activity may be affected by both Mg2+ levels and ROS levels, two things that are known 
to be altered in the tumor environment. Thus, another question that remains unanswered in 
RhoG function is its sensitivity towards oxidants. 
Based on our nucleotide dissociation results (Figure 31), we hypothesize that Lys30 in 
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Figure 31. A model of the RhoG lysine switch hypothesis. 
(A) Overlay of Rac1GTP (green; PDB ID: 1E96) and Rac1GDP (cyan; PDB ID: 2P2L) structures 
with Mg2+ shown in black, and GTP shown as a stick representation and color coded by atom (O-
red, N-blue, C-green, and P-orange). Switch I of Rac1GTP is colored blue, switch II is colored 
purple, and the p-loop is colored yellow to highlight these regions. The major changes within the 
two structures are located within switch I and switch II. (B) The tetratrico-peptide repeat (TPR) 
domain of p67, a subunit of NADPH oxidase (red), bound to Rac1 (green) with Gly30 shown as 
spheres. Switch I is colored blue, switch II is purple, and the p-loop is shown in yellow. Activated 
GTP-bound Rac1 binds to effectors with higher affinity than the GDP-bound state. Rac1 residues 
important for effector recognition are Ser22, Asn26, Gly30, and Gln162. In RhoG, two of these 
residues are substituted, S22C and G30K, and only the latter comprises a non-conservative 
substitution. Gly30 plays a significant role in effector recognition for Rac1. (C) We propose that 
Lys30 is normally solvent accessible and plays a role in RhoG-specific effector recognition. 
However, Lys30 may be able to replace Mg2+ and simulate a GTP-like conformation. As the rest of 
this binding interface is virtually unchanged, we hypothesize that RhoG may be able to bind to 
and activate Rac1 effectors under certain cellular conditions. 
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RhoG reorientates upon dissociation of Mg2+. Moreover, as highlighted in Figure 32C, we 
further propose that this interaction may stabilize nucleotide binding in the absence of Mg2+. 
Future studies to determine the structure of RhoG should aid in understanding the role of 
Lys30 in RhoG. In addition, effector binding studies in the presence and absence of Mg2+ 
should be performed. If effector binding in the absence of bound Mg2+ but not in the 
presence of Mg2+ is observed, then these results would provide an explanation for previously 
published reports where RhoG was able to independently activate Rac1-specific pathways. 
As Mg2+ depletion is tied to reactive oxygen species (ROS) production in the cell, and both of 
these cellular agents have been connected to deregulated growth, understanding the 
connections between RhoG and the expression of its regulatory proteins, Mg2+, and ROS will 
provide new direction and drug targets in cancer research. 
  
136 
Chapter 8: Conclusions and future directions 
 
While our studies on Ras GTPases has answered some pertinent questions in the field, 
questions remain regarding the role of the thiol in RasG12C-driven cancers. In this study, we 
have shown that role of glutathiolation in Ras is merely a consequence of free radical-
mediated oxidation at Cys118. This project was needed in the Ras oxidation field as many 
papers had stated that glutathiolation activated Ras (71, 77, 94, 100, 101). Thus, by 
generating glutathiolated Ras, we were able to show definitively that glutathiolation has no 
effect on exchange, hydrolysis, or the structure. Thus, our data suggested that the activation 
of glutathiolated Ras that has been previously detected was due to the presence of free 
radicals in their assays.  
Furthermore, we were also able to build on previous studies of Ras ubiquitination. 
After a study by Baker et al (15), which showed that loss of GAP responsiveness in mUbRas 
was due to ubiquitin modification at position 147, it was unclear as to whether ubiquitin 
itself was important for GAP function or whether any modification would suffice. Thus, 
using a RasK147C variant, we oxidized Ras and modified the protein specifically at position 
147. We showed that small molecule modifications, such as acetylation and glutathiolation, 
do not impair GAP activity on Ras. Taking the study a step further, we showed that there 
appears to be a minimal linker length (between ubiquitin and Ras) that is critical for 
inhibiting Ras sensitivity to GAPs. While this study made strides toward understanding how 
this modification regulates Ras, it left unanswered whether the linker length could be longer 
than the minimal size that was determined and whether the size of the modification was 
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required to be approximately 8 kDa. Thus, moving forward, these will be key questions to 
answer. 
In yet another study involving thiols in Ras, the RasG12C oncogenic mutant has shown 
that part of its unique phenotype may be due to the presence of a thiol in the p-loop. The 
RasG12C mutant has been shown to be a common mutation in lung cancer. Our objective is to 
determine how this residue participates in Ras activity and use the resulting data to 
determine whether RasG12C, or other position 12 mutants, can be selectively inhibited. Thus, 
we are currently working in collaboration with Chris Counter to determine how oxidation of 
RasG12C can alternatively regulate Ras activity. Toward this end, we have characterized the 
mutant RasG12C and shown that this thiol is redox sensitive in addition to being GAP 
insensitive. As the Counter laboratory has shown Ras regulation by eNOS through Cys118, his 
lab is perfectly equipped to aid in answering how similar pathways might regulate RasG12C in 
oncogenic settings.  
While Rho family GTPases have been shown to be regulated by redox agents in in vitro 
systems, there is less evidence for direct modification of these GTPases in cell and animal 
models. However, Rho GTPases regulate pathways that have been shown to be directly 
regulated by the cellular redox state. Future studies need to determine the effects of direct 
oxidation of Rho GTPases in an in vitro context to allow for a clearer understanding of the 
cellular effects. Further, future cellular studies that observe redox-mediated regulation of 
these GTPases need to use redox-inactive variants to confirm the effects in cells. In addition, 
many of the current in cell studies have focused on exogenous oxidants, and more studies 
with endogenously produced oxidants are necessary to better characterize the how the Rho 
GTPases are regulated by oxidation in vivo. While the study by Aghajanian et al (81) was one 
of the first such studies to show in-cell activation of RhoA due to exogenously and 
endogenously applied oxidants, these studies are scarce on other Rho family GTPases, and 
this remains the only study on RhoA to determine the effects of direct oxidation on RhoA in 
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cells where the redox-sensitive cysteine residues were mutated to a redox-insensitive 
variant.  
However, increasing numbers of studies are showing that the Rho signaling pathways 
are involved in redox signaling, and it has been shown that Rac1 directly interacts with SOD 
and NADPH oxidase; therefore, it is likely that a majority of the Rho family GTPases can also 
be regulated by the redox signaling enzymes. As we have generated and characterized a new 
redox sensitive variant of RhoA, RhoAC20S, that has similar nucleotide binding kinetics, 
nucleotide hydrolysis, and stability as RhoAWT, future studies probing the role of the Rho 
signaling pathway will be greatly benefited by use of the RhoAC20S variant. In conclusion, in 
the cell, it is likely that activation of these GTPases occurs when they are modified by a free 
radical at Cys20 (or Cys18 in other Rho GTPases), which will result in nucleotide dissociation 
and GTP loading. However, this will result in the formation of a thiolate (RS-) at the site of 
oxidation, which will have an increased sensitivity towards further oxidation to both one-
electron and two-electron oxidation events, and the type of oxidation, such as nitrosation, 
glutathiolation, sulfenic, sulfinic, sulfonic acid, or disulfide formation in RhoA, will have 
differing effects on the level of activation observed.  
Concluding thoughts 
Herein, we discussed the importance of ROS/RNS in modulating the activity of select 
Ras and Rho GTPases and the role of these GTPases in controlling the expression and 
activity of ROS/RNS-regulating enzymes. In addition, our data and a growing body of 
literature suggest that Rho GTPases are particularly susceptible to redox control given their 
unique redox-sensitive cysteine-containing p-loop motif. This redox-sensitive cysteine 
interacts with the bound nucleotide, and 1e- and 2e- redox modifications at this cysteine 
enhance nucleotide exchange, likely by disrupting interactions with the bound nucleotide. 
Under physiological conditions, ROS/RNS likely activate Ras and Rho GTPases, whereas 
oxidative stress may promote their inactivation. To aid in discerning whether oxidative 
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regulation of Rho GTPases is direct or indirect, we have identified redox-insensitive variants 
that mimic the wild-type proteins. Moreover, future cell-based studies should be performed 
with endogenous ROS/RNS sources, redox state characterization, and absent GTPase 
overexpression. Further, Rho and Ras subclasses also regulate expression and activity of key 
redox regulating enzymes. RhoA and Ras regulate NOS expression and activity, Rap1A has 
been implicated in Nox regulation. Rac controls NOS and Nox, and Rac1 has recently been 
shown to directly interact with SOD1. Given that Rac1 and SOD1 are ubiquitously expressed 
proteins involved in numerous cell functions, future experiments should be directed to 
discerning the mechanism of and effects from this interaction. Further, as the literature is 
increasingly dedicated to redox-based signaling, perhaps future studies will better define 
how ROS/RNS regulate Ras and Rho GTPase activity and whether these GTPases are 
regulated by or control additional redox-modulating enzymes.  
  
140 
REFERENCES 
 
1. Keefer, L. K., Nims, R. W., Davies, K. M., and Wink, D. A. (1996) "NONOates" (1-
substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide 
dosage forms, Methods Enzymol 268, 281-293. 
2. Maragos, C. M., Morley, D., Wink, D. A., Dunams, T. M., Saavedra, J. E., Hoffman, 
A., Bove, A. A., Isaac, L., Hrabie, J. A., and Keefer, L. K. (1991) Complexes of .NO 
with nucleophiles as agents for the controlled biological release of nitric oxide. 
Vasorelaxant effects, J Med Chem 34, 3242-3247. 
3. Maragos, C. M., Wang, J. M., Hrabie, J. A., Oppenheim, J. J., and Keefer, L. K. (1993) 
Nitric oxide/nucleophile complexes inhibit the in vitro proliferation of A375 
melanoma cells via nitric oxide release, Cancer Res 53, 564-568. 
4. Jaffe, A. B., and Hall, A. (2005) Rho GTPases: biochemistry and biology, Annu Rev 
Cell Dev Biol 21, 247-269. 
5. Visvikis, O., Maddugoda, M. P., and Lemichez, E. (2010) Direct modifications of Rho 
proteins: deconstructing GTPase regulation, Biol Cell 102, 377-389. 
6. Adamson, P., Marshall, C. J., Hall, A., and Tilbrook, P. A. (1992) Post-translational 
modifications of p21rho proteins, J Biol Chem 267, 20033-20038. 
7. Adamson, P., Paterson, H. F., and Hall, A. (1992) Intracellular localization of the 
P21rho proteins, J Cell Biol 119, 617-627. 
8. Bokoch, G. M., Bohl, B. P., and Chuang, T. H. (1994) Guanine nucleotide exchange 
regulates membrane translocation of Rac/Rho GTP-binding proteins, J Biol Chem 
269, 31674-31679. 
9. Johnson, J. L., Erickson, J. W., and Cerione, R. A. (2009) New insights into how the 
Rho guanine nucleotide dissociation inhibitor regulates the interaction of Cdc42 with 
membranes, J Biol Chem 284, 23860-23871. 
10. Navarro-Lerida, I., Sanchez-Perales, S., Calvo, M., Rentero, C., Zheng, Y., Enrich, C., 
and Del Pozo, M. A. (2012) A palmitoylation switch mechanism regulates Rac1 
function and membrane organization, Embo J 31, 534-551. 
11. Ellerbroek, S. M., Wennerberg, K., and Burridge, K. (2003) Serine phosphorylation 
negatively regulates RhoA in vivo, J Biol Chem 278, 19023-19031. 
12. Forget, M. A., Desrosiers, R. R., Gingras, D., and Beliveau, R. (2002) 
Phosphorylation states of Cdc42 and RhoA regulate their interactions with Rho GDP 
dissociation inhibitor and their extraction from biological membranes, Biochem J 
361, 243-254. 
141 
13. de la Vega, M., Burrows, J. F., and Johnston, J. A. (2011) Ubiquitination: Added 
complexity in Ras and Rho family GTPase function, Small GTPases 2, 192-201. 
14. Sadowski, M., Suryadinata, R., Tan, A. R., Roesley, S. N., and Sarcevic, B. (2012) 
Protein monoubiquitination and polyubiquitination generate structural diversity to 
control distinct biological processes, IUBMB Life 64, 136-142. 
15. Baker, R., Lewis, S. M., Sasaki, A. T., Wilkerson, E. M., Locasale, J. W., Cantley, L. C., 
Kuhlman,B., Dohlman, H. G., and Campbell, S. L. (2013) Site-specific 
monoubiquitination activates Ras by impeding GTPase-activating protein function, 
Nat Struct Mol Biol 20, 46-52. 
16. Sasaki, A. T., Carracedo, A., Locasale, J. W., Anastasiou, D., Takeuchi, K., Kahoud, E. 
R., Haviv, S., Asara, J. M., Pandolfi, P. P., and Cantley, L. C. (2011) Ubiquitination of 
K-Ras enhances activation and facilitates binding to select downstream effectors, Sci 
Signal 4, ra13. 
17. Nethe, M., and Hordijk, P. L. (2010) The role of ubiquitylation and degradation in 
RhoGTPase signalling, J Cell Sci 123, 4011-4018. 
18. Nethe, M., Anthony, E. C., Fernandez-Borja, M., Dee, R., Geerts, D., Hensbergen, P. 
J., Deelder, A. M., Schmidt, G., and Hordijk, P. L. (2010) Focal-adhesion targeting 
links caveolin-1 to a Rac1-degradation pathway, J Cell Sci 123, 1948-1958. 
19. Wei, J., Mialki, R. K., Dong, S., Khoo, A., Mallampalli, R. K., Zhao, Y., and Zhao, J. 
(2013) A new mechanism of RhoA ubiquitination and degradation: Roles of SCF E3 
ligase and Erk2, Biochim Biophys Acta. 
20. Visvikis, O., Lores, P., Boyer, L., Chardin, P., Lemichez, E., and Gacon, G. (2008) 
Activated Rac1, but not the tumorigenic variant Rac1b, is ubiquitinated on Lys 147 
through a JNK-regulated process, Febs J 275, 386-396. 
21. Lander, H. M., Hajjar, D. P., Hempstead, B. L., Mirza, U. A., Chait, B. T., Campbell, 
S., and Quilliam, L. A. (1997) A molecular redox switch on p21(ras). Structural basis 
for the nitric oxide-p21(ras) interaction, J Biol Chem 272, 4323-4326. 
22. Thannickal, V. J., and Fanburg, B. L. (2000) Reactive oxygen species in cell 
signaling, Am J Physiol Lung Cell Mol Physiol 279, L1005-1028. 
23. Ray, P. D., Huang, B. W., and Tsuji, Y. (2012) Reactive oxygen species (ROS) 
homeostasis and redox regulation in cellular signaling, Cell Signal 24, 981-990. 
24. Forman, H. J., Fukuto, J. M., and Torres, M. (2004) Redox signaling: thiol chemistry 
defines which reactive oxygen and nitrogen species can act as second messengers, 
Am J Physiol Cell Physiol 287, C246-256. 
25. Spadaro, D., Yun, B. W., Spoel, S. H., Chu, C., Wang, Y. Q., and Loake, G. J. (2010) 
The redox switch: dynamic regulation of protein function by cysteine modifications, 
Physiol Plant 138, 360-371. 
142 
26. Poole, L. B., Karplus, P. A., and Claiborne, A. (2004) Protein sulfenic acids in redox 
signaling, Annu Rev Pharmacol Toxicol 44, 325-347. 
27. Winterbourn, C. C., and Hampton, M. B. (2008) Thiol chemistry and specificity in 
redox signaling, Free Radic Biol Med 45, 549-561. 
28. Sanchez, R., Riddle, M., Woo, J., and Momand, J. (2008) Prediction of reversibly 
oxidized protein cysteine thiols using protein structure properties, Protein Sci 17, 
473-481. 
29. Trujillo, M., and Radi, R. (2002) Peroxynitrite reaction with the reduced and the 
oxidized forms of lipoic acid: new insights into the reaction of peroxynitrite with 
thiols, Arch Biochem Biophys 397, 91-98. 
30. Barton, J. P., Packer, J. E., and Sims, R. J. (1973) Kinetics of Reaction of Hydrogen-
Peroxide with Cysteine and Cysteamine, J Chem Soc Perk T 2, 1547-1549. 
31. Folkes, L. K., and Wardman, P. (2004) Kinetics of the reaction between nitric oxide 
and glutathione: implications for thiol depletion in cells, Free Radic Biol Med 37, 
549-556. 
32. Florence, T. M. (1995) The Role of Free-Radicals in Disease, Aust Nz J Ophthalmol 
23, 3-7. 
33. Seet, R. C. S., Lee, C. Y. J., Lim, E. C. H., Tan, J. J. H., Quek, A. M. L., Chong, W. L., 
Looi, W. F., Huang, S. H., Wang, H. S., Chan, Y. H., and Halliwell, B. (2010) 
Oxidative damage in Parkinson disease: Measurement using accurate biomarkers, 
Free Radical Bio Med 48, 560-566. 
34. Gruber, J., Schaffer, S., and Halliwell, B. (2008) The mitochondrial free radical 
theory of ageing--where do we stand?, Front Biosci 13, 6554-6579. 
35. Wardman, P., and Vonsonntag, C. (1995) Kinetic Factors That Control the Fate of 
Thiyl Radicals in Cells, Method Enzymol 251, 31-45. 
36. Ross, D., Norbeck, K., and Moldeus, P. (1985) The Generation and Subsequent Fate 
of Glutathionyl Radicals in Biological-Systems, Journal of Biological Chemistry 260, 
5028-5032. 
37. Apel, K., and Hirt, H. (2004) Reactive oxygen species: metabolism, oxidative stress, 
and signal transduction, Annu Rev Plant Biol 55, 373-399. 
38. Antunes, F., and Cadenas, E. (2000) Estimation of H2O2 gradients across 
biomembranes, Febs Lett 475, 121-126. 
39. Touyz, R. M., Briones, A. M., Sedeek, M., Burger, D., and Montezano, A. C. (2011) 
NOX isoforms and reactive oxygen species in vascular health, Mol Interv 11, 27-35. 
143 
40. Dang, P. M., Cross, A. R., Quinn, M. T., and Babior, B. M. (2002) Assembly of the 
neutrophil respiratory burst oxidase: a direct interaction between p67PHOX and 
cytochrome b558 II, Proc Natl Acad Sci U S A 99, 4262-4265. 
41. Cuzzocrea, S., Mazzon, E., Dugo, L., Di Paola, R., Caputi, A. P., and Salvemini, D. 
(2004) Superoxide: a key player in hypertension, Faseb J 18, 94-101. 
42. Fransen, M., Nordgren, M., Wang, B., and Apanasets, O. (2012) Role of peroxisomes 
in ROS/RNS-metabolism: implications for human disease, Biochim Biophys Acta 
1822, 1363-1373. 
43. Forstermann, U., and Sessa, W. C. (2012) Nitric oxide synthases: regulation and 
function, Eur Heart J 33, 829-837, 837a-837d. 
44. Zhou, L., and Zhu, D. Y. (2009) Neuronal nitric oxide synthase: structure, subcellular 
localization, regulation, and clinical implications, Nitric Oxide 20, 223-230. 
45. Hemmens, B., and Mayer, B. (1998) Enzymology of nitric oxide synthases, Methods 
Mol Biol 100, 1-32. 
46. Garcia-Cardena, G., Fan, R., Shah, V., Sorrentino, R., Cirino, G., Papapetropoulos, A., 
and Sessa, W. C. (1998) Dynamic activation of endothelial nitric oxide synthase by 
Hsp90, Nature 392, 821-824. 
47. Fleming, I., and Busse, R. (2003) Molecular mechanisms involved in the regulation 
of the endothelial nitric oxide synthase, Am J Physiol Regul Integr Comp Physiol 
284, R1-12. 
48. Beck, K. F., Eberhardt, W., Frank, S., Huwiler, A., Messmer, U. K., Muhl, H., and 
Pfeilschifter, J. (1999) Inducible NO synthase: role in cellular signalling, J Exp Biol 
202, 645-653. 
49. Birben, E., Sahiner, U. M., Sackesen, C., Erzurum, S., and Kalayci, O. (2012) 
Oxidative stress and antioxidant defense, World Allergy Organ J 5, 9-19. 
50. Anderson, M. E. (1998) Glutathione: an overview of biosynthesis and modulation, 
Chem Biol Interact 111-112, 1-14. 
51. Buettner, G. R. (1993) The pecking order of free radicals and antioxidants: lipid 
peroxidation, alpha-tocopherol, and ascorbate, Arch Biochem Biophys 300, 535-543. 
52. Maritim, A. C., Sanders, R. A., and Watkins, J. B., 3rd. (2003) Diabetes, oxidative 
stress, and antioxidants: a review, J Biochem Mol Toxicol 17, 24-38. 
53. Gaston, B. (1999) Nitric oxide and thiol groups, Biochim Biophys Acta 1411, 323-333. 
54. Biswas, S., Chida, A. S., and Rahman, I. (2006) Redox modifications of protein-
thiols: emerging roles in cell signaling, Biochem Pharmacol 71, 551-564. 
144 
55. Findlay, V. J., Tapiero, H., and Townsend, D. M. (2005) Sulfiredoxin: a potential 
therapeutic agent?, Biomed Pharmacother 59, 374-379. 
56. Ying, J., Clavreul, N., Sethuraman, M., Adachi, T., and Cohen, R. A. (2007) Thiol 
oxidation in signaling and response to stress: detection and quantification of 
physiological and pathophysiological thiol modifications, Free Radic Biol Med 43, 
1099-1108. 
57. Davis, M. F., Vigil, D., and Campbell, S. L. (2011) Regulation of Ras proteins by 
reactive nitrogen species, Free Radic Biol Med 51, 565-575. 
58. Lander, H. M., Ogiste, J. S., Teng, K. K., and Novogrodsky, A. (1995) p21ras as a 
common signaling target of reactive free radicals and cellular redox stress, J Biol 
Chem 270, 21195-21198. 
59. Lander, H. M., Milbank, A. J., Tauras, J. M., Hajjar, D. P., Hempstead, B. L., 
Schwartz, G. D., Kraemer, R. T., Mirza, U. A., Chait, B. T., Burk, S. C., and Quilliam, 
L. A. (1996) Redox regulation of cell signalling, Nature 381, 380-381. 
60. Mott, H. R., Carpenter, J. W., and Campbell, S. L. (1997) Structural and functional 
analysis of a mutant Ras protein that is insensitive to nitric oxide activation, 
Biochemistry 36, 3640-3644. 
61. Tsujita, M., Batista, W. L., Ogata, F. T., Stern, A., Monteiro, H. P., and Arai, R. J. 
(2008) The nitric oxide-sensitive p21Ras-ERK pathway mediates S-
nitrosoglutathione-induced apoptosis, Biochem Biophys Res Commun 369, 1001-
1006. 
62. Heo, J., and Campbell, S. L. (2004) Mechanism of p21Ras S-nitrosylation and 
kinetics of nitric oxide-mediated guanine nucleotide exchange, Biochemistry 43, 
2314-2322. 
63. Lim, K. H., Ancrile, B. B., Kashatus, D. F., and Counter, C. M. (2008) Tumour 
maintenance is mediated by eNOS, Nature 452, 646-649. 
64. Ibiza, S., Perez-Rodriguez, A., Ortega, A., Martinez-Ruiz, A., Barreiro, O., Garcia-
Dominguez, C. A., Victor, V. M., Esplugues, J. V., Rojas, J. M., Sanchez-Madrid, F., 
and Serrador, J. M. (2008) Endothelial nitric oxide synthase regulates N-Ras 
activation on the Golgi complex of antigen-stimulated T cells, Proc Natl Acad Sci U S 
A 105, 10507-10512. 
65. Kjeldgaard, M., Nyborg, J., and Clark, B. F. (1996) The GTP binding motif: variations 
on a theme, Faseb J 10, 1347-1368. 
66. Williams, J. G., Pappu, K., and Campbell, S. L. (2003) Structural and biochemical 
studies of p21Ras S-nitrosylation and nitric oxide-mediated guanine nucleotide 
exchange, Proc Natl Acad Sci U S A 100, 6376-6381. 
145 
67. Davis, M. F., Zhou, L., Ehrenshaft, M., Ranguelova, K., Gunawardena, H. P., Chen, 
X., Bonini, M., Mason, R. P., and Campbell, S. L. (2012) Detection of Ras GTPase 
protein radicals through immuno-spin trapping, Free Radic Biol Med. 
68. Heo, J., Prutzman, K. C., Mocanu, V., and Campbell, S. L. (2005) Mechanism of free 
radical nitric oxide-mediated Ras guanine nucleotide dissociation, J Mol Biol 346, 
1423-1440. 
69. Heo, J., and Campbell, S. L. (2006) Ras regulation by reactive oxygen and nitrogen 
species, Biochemistry 45, 2200-2210. 
70. Heo, J. (2011) Redox control of GTPases: from molecular mechanisms to functional 
significance in health and disease, Antioxid Redox Signal 14, 689-724. 
71. Clavreul, N., Adachi, T., Pimental, D. R., Ido, Y., Schoneich, C., and Cohen, R. A. 
(2006) S-glutathiolation by peroxynitrite of p21ras at cysteine-118 mediates its direct 
activation and downstream signaling in endothelial cells, The FASEB journal : 
official publication of the Federation of American Societies for Experimental 
Biology 20, 518-520. 
72. Clavreul, N., Bachschmid, M. M., Hou, X., Shi, C., Idrizovic, A., Ido, Y., Pimentel, D., 
and Cohen, R. A. (2006) S-glutathiolation of p21ras by peroxynitrite mediates 
endothelial insulin resistance caused by oxidized low-density lipoprotein, 
Arterioscler Thromb Vasc Biol 26, 2454-2461. 
73. Clavreul, N., Adachi, T., Pimental, D. R., Ido, Y., Schoneich, C., and Cohen, R. A. 
(2006) S-glutathiolation by peroxynitrite of p21ras at cysteine-118 mediates its direct 
activation and downstream signaling in endothelial cells, Faseb J 20, 518-520. 
74. Merenyi, G., Lind, J., Goldstein, S., and Czapski, G. (1998) Peroxynitrous acid 
homolyzes into *OH and *NO2 radicals, Chem Res Toxicol 11, 712-713. 
75. Kissner, R., and Koppenol, W. H. (2002) Product distribution of peroxynitrite decay 
as a function of pH, temperature, and concentration, J Am Chem Soc 124, 234-239. 
76. Szabo, C., Ischiropoulos, H., and Radi, R. (2007) Peroxynitrite: biochemistry, 
pathophysiology and development of therapeutics, Nat Rev Drug Discov 6, 662-680. 
77. Adachi, T., Pimentel, D. R., Heibeck, T., Hou, X., Lee, Y. J., Jiang, B., Ido, Y., and 
Cohen, R. A. (2004) S-glutathiolation of Ras mediates redox-sensitive signaling by 
angiotensin II in vascular smooth muscle cells, J Biol Chem 279, 29857-29862. 
78. Heo, J., and Campbell, S. L. (2005) Mechanism of redox-mediated guanine 
nucleotide exchange on redox-active Rho GTPases, J Biol Chem 280, 31003-31010. 
79. Heo, J., and Campbell, S. L. (2005) Mechanism of redox-mediated guanine 
nucleotide exchange on redox-active Rho GTPases, J Biol Chem 280, 31003-31010. 
80. Heo, J., Raines, K. W., Mocanu, V., and Campbell, S. L. (2006) Redox regulation of 
RhoA, Biochemistry 45, 14481-14489. 
146 
81. Aghajanian, A., Wittchen, E. S., Campbell, S. L., and Burridge, K. (2009) Direct 
activation of RhoA by reactive oxygen species requires a redox-sensitive motif, PLoS 
One 4, e8045. 
82. Raines, K. W., Bonini, M. G., and Campbell, S. L. (2007) Nitric oxide cell signaling: 
S-nitrosation of Ras superfamily GTPases, Cardiovasc Res 75, 229-239. 
83. Gerhard, R., John, H., Aktories, K., and Just, I. (2003) Thiol-modifying phenylarsine 
oxide inhibits guanine nucleotide binding of Rho but not of Rac GTPases, Mol 
Pharmacol 63, 1349-1355. 
84. Oxford, G., and Theodorescu, D. (2003) Ras superfamily monomeric G proteins in 
carcinoma cell motility, Cancer Lett 189, 117-128. 
85. Paduch, M., Jelen, F., and Otlewski, J. (2001) Structure of small G proteins and their 
regulators, Acta Biochim Pol 48, 829-850. 
86. Takai, Y., Sasaki, T., and Matozaki, T. (2001) Small GTP-binding proteins, Physiol 
Rev 81, 153-208. 
87. John, J., Rensland, H., Schlichting, I., Vetter, I., Borasio, G. D., Goody, R. S., and 
Wittinghofer, A. (1993) Kinetic and structural analysis of the Mg(2+)-binding site of 
the guanine nucleotide-binding protein p21H-ras, J Biol Chem 268, 923-929. 
88. Sprang, S. (2001) GEFs: master regulators of G-protein activation, Trends Biochem 
Sci 26, 266-267. 
89. Geyer, M., and Wittinghofer, A. (1997) GEFs, GAPs, GDIs and effectors: taking a 
closer (3D) look at the regulation of Ras-related GTP-binding proteins, Curr Opin 
Struct Biol 7, 786-792. 
90. Sprang, S. R. (1997) G proteins, effectors and GAPs: structure and mechanism, Curr 
Opin Struct Biol 7, 849-856. 
91. Barbacid, M. (1987) ras genes, Annu Rev Biochem 56, 779-827. 
92. Bos, J. L. (1989) ras oncogenes in human cancer: a review, Cancer Res 49, 4682-
4689. 
93. Lowy, D. R., and Willumsen, B. M. (1993) Function and regulation of ras, Annu Rev 
Biochem 62, 851-891. 
94. Lancaster, J. R., Jr. (2008) Protein cysteine thiol nitrosation: maker or marker of 
reactive nitrogen species-induced nonerythroid cellular signaling?, Nitric Oxide 19, 
68-72. 
95. Mitchell, L., Hobbs, G. A., Aghajanian, A., and Campbell, S. L. (2012) Redox 
Regulation of Ras and Rho GTPases: Mechanism and Function, Antioxid Redox 
Signal. 
147 
96. Sethuraman, M., Clavreul, N., Huang, H., McComb, M. E., Costello, C. E., and Cohen, 
R. A. (2007) Quantification of oxidative posttranslational modifications of cysteine 
thiols of p21ras associated with redox modulation of activity using isotope-coded 
affinity tags and mass spectrometry, Free Radic Biol Med 42, 823-829. 
97. Kuster, G. M., Pimentel, D. R., Adachi, T., Ido, Y., Brenner, D. A., Cohen, R. A., Liao, 
R., Siwik, D. A., and Colucci, W. S. (2005) Alpha-adrenergic receptor-stimulated 
hypertrophy in adult rat ventricular myocytes is mediated via thioredoxin-1-sensitive 
oxidative modification of thiols on Ras, Circulation 111, 1192-1198. 
98. Kuster, G. M., Siwik, D. A., Pimentel, D. R., and Colucci, W. S. (2006) Role of 
reversible, thioredoxin-sensitive oxidative protein modifications in cardiac myocytes, 
Antioxid Redox Signal 8, 2153-2159. 
99. Pimentel, D. R., Adachi, T., Ido, Y., Heibeck, T., Jiang, B., Lee, Y., Melendez, J. A., 
Cohen, R. A., and Colucci, W. S. (2006) Strain-stimulated hypertrophy in cardiac 
myocytes is mediated by reactive oxygen species-dependent Ras S-glutathiolation, J 
Mol Cell Cardiol 41, 613-622. 
100. Clavreul, N., Bachschmid, M. M., Hou, X., Shi, C., Idrizovic, A., Ido, Y., Pimentel, D., 
and Cohen, R. A. (2006) S-glutathiolation of p21ras by peroxynitrite mediates 
endothelial insulin resistance caused by oxidized low-density lipoprotein, 
Arterioscler Thromb Vasc Biol 26, 2454-2461. 
101. Adachi, T., Weisbrod, R. M., Pimentel, D. R., Ying, J., Sharov, V. S., Schoneich, C., 
and Cohen, R. A. (2004) S-Glutathiolation by peroxynitrite activates SERCA during 
arterial relaxation by nitric oxide, Nat Med 10, 1200-1207. 
102. Bonini, M. G., and Augusto, O. (2001) Carbon dioxide stimulates the production of 
thiyl, sulfinyl, and disulfide radical anion from thiol oxidation by peroxynitrite, J Biol 
Chem 276, 9749-9754. 
103. Liaudet, L., Vassalli, G., and Pacher, P. (2009) Role of peroxynitrite in the redox 
regulation of cell signal transduction pathways, Front Biosci 14, 4809-4814. 
104. Ushio-Fukai, M., Alexander, R. W., Akers, M., Yin, Q., Fujio, Y., Walsh, K., and 
Griendling, K. K. (1999) Reactive oxygen species mediate the activation of 
Akt/protein kinase B by angiotensin II in vascular smooth muscle cells, J Biol Chem 
274, 22699-22704. 
105. Lee, C., Miura, K., Liu, X., and Zweier, J. L. (2000) Biphasic regulation of leukocyte 
superoxide generation by nitric oxide and peroxynitrite, J Biol Chem 275, 38965-
38972. 
106. John, J., Schlichting, I., Schiltz, E., Rosch, P., and Wittinghofer, A. (1989) C-terminal 
truncation of p21H preserves crucial kinetic and structural properties, J Biol Chem 
264, 13086-13092. 
107. Gunawardena, H. P., Huang, Y., Kenjale, R., Wang, H., Xie, L., and Chen, X. (2011) 
Unambiguous characterization of site-specific phosphorylation of leucine-rich repeat 
148 
Fli-I-interacting protein 2 (LRRFIP2) in Toll-like receptor 4 (TLR4)-mediated 
signaling, J Biol Chem 286, 10897-10910. 
108. Lenzen, C., Cool, R. H., Prinz, H., Kuhlmann, J., and Wittinghofer, A. (1998) Kinetic 
analysis by fluorescence of the interaction between Ras and the catalytic domain of 
the guanine nucleotide exchange factor Cdc25Mm, Biochemistry 37, 7420-7430. 
109. Lenzen, C., Cool, R. H., and Wittinghofer, A. (1995) Analysis of intrinsic and CDC25-
stimulated guanine nucleotide exchange of p21ras-nucleotide complexes by 
fluorescence measurements, Methods Enzymol 255, 95-109. 
110. Sondermann, H., Soisson, S. M., Boykevisch, S., Yang, S. S., Bar-Sagi, D., and 
Kuriyan, J. (2004) Structural analysis of autoinhibition in the Ras activator Son of 
sevenless, Cell 119, 393-405. 
111. Shutes, A., and Der, C. J. (2006) Real-time in vitro measurement of intrinsic and Ras 
GAP-mediated GTP hydrolysis, Methods Enzymol 407, 9-22. 
112. Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmuller, L., Lautwein, A., Schmitz, 
F., and Wittinghofer, A. (1997) The Ras-RasGAP complex: structural basis for 
GTPase activation and its loss in oncogenic Ras mutants, Science 277, 333-338. 
113. Gu, H., Lalonde, S., Okumoto, S., Looger, L. L., Scharff-Poulsen, A. M., Grossman, A. 
R., Kossmann, J., Jakobsen, I., and Frommer, W. B. (2006) A novel analytical 
method for in vivo phosphate tracking, Febs Lett 580, 5885-5893. 
114. Brune, M., Hunter, J. L., Corrie, J. E., and Webb, M. R. (1994) Direct, real-time 
measurement of rapid inorganic phosphate release using a novel fluorescent probe 
and its application to actomyosin subfragment 1 ATPase, Biochemistry 33, 8262-
8271. 
115. Grzesiek, S., and Bax, A. (1993) Measurement of amide proton exchange rates and 
NOEs with water in 13C/15N-enriched calcineurin B, J Biomol NMR 3, 627-638. 
116. Bax, A., Ikura, M., Kay, L. E., Barbato, G., and Spera, S. (1991) Multidimensional 
triple resonance NMR spectroscopy of isotopically uniformly enriched proteins: a 
powerful new strategy for structure determination, Ciba Found Symp 161, 108-119; 
discussion 119-135. 
117. Delaglio, F., Grzesiek, S., Vuister, G. W., Zhu, G., Pfeifer, J., and Bax, A. (1995) 
NMRPipe: a multidimensional spectral processing system based on UNIX pipes, 
Journal of biomolecular NMR 6, 277-293. 
118. John, J., Rensland, H., Schlichting, I., Vetter, I., Borasio, G. D., Goody, R. S., and 
Wittinghofer, A. (1993) Kinetic and structural analysis of the Mg(2+)-binding site of 
the guanine nucleotide-binding protein p21H-ras, J Biol Chem 268, 923-929. 
119. Beckman, J. S., and Koppenol, W. H. (1996) Nitric oxide, superoxide, and 
peroxynitrite: the good, the bad, and ugly, Am J Physiol 271, C1424-1437. 
149 
120. Jourd'heuil, D., Jourd'heuil, F. L., and Feelisch, M. (2003) Oxidation and nitrosation 
of thiols at low micromolar exposure to nitric oxide. Evidence for a free radical 
mechanism, J Biol Chem 278, 15720-15726. 
121. Ushio-Fukai, M., Alexander, R. W., Akers, M., and Griendling, K. K. (1998) p38 
Mitogen-activated protein kinase is a critical component of the redox-sensitive 
signaling pathways activated by angiotensin II. Role in vascular smooth muscle cell 
hypertrophy, J Biol Chem 273, 15022-15029. 
122. Han, D., Hanawa, N., Saberi, B., and Kaplowitz, N. (2006) Mechanisms of liver 
injury. III. Role of glutathione redox status in liver injury, Am J Physiol Gastrointest 
Liver Physiol 291, G1-7. 
123. Lofgren, S., Fernando, M. R., Xing, K. Y., Wang, Y., Kuszynski, C. A., Ho, Y. S., and 
Lou, M. F. (2008) Effect of thioltransferase (glutaredoxin) deletion on cellular 
sensitivity to oxidative stress and cell proliferation in lens epithelial cells of 
thioltransferase knockout mouse, Invest Ophthalmol Vis Sci 49, 4497-4505. 
124. Franco, R., and Cidlowski, J. A. (2009) Apoptosis and glutathione: beyond an 
antioxidant, Cell Death Differ 16, 1303-1314. 
125. Meyer, E. B., and Wells, W. W. (1999) Thioltransferase overexpression increases 
resistance of MCF-7 cells to adriamycin, Free Radic Biol Med 26, 770-776. 
126. Eom, Y. W., Kim, M. A., Park, S. S., Goo, M. J., Kwon, H. J., Sohn, S., Kim, W. H., 
Yoon, G., and Choi, K. S. (2005) Two distinct modes of cell death induced by 
doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by 
senescence-like phenotype, Oncogene 24, 4765-4777. 
127. Bos, J. L., Rehmann, H., and Wittinghofer, A. (2007) GEFs and GAPs: critical 
elements in the control of small G proteins, Cell 129, 865-877. 
128. Prior, I. A., Lewis, P. D., and Mattos, C. (2012) A comprehensive survey of Ras 
mutations in cancer, Cancer Res 72, 2457-2467. 
129. Lowy, D. R., Zhang, K., DeClue, J. E., and Willumsen, B. M. (1991) Regulation of 
p21ras activity, Trends Genet 7, 346-351. 
130. Fernandez-Medarde, A., and Santos, E. (2011) Ras in cancer and developmental 
diseases, Genes Cancer 2, 344-358. 
131. Hobbs, G. A., Bonini, M. G., Gunawardena, H. P., Chen, X., and Campbell, S. L. 
(2013) Glutathiolated Ras: characterization and implications for Ras activation, Free 
Radic Biol Med 57, 221-229. 
132. Gu, J., and Lewis, R. S. (2007) Effect of pH and metal ions on the decomposition rate 
of S-nitrosocysteine, Ann Biomed Eng 35, 1554-1560. 
133. Shutes, A., and Der, C. J. (2005) Real-time in vitro measurement of GTP hydrolysis, 
Methods 37, 183-189. 
150 
134. Kelly, S. M., and Price, N. C. (2006) Circular dichroism to study protein interactions, 
Curr Protoc Protein Sci Chapter 20, Unit 20 10. 
135. Franken, S. M., Scheidig, A. J., Krengel, U., Rensland, H., Lautwein, A., Geyer, M., 
Scheffzek, K., Goody, R. S., Kalbitzer, H. R., Pai, E. F., and et al. (1993) Three-
dimensional structures and properties of a transforming and a nontransforming 
glycine-12 mutant of p21H-ras, Biochemistry 32, 8411-8420. 
136. Krengel, U., Schlichting, I., Scherer, A., Schumann, R., Frech, M., John, J., Kabsch, 
W., Pai, E. F., and Wittinghofer, A. (1990) Three-dimensional structures of H-ras p21 
mutants: molecular basis for their inability to function as signal switch molecules, 
Cell 62, 539-548. 
137. Nava, C., Hanna, N., Michot, C., Pereira, S., Pouvreau, N., Niihori, T., Aoki, Y., 
Matsubara, Y., Arveiler, B., Lacombe, D., Pasmant, E., Parfait, B., Baumann, C., 
Heron, D., Sigaudy, S., Toutain, A., Rio, M., Goldenberg, A., Leheup, B., Verloes, A., 
and Cave, H. (2007) Cardio-facio-cutaneous and Noonan syndromes due to 
mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships 
and overlap with Costello syndrome, J Med Genet 44, 763-771. 
138. Dance-Barnes, S. T., Kock, N. D., Floyd, H. S., Moore, J. E., Mosley, L. J., D'Agostino, 
R. B., Jr., Pettenati, M. J., and Miller, M. S. (2008) Effects of mutant human Ki-
ras(G12C) gene dosage on murine lung tumorigenesis and signaling to its 
downstream effectors, Toxicol Appl Pharmacol. 
139. Jemal, A., Cokkinides, V. E., Shafey, O., and Thun, M. J. (2003) Lung cancer trends 
in young adults: an early indicator of progress in tobacco control (United States), 
Cancer Causes Control 14, 579-585. 
140. Aoki, Y., Niihori, T., Kawame, H., Kurosawa, K., Ohashi, H., Tanaka, Y., Filocamo, 
M., Kato, K., Suzuki, Y., Kure, S., and Matsubara, Y. (2005) Germline mutations in 
HRAS proto-oncogene cause Costello syndrome, Nat Genet 37, 1038-1040. 
141. Colby, W. W., Hayflick, J. S., Clark, S. G., and Levinson, A. D. (1986) Biochemical 
characterization of polypeptides encoded by mutated human Ha-ras1 genes, Mol Cell 
Biol 6, 730-734. 
142. Gremer, L., Gilsbach, B., Ahmadian, M. R., and Wittinghofer, A. (2008) Fluoride 
complexes of oncogenic Ras mutants to study the Ras-RasGap interaction, Biol Chem 
389, 1163-1171. 
143. Leone-Kabler, S., Wessner, L. L., McEntee, M. F., D'Agostino, R. B., Jr., and Miller, 
M. S. (1997) Ki-ras mutations are an early event and correlate with tumor stage in 
transplacentally-induced murine lung tumors, Carcinogenesis 18, 1163-1168. 
144. Rodenhuis, S., Slebos, R. J., Boot, A. J., Evers, S. G., Mooi, W. J., Wagenaar, S. S., 
van Bodegom, P. C., and Bos, J. L. (1988) Incidence and possible clinical significance 
of K-ras oncogene activation in adenocarcinoma of the human lung, Cancer Res 48, 
5738-5741. 
151 
145. Campbell, S. L., Khosravi-Far, R., Rossman, K. L., Clark, G. J., and Der, C. J. (1998) 
Increasing complexity of Ras signaling, Oncogene 17, 1395-1413. 
146. Malliri, A., and Collard, J. G. (2003) Role of Rho-family proteins in cell adhesion and 
cancer, Curr Opin Cell Biol 15, 583-589. 
147. Shields, J. M., Pruitt, K., McFall, A., Shaub, A., and Der, C. J. (2000) Understanding 
Ras: 'it ain't over 'til it's over', Trends Cell Biol 10, 147-154. 
148. Heo, J., and Campbell, S. L. (2005) Superoxide anion radical modulates the activity 
of Ras and Ras-related GTPases by a radical-based mechanism similar to that of 
nitric oxide, J Biol Chem 280, 12438-12445. 
149. Del Villar, K., Dorin, D., Sattler, I., Urano, J., Poullet, P., Robinson, N., Mitsuzawa, 
H., and Tamanoi, F. (1996) C-terminal motifs found in Ras-superfamily G-proteins: 
CAAX and C-seven motifs, Biochem Soc Trans 24, 709-713. 
150. Reuther, G. W., and Der, C. J. (2000) The Ras branch of small GTPases: Ras family 
members don't fall far from the tree, Curr Opin Cell Biol 12, 157-165. 
151. Hirshberg, M., Stockley, R. W., Dodson, G., and Webb, M. R. (1997) The crystal 
structure of human rac1, a member of the rho-family complexed with a GTP 
analogue, Nat Struct Biol 4, 147-152. 
152. Ihara, K., Muraguchi, S., Kato, M., Shimizu, T., Shirakawa, M., Kuroda, S., Kaibuchi, 
K., and Hakoshima, T. (1998) Crystal structure of human RhoA in a dominantly 
active form complexed with a GTP analogue, J Biol Chem 273, 9656-9666. 
153. Feltham, J. L., Dotsch, V., Raza, S., Manor, D., Cerione, R. A., Sutcliffe, M. J., 
Wagner, G., and Oswald, R. E. (1997) Definition of the switch surface in the solution 
structure of Cdc42Hs, Biochemistry 36, 8755-8766. 
154. Andreyev, H. J., Norman, A. R., Cunningham, D., Oates, J. R., and Clarke, P. A. 
(1998) Kirsten ras mutations in patients with colorectal cancer: the multicenter 
"RASCAL" study, J Natl Cancer Inst 90, 675-684. 
155. Vega, F., Iniesta, P., Caldes, T., Sanchez, A., Lopez, J., Dejuan, C., Diazrubio, E., 
Torres, A., Balibrea, J., and Benito, M. (1996) Association of K-ras codon 12 
transversions with short survival in non-small cell lung cancer, Int J Oncol 9, 1307-
1311. 
156. Al-Mulla, F., Milner-White, E. J., Going, J. J., and Birnie, G. D. (1999) Structural 
differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma 
aggression, J Pathol 187, 433-438. 
157. Shields, J. M., Pruitt, K., McFall, A., Shaub, A., and Der, C. J. (2000) Understanding 
Ras: 'it ain't over 'til it's over', Trends in cell biology 10, 147-154. 
158. Burridge, K., and Wennerberg, K. (2004) Rho and Rac take center stage, Cell 116, 
167-179. 
152 
159. Kaibuchi, K., Kuroda, S., and Amano, M. (1999) Regulation of the cytoskeleton and 
cell adhesion by the Rho family GTPases in mammalian cells, Annual review of 
biochemistry 68, 459-486. 
160. Scita, G., Tenca, P., Frittoli, E., Tocchetti, A., Innocenti, M., Giardina, G., and Di 
Fiore, P. P. (2000) Signaling from Ras to Rac and beyond: not just a matter of GEFs, 
The EMBO journal 19, 2393-2398. 
161. Bokoch, G. M. (2000) Regulation of cell function by Rho family GTPases, Immunol 
Res 21, 139-148. 
162. Hall, A., and Nobes, C. D. (2000) Rho GTPases: molecular switches that control the 
organization and dynamics of the actin cytoskeleton, Philosophical transactions of 
the Royal Society of London. Series B, Biological sciences 355, 965-970. 
163. Nobes, C. D., and Hall, A. (1995) Rho, rac and cdc42 GTPases: regulators of actin 
structures, cell adhesion and motility, Biochemical Society transactions 23, 456-459. 
164. Mitchell, L., Hobbs, G. A., Aghajanian, A., and Campbell, S. L. (2013) Redox 
regulation of Ras and Rho GTPases: mechanism and function, Antioxid Redox Signal 
18, 250-258. 
165. Ihara, K., Muraguchi, S., Kato, M., Shimizu, T., Shirakawa, M., Kuroda, S., Kaibuchi, 
K., and Hakoshima, T. (1998) Crystal structure of human RhoA in a dominantly 
active form complexed with a GTP analogue, J Biol Chem 273, 9656-9666. 
166. Zhang, B., Zhang, Y., Wang, Z., and Zheng, Y. (2000) The role of Mg2+ cofactor in 
the guanine nucleotide exchange and GTP hydrolysis reactions of Rho family GTP-
binding proteins, J Biol Chem 275, 25299-25307. 
167. Zuckerbraun, B. S., Stoyanovsky, D. A., Sengupta, R., Shapiro, R. A., Ozanich, B. A., 
Rao, J., Barbato, J. E., and Tzeng, E. (2007) Nitric oxide-induced inhibition of 
smooth muscle cell proliferation involves S-nitrosation and inactivation of RhoA, Am 
J Physiol Cell Physiol 292, C824-831. 
168. Chang, Y., Ceacareanu, B., Dixit, M., Sreejayan, N., and Hassid, A. (2002) Nitric 
oxide-induced motility in aortic smooth muscle cells: role of protein tyrosine 
phosphatase SHP-2 and GTP-binding protein Rho, Circ Res 91, 390-397. 
169. Chandra, S., Romero, M. J., Shatanawi, A., Alkilany, A. M., Caldwell, R. B., and 
Caldwell, R. W. (2012) Oxidative species increase arginase activity in endothelial cells 
through the RhoA/Rho kinase pathway, Brit J Pharmacol 165, 506-519. 
170. Rossman, K. L., Worthylake, D. K., Snyder, J. T., Siderovski, D. P., Campbell, S. L., 
and Sondek, J. (2002) A crystallographic view of interactions between Dbs and 
Cdc42: PH domain-assisted guanine nucleotide exchange, Embo J 21, 1315-1326. 
171. Kelly, S. M., Jess, T. J., and Price, N. C. (2005) How to study proteins by circular 
dichroism, Biochim Biophys Acta 1751, 119-139. 
153 
172. Gasmi-Seabrook, G. M., Marshall, C. B., Cheung, M., Kim, B., Wang, F., Jang, Y. J., 
Mak, T. W., Stambolic, V., and Ikura, M. (2010) Real-time NMR study of guanine 
nucleotide exchange and activation of RhoA by PDZ-RhoGEF, J Biol Chem 285, 
5137-5145. 
173. Heo, J., Thapar, R., and Campbell, S. L. (2005) Recognition and activation of Rho 
GTPases by Vav1 and Vav2 guanine nucleotide exchange factors, Biochemistry 44, 
6573-6585. 
174. Chitaley, K., and Webb, R. C. (2002) Nitric oxide induces dilation of rat aorta via 
inhibition of rho-kinase signaling, Hypertension 39, 438-442. 
175. Sauzeau, V., Le Jeune, H., Cario-Toumaniantz, C., Smolenski, A., Lohmann, S. M., 
Bertoglio, J., Chardin, P., Pacaud, P., and Loirand, G. (2000) Cyclic GMP-dependent 
protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of 
contraction in vascular smooth muscle, J Biol Chem 275, 21722-21729. 
176. Sawada, N., Itoh, H., Yamashita, J., Doi, K., Inoue, M., Masatsugu, K., Fukunaga, Y., 
Sakaguchi, S., Sone, M., Yamahara, K., Yurugi, T., and Nakao, K. (2001) cGMP-
dependent protein kinase phosphorylates and inactivates RhoA, Biochem Biophys 
Res Commun 280, 798-805. 
177. Poole, L. B., and Nelson, K. J. (2008) Discovering mechanisms of signaling-mediated 
cysteine oxidation, Curr Opin Chem Biol 12, 18-24. 
178. Davis, M. F., Zhou, L., Ehrenshaft, M., Ranguelova, K., Gunawardena, H. P., Chen, 
X., Bonini, M. G., Mason, R. P., and Campbell, S. L. (2012) Detection of Ras GTPase 
protein radicals through immuno-spin trapping, Free Radic Biol Med 53, 1339-1345. 
179. Young, A., Lou, D., and McCormick, F. (2013) Oncogenic and wild-type Ras play 
divergent roles in the regulation of mitogen-activated protein kinase signaling, 
Cancer Discov 3, 112-123. 
180. Hicke, L. (2001) Protein regulation by monoubiquitin, Nat Rev Mol Cell Biol 2, 195-
201. 
181. Jura, N., Scotto-Lavino, E., Sobczyk, A., and Bar-Sagi, D. (2006) Differential 
modification of Ras proteins by ubiquitination, Mol Cell 21, 679-687. 
182. Komander, D., Clague, M. J., and Urbe, S. (2009) Breaking the chains: structure and 
function of the deubiquitinases, Nat Rev Mol Cell Biol 10, 550-563. 
183. Wennerberg, K., Rossman, K. L., and Der, C. J. (2005) The Ras superfamily at a 
glance, J Cell Sci 118, 843-846. 
184. Feig, L. A., and Cooper, G. M. (1988) Relationship among guanine nucleotide 
exchange, GTP hydrolysis, and transforming potential of mutated ras proteins, Mol 
Cell Biol 8, 2472-2478. 
154 
185. Micel, L. N., Tentler, J. J., Smith, P. G., and Eckhardt, G. S. (2013) Role of ubiquitin 
ligases and the proteasome in oncogenesis: novel targets for anticancer therapies, J 
Clin Oncol 31, 1231-1238. 
186. Gremer, L., Gilsbach, B., Ahmadian, M. R., and Wittinghofer, A. (2008) Fluoride 
complexes of oncogenic Ras mutants to study the Ras-RasGap interaction, Biol Chem 
389, 1163-1171. 
187. Gao, C., and Eriksson, L. A. (2013) Impact of Mutations on K-Ras-p120GAP 
Interaction, Computational Molecular Bioscience, 9-17. 
188. Aitken, A., and Learmonth, M. (2002) Carboxymethylation of Cysteine using 
Iodoacetamide/iodoacetic acid, The Protein Protocols Handbook 2nd Edition, 455-
456. 
189. Smythe, C. V. (1936) The Reaction of Iodoacetate and of Iodoacetamide with various 
sulfhydryl groups, with urease, and with yeast preparations, J Biol Chem, 601-612. 
190. Camps, J., Carrillo, O., Emperador, A., Orellana, L., Hospital, A., Rueda, M., Cicin-
Sain, D., D'Abramo, M., Gelpi, J. L., and Orozco, M. (2009) FlexServ: an integrated 
tool for the analysis of protein flexibility, Bioinformatics 25, 1709-1710. 
191. Kotting, C., Kallenbach, A., Suveyzdis, Y., Wittinghofer, A., and Gerwert, K. (2008) 
The GAP arginine finger movement into the catalytic site of Ras increases the 
activation entropy, Proc Natl Acad Sci U S A 105, 6260-6265. 
192. Kotting, C., and Gerwert, K. (2013) The dynamics of the catalytic site in small 
GTPases, variations on a common motif, Febs Lett. 
193. Rudack, T., Xia, F., Schlitter, J., Kotting, C., and Gerwert, K. (2012) Ras and GTPase-
activating protein (GAP) drive GTP into a precatalytic state as revealed by combining 
FTIR and biomolecular simulations, Proc Natl Acad Sci U S A 109, 15295-15300. 
194. Rudack, T., Xia, F., Schlitter, J., Kotting, C., and Gerwert, K. (2012) The role of 
magnesium for geometry and charge in GTP hydrolysis, revealed by quantum 
mechanics/molecular mechanics simulations, Biophys J 103, 293-302. 
195. Grigorenko, B. L., Nemukhin, A. V., Shadrina, M. S., Topol, I. A., and Burt, S. K. 
(2007) Mechanisms of guanosine triphosphate hydrolysis by Ras and Ras-GAP 
proteins as rationalized by ab initio QM/MM simulations, Proteins 66, 456-466. 
196. Netto, L. E., de Oliveira, M. A., Monteiro, G., Demasi, A. P., Cussiol, J. R., Discola, K. 
F., Demasi, M., Silva, G. M., Alves, S. V., Faria, V. G., and Horta, B. B. (2007) 
Reactive cysteine in proteins: protein folding, antioxidant defense, redox signaling 
and more, Comp Biochem Physiol C Toxicol Pharmacol 146, 180-193. 
197. Martinez-Ruiz, A., and Lamas, S. (2007) Signalling by NO-induced protein S-
nitrosylation and S-glutathionylation: convergences and divergences, Cardiovasc 
Res 75, 220-228. 
155 
198. Mieyal, J. J., and Chock, P. B. (2012) Posttranslational modification of cysteine in 
redox signaling and oxidative stress: Focus on s-glutathionylation, Antioxid Redox 
Signal 16, 471-475. 
199. Wang, Y., Yang, J., and Yi, J. (2012) Redox sensing by proteins: oxidative 
modifications on cysteines and the consequent events, Antioxid Redox Signal 16, 
649-657. 
200. Adler, V., Yin, Z., Tew, K. D., and Ronai, Z. (1999) Role of redox potential and 
reactive oxygen species in stress signaling, Oncogene 18, 6104-6111. 
201. Reddie, K. G., and Carroll, K. S. (2008) Expanding the functional diversity of 
proteins through cysteine oxidation, Curr Opin Chem Biol 12, 746-754. 
202. Roos, G., Foloppe, N., and Messens, J. (2013) Understanding the pK(a) of Redox 
Cysteines: The Key Role of Hydrogen Bonding, Antioxid Redox Signal 18, 94-127. 
203. Bulaj, G., Kortemme, T., and Goldenberg, D. P. (1998) Ionization-reactivity 
relationships for cysteine thiols in polypeptides, Biochemistry 37, 8965-8972. 
204. Nelson, K. J., Parsonage, D., Hall, A., Karplus, P. A., and Poole, L. B. (2008) Cysteine 
pK(a) values for the bacterial peroxiredoxin AhpC, Biochemistry 47, 12860-12868. 
205. Dyson, H. J., Jeng, M. F., Tennant, L. L., Slaby, I., Lindell, M., Cui, D. S., Kuprin, S., 
and Holmgren, A. (1997) Effects of buried charged groups on cysteine thiol ionization 
and reactivity in Escherichia coli thioredoxin: structural and functional 
characterization of mutants of Asp 26 and Lys 57, Biochemistry 36, 2622-2636. 
206. Chivers, P. T., Prehoda, K. E., Volkman, B. F., Kim, B. M., Markley, J. L., and Raines, 
R. T. (1997) Microscopic pKa values of Escherichia coli thioredoxin, Biochemistry 36, 
14985-14991. 
207. Tosatto, S. C., Bosello, V., Fogolari, F., Mauri, P., Roveri, A., Toppo, S., Flohe, L., 
Ursini, F., and Maiorino, M. (2008) The catalytic site of glutathione peroxidases, 
Antioxid Redox Signal 10, 1515-1526. 
208. Isom, D. G., Marguet, P. R., Oas, T. G., and Hellinga, H. W. (2011) A miniaturized 
technique for assessing protein thermodynamics and function using fast 
determination of quantitative cysteine reactivity, Proteins 79, 1034-1047. 
209. Chait, B. T. (2006) Chemistry. Mass spectrometry: bottom-up or top-down?, Science 
314, 65-66. 
210. Yates, J. R., Ruse, C. I., and Nakorchevsky, A. (2009) Proteomics by mass 
spectrometry: approaches, advances, and applications, Annu Rev Biomed Eng 11, 49-
79. 
211. Grossi, L., and Montevecchi, P. C. (2002) S-nitrosocysteine and cystine from reaction 
of cysteine with nitrous acid. A kinetic investigation, J Org Chem 67, 8625-8630. 
156 
212. Moore, K. P., and Mani, A. R. (2002) Measurement of protein nitration and S-
nitrosothiol formation in biology and medicine, Methods Enzymol 359, 256-268. 
213. Jones, D. P. (2008) Radical-free biology of oxidative stress, Am J Physiol Cell Physiol 
295, C849-868. 
214. Sander, R. (1999) Compilation of Henry’s Law Constants for Inorganic and Organic 
Species of Potential Importance in Environmental Chemistry. 
215. Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F., Gelb, M. H., and Aebersold, R. (1999) 
Quantitative analysis of complex protein mixtures using isotope-coded affinity tags, 
Nat Biotechnol 17, 994-999. 
216. Chiappetta, G., Ndiaye, S., Igbaria, A., Kumar, C., Vinh, J., and Toledano, M. B. 
(2010) Proteome screens for Cys residues oxidation: the redoxome, Methods 
Enzymol 473, 199-216. 
217. Marino, S. M., Li, Y., Fomenko, D. E., Agisheva, N., Cerny, R. L., and Gladyshev, V. 
N. (2010) Characterization of surface-exposed reactive cysteine residues in 
Saccharomyces cerevisiae, Biochemistry 49, 7709-7721. 
218. Sethuraman, M., McComb, M. E., Huang, H., Huang, S., Heibeck, T., Costello, C. E., 
and Cohen, R. A. (2004) Isotope-coded affinity tag (ICAT) approach to redox 
proteomics: identification and quantitation of oxidant-sensitive cysteine thiols in 
complex protein mixtures, J Proteome Res 3, 1228-1233. 
219. Leichert, L. I., Gehrke, F., Gudiseva, H. V., Blackwell, T., Ilbert, M., Walker, A. K., 
Strahler, J. R., Andrews, P. C., and Jakob, U. (2008) Quantifying changes in the thiol 
redox proteome upon oxidative stress in vivo, Proc Natl Acad Sci U S A 105, 8197-
8202. 
220. Chouchani, E. T., James, A. M., Fearnley, I. M., Lilley, K. S., and Murphy, M. P. 
(2011) Proteomic approaches to the characterization of protein thiol modification, 
Curr Opin Chem Biol 15, 120-128. 
221. Wisniewski, J. R., Ostasiewicz, P., and Mann, M. (2011) High recovery FASP applied 
to the proteomic analysis of microdissected formalin fixed paraffin embedded cancer 
tissues retrieves known colon cancer markers, J Proteome Res 10, 3040-3049. 
222. Wisniewski, J. R., Zielinska, D. F., and Mann, M. (2011) Comparison of ultrafiltration 
units for proteomic and N-glycoproteomic analysis by the filter-aided sample 
preparation method, Anal Biochem 410, 307-309. 
223. Wisniewski, J. R., Zougman, A., and Mann, M. (2009) Combination of FASP and 
StageTip-based fractionation allows in-depth analysis of the hippocampal membrane 
proteome, J Proteome Res 8, 5674-5678. 
224. Wisniewski, J. R., Zougman, A., Nagaraj, N., and Mann, M. (2009) Universal sample 
preparation method for proteome analysis, Nat Methods 6, 359-362. 
157 
225. Houk, J., Singh, R., and Whitesides, G. M. (1987) Measurement of thiol-disulfide 
interchange reactions and thiol pKa values, Methods Enzymol 143, 129-140. 
226. Lukesh, J. C., 3rd, Palte, M. J., and Raines, R. T. (2012) A potent, versatile disulfide-
reducing agent from aspartic acid, J Am Chem Soc 134, 4057-4059. 
227. Saville, B. (1958) A Scheme for the Colorimetric Determination of Microgram 
Amounts of Thiols, Analyst 83, 670-672. 
228. Keshive, M., Singh, S., Wishnok, J. S., Tannenbaum, S. R., and Deen, W. M. (1996) 
Kinetics of S-nitrosation of thiols in nitric oxide solutions, Chem Res Toxicol 9, 988-
993. 
229. Hobbs, G. A., Bonini, M. G., Gunawardena, H. P., Chen, X., and Campbell, S. L. 
(2012) Glutathiolated Ras: Characterization and Implications for Ras Activation, 
Free Radic Biol Med. 
230. Yu, Y., Xie, L., Gunawardena, H. P., Khatun, J., Maier, C., Spitzer, W., Leerkes, M., 
Giddings, M. C., and Chen, X. (2012) GOFAST: an integrated approach for efficient 
and comprehensive membrane proteome analysis, Anal Chem 84, 9008-9014. 
231. Bishop, A. L., and Hall, A. (2000) Rho GTPases and their effector proteins, Biochem 
J 348 Pt 2, 241-255. 
232. Repasky, G. A., Chenette, E. J., and Der, C. J. (2004) Renewing the conspiracy theory 
debate: does Raf function alone to mediate Ras oncogenesis?, Trends Cell Biol 14, 
639-647. 
233. Kaibuchi, K., Kuroda, S., and Amano, M. (1999) Regulation of the cytoskeleton and 
cell adhesion by the Rho family GTPases in mammalian cells, Annu Rev Biochem 68, 
459-486. 
234. Scita, G., Tenca, P., Frittoli, E., Tocchetti, A., Innocenti, M., Giardina, G., and Di 
Fiore, P. P. (2000) Signaling from Ras to Rac and beyond: not just a matter of GEFs, 
Embo J 19, 2393-2398. 
235. Wei, W., Das, B., Park, W., and Broek, D. (1994) Cloning and analysis of human 
cDNAs encoding a 140-kDa brain guanine nucleotide-exchange factor, Cdc25GEF, 
which regulates the function of Ras, Gene 151, 279-284. 
236. Simon, I., Zerial, M., and Goody, R. S. (1996) Kinetics of interaction of Rab5 and 
Rab7 with nucleotides and magnesium ions, J Biol Chem 271, 20470-20478. 
237. Jiang, W. G., Watkins, G., Lane, J., Cunnick, G. H., Douglas-Jones, A., Mokbel, K., 
and Mansel, R. E. (2003) Prognostic value of rho GTPases and rho guanine 
nucleotide dissociation inhibitors in human breast cancers, Clin Cancer Res 9, 6432-
6440. 
238. Ellenbroek, S. I., and Collard, J. G. (2007) Rho GTPases: functions and association 
with cancer, Clin Exp Metastasis 24, 657-672. 
158 
239. Touyz, R. M. (2006) Magnesium and hypertension, Curr Opin Nephrol Hypertens 
15, 141-144. 
240. Katoh, H., Hiramoto, K., and Negishi, M. (2006) Activation of Rac1 by RhoG 
regulates cell migration, J Cell Sci 119, 56-65. 
241. Wennerberg, K., Ellerbroek, S. M., Liu, R. Y., Karnoub, A. E., Burridge, K., and Der, 
C. J. (2002) RhoG signals in parallel with Rac1 and Cdc42, J Biol Chem 277, 47810-
47817. 
242. Prieto-Sanchez, R. M., and Bustelo, X. R. (2003) Structural basis for the signaling 
specificity of RhoG and Rac1 GTPases, J Biol Chem 278, 37916-37925. 
243. Thapar, R., Williams, J. G., and Campbell, S. L. (2004) NMR characterization of full-
length farnesylated and non-farnesylated H-Ras and its implications for Raf 
activation, J Mol Biol 343, 1391-1408. 
244. Abe, K., Rossman, K. L., Liu, B., Ritola, K. D., Chiang, D., Campbell, S. L., Burridge, 
K., and Der, C. J. (2000) Vav2 is an activator of Cdc42, Rac1, and RhoA, J Biol Chem 
275, 10141-10149. 
245. Hiramoto, K., Negishi, M., and Katoh, H. (2006) Dock4 is regulated by RhoG and 
promotes Rac-dependent cell migration, Exp Cell Res 312, 4205-4216. 
246. Ellerbroek, S. M., Wennerberg, K., Arthur, W. T., Dunty, J. M., Bowman, D. R., 
DeMali, K. A., Der, C., and Burridge, K. (2004) SGEF, a RhoG guanine nucleotide 
exchange factor that stimulates macropinocytosis, Mol Biol Cell 15, 3309-3319. 
247. Gentile, S., Darden, T., Erxleben, C., Romeo, C., Russo, A., Martin, N., Rossie, S., and 
Armstrong, D. L. (2006) Rac GTPase signaling through the PP5 protein phosphatase, 
Proc Natl Acad Sci U S A 103, 5202-5206. 
248. Wennerberg, K., and Der, C. J. (2004) Rho-family GTPases: it's not only Rac and 
Rho (and I like it), J Cell Sci 117, 1301-1312. 
249. Lapouge, K., Smith, S. J., Walker, P. A., Gamblin, S. J., Smerdon, S. J., and Rittinger, 
K. (2000) Structure of the TPR domain of p67phox in complex with Rac.GTP, Mol 
Cell 6, 899-907. 
250. Schumacker, P. T. (2006) Reactive oxygen species in cancer cells: live by the sword, 
die by the sword, Cancer Cell 10, 175-176. 
251. Katoh, H., Yasui, H., Yamaguchi, Y., Aoki, J., Fujita, H., Mori, K., and Negishi, M. 
(2000) Small GTPase RhoG is a key regulator for neurite outgrowth in PC12 cells, 
Mol Cell Biol 20, 7378-7387. 
252. Bokoch, G. M. (1995) Regulation of the phagocyte respiratory burst by small GTP-
binding proteins, Trends Cell Biol 5, 109-113. 
159 
253. Cheng, G., Diebold, B. A., Hughes, Y., and Lambeth, J. D. (2006) Nox1-dependent 
reactive oxygen generation is regulated by Rac1, J Biol Chem 281, 17718-17726. 
254. Condliffe, A. M., Webb, L. M., Ferguson, G. J., Davidson, K., Turner, M., Vigorito, E., 
Manifava, M., Chilvers, E. R., Stephens, L. R., and Hawkins, P. T. (2006) RhoG 
regulates the neutrophil NADPH oxidase, J Immunol 176, 5314-5320. 
